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The aldehyde dehydrogenase (ALDH) superfamily is gaining momentum in 
regard to stem cell and cancer research. However, their regulation and 
expression in the cancer microenvironment is poorly understood. The aim of 
this work was to understand the role of selected ALDH isoforms (1A1, 1A2, 
1A3, 1B1, 2, 3A1 and 7A1) in colorectal cancer (CRC) and explore the 
impact of hypoxia on their expression. CRC cell lines (HT29, DLD-1, SW480 
and HCT116) were grown under normoxic or hypoxic conditions (0.1% O2) 
and HT29 and DLD-1 in spinner flasks to generate multicellular spheroids 
(MCS). Hypoxia was demonstrated to have an impact on the ALDH 
expression, which appeared cell-specific. Notably, ALDH7A1 was induced 
upon exposure to hypoxia in both HT29 and DLD-1 cells, shown to be 
expressed in the hypoxic region of the MCS variants and in 5/5 CRC 
xenografts (HT29, DLD-1, HCT116, SW620, and COLO205). ALDH7A1 
siRNA knockdown studies in DLD-1 cells resulted in significant reduction of 
viable cells and significant increase in ROS levels, suggesting ALDH7A1 to 
possess antioxidant properties. These findings were further supported using 
isogenic H1299/RFP and H1299/ALDH7A1 lung cancer cell lines. ALDH7A1, 
however, was found not to be involved in inhibiting the pharmacological 
effect or causing resistance to different cytotoxic and molecularly targeted 
anticancer drugs. To unravel the functional role of ALDH7A1, 9 compounds 
obtained from a virtual screening of 24,000 compounds from the Maybridge 
collection of compounds were used to probe ALDH7A1 functional activity. 
ii 
One compound, HAN00316, was found to inhibit the antioxidant properties of 
ALDH7A1 and thus could be a good starting point for further chemical tool 
development. Although this study underpins a potential important role of 
ALDH7A1 in hypoxic CRC, further work is required to fully validate its 
potential as a biomarker and/or pharmacological target. 
  
iii 
Acknowledgements 
First and foremost I thank my God for giving me the strength throughout my 
life. I am blessed and I thank God every day for everything that happens to 
me. I am grateful for the favour which God has bestowed upon me. 
I would like to offer my sincerest gratitude to my supervisor, Dr. Klaus Pors, 
who has supported me throughout my work with his patience and knowledge 
whilst allowing me the room to work in my own way. He holds the credit of 
keeping me on the right track through his continuous guidance and 
stimulating discussions. I am also thankful to him for encouraging the use of 
correct grammar and consistent notation in my writings and for carefully 
reading and commenting on revisions of this thesis. One simply could not 
wish for a better or friendlier supervisor. 
I am also thankful for Prof Laurence Patterson for his generous and 
unconditional support. 
I’m deeply grateful to Prof. Roger Phillips for his guidance and patience 
throughout the period of study. I consider myself very fortunate for being able 
to work with a very considerate and encouraging instructor like him. I am 
thankful to him for his advices that helped me sort out the technical details of 
my work. 
I would like to thank Mrs Patricia Cooper and Mr Gary Lawson for their help 
in cell culture lab. I extend my sincere thanks to Dr Mark Sutherland who 
taught me the techniques of gene analysis. I’d like also to thank Dr Charlotte 
Evan and Haneen Basheer who taught me how to culture spheroids. I’m also 
indebted to Amit, Hanady and Djev who showed me how to do histology 
experiments. 
I would like to express my appreciation to Dr. Simon Allison for teaching me 
western blot, knockdown, ROS detection and cell cycle procedures and 
helping me with his pointers and expertise in molecular biology and cell 
culture lab work. 
In my daily work, I have also been blessed with a friendly and cheerful group 
of PhD students (Sara, Rene, Manar, Rida, Dany) who supported me during 
lab work.  
I’d like to convey my heartfelt thanks to my home university, Jordan 
University of Science and Technology, for their generous sponsorship and 
continuous support. 
I'd like to also thank my flatmate, Sara, with whom I shared a living for three 
months. It was great time during which we were mutually supportive for each 
iv 
other. Sara was my backbone when I couldn’t stand up for myself. She was 
like a real sister. 
Finally, and most importantly, I wish to express my sincere thanks to my 
family. I would like to thank my husband Dr. Ahmad Jumah. His full support, 
encouragement, quiet patience and unwavering love were undeniably the 
bedrock upon which the past five years of my life have been built. His 
tolerance of my occasional bad moods is a testament in itself of his 
unyielding devotion and love. He has done all that and more while working 
on his own PhD! 
I also would like to thank my parents (Dr MohammedSuhail Elsalem and Mrs 
Rasmieh Elkateeb) and my brothers (Ala’a, Omar and Anas), for their faith in 
me and allowing me to be as ambitious as I wanted. It was under their 
watchful eye that I gained so much drive and an ability to tackle challenges. I 
owe them everything and wish I could show them just how much I love and 
appreciate them. I’m also thankful to my sisters-in-law (Ayat and Sarait), and 
my darling candy nephew, Amr, your smiley face was my inspiration 
throughout my writing period. 
This work is dedicated for my late father-in-law (Mr Abdelhaleem Jumah). I 
hope it will make him proud of me and my other half, Ahmad. 
  
v 
Table of Content 
Abstract ........................................................................................................... i 
Acknowledgements ........................................................................................ iii 
Table of Content ............................................................................................ v 
List of Figures ................................................................................................ xi 
List of Tables............................................................................................... xvii 
List of Abbreviations ................................................................................... xviii 
Chapter 1: Introduction .................................................................................. 1 
1.1 Cancer definition and epidemiology .......................................................... 2 
1.2 Hallmarks of cancer .................................................................................. 2 
1.3 Tumour hypoxia........................................................................................ 4 
  1.3.1 Causes of hypoxia ................................................................................ 5
  1.3.2 Measuring tumour hypoxia ................................................................... 6
  1.3.3 Hypoxia-inducible factors ...................................................................... 7
  1.3.4 Hypoxia-inducible factors in cancer progression ................................... 9
1.4 Aldehyde dehydrogenase superfamily .................................................... 12 
  1.4.1 Aldehyde compounds ......................................................................... 12
  1.4.2 ALDH in normal physiological processes ............................................ 13
  1.4.3 ALDH in cancer .................................................................................. 18
  1.4.4 ALDH and drug resistance .................................................................. 23
  1.4.5 ALDH in cancer stem cells (CSCs) ..................................................... 26
1.4.5.1 The use of ALDH to isolate CSCs ...................................................... 30 
1.4.5.1.1 The ALDEFLUOR assay .................................................................... 31 
1.4.5.1.2 The selectivity of the ALDEFLUOR assay .......................................... 32 
1.4.5.1.3 AldeRed-588-A: New red substrate for detecting ALDH activity ........ 34 
1.5 The role of hypoxia in the regulation of ALDH expression ...................... 36 
  1.5.1 Hypoxia, oxidative stress and ALDH ................................................... 36
  1.5.2 Hypoxia and ALDH expression ........................................................... 38
1.6 Aims and objectives ............................................................................... 40 
Chapter 2: The impact of hypoxia on the expression of aldehyde 
dehydrogenases in 2D and 3D colorectal cancer models ............................ 41 
2.1 Introduction ............................................................................................ 42 
2.2 Materials and Methods ........................................................................... 51 
  2.2.1 The expression of ALDH in a panel of colorectal cancer cell lines ...... 51
2.2.1.1 Cell culture .......................................................................................... 51 
vi 
2.2.1.1.1 Passaging of mammalian cells ........................................................... 51 
2.2.1.1.2 Determination of the cell concentration .............................................. 52 
2.2.1.2 Exposure of CRC cell lines to hypoxia ............................................... 53 
2.2.1.3 Analysis of ALDH gene expression of CRC cell lines using 
quantitative real time polymerase chain reaction (qRT-PCR) ............................ 54 
2.2.1.3.1 Cell harvesting .................................................................................... 54 
2.2.1.3.2 RNA extraction and quantification ...................................................... 54 
2.2.1.3.3 Complementary DNA synthesis .......................................................... 55 
2.2.1.3.4 QRT-PCR primers design ................................................................... 56 
2.2.1.3.5 QRT-PCR method .............................................................................. 56 
2.2.1.3.6 Data analysis ...................................................................................... 57 
2.2.1.3.7 Statistical analysis .............................................................................. 59 
2.2.1.4 Analysis of ALDH protein expression of CRC cell lines using western 
blot 59 
2.2.1.4.1 Sample preparation ............................................................................ 59 
2.2.1.4.2 Determination of protein concentration............................................... 60 
2.2.1.4.3 Polyacrylamide gel preparation .......................................................... 60 
2.2.1.4.4 Protein transfer to nitrocellulose membrane ....................................... 61 
2.2.1.4.5 Immunodetection of electrophoresed proteins after transfer to 
nitrocellulose membrane ....................................................................................... 61 
2.2.1.4.6 Enhanced chemiluminescent detection .............................................. 62 
2.2.1.4.7 Data analysis ...................................................................................... 62 
  2.2.2 The expression of ALDH in colorectal cancer spheroids ..................... 63
2.2.2.1 Spheroids culture ................................................................................ 63 
2.2.2.1.1 Spheroids formation............................................................................ 63 
2.2.2.1.2 Spheroids growth curve ...................................................................... 63 
2.2.2.2 Histology of spheroids ........................................................................ 63 
2.2.2.2.1 Fixation ............................................................................................... 63 
2.2.2.2.2 Processing .......................................................................................... 64 
2.2.2.2.3 Sectioning ........................................................................................... 64 
2.2.2.2.4 Haematoxylin and Eosin Staining ....................................................... 64 
2.2.2.3 Hypoxia detection ............................................................................... 65 
2.2.2.3.1 Spheroids treatment with the hypoxic marker pimonidazole .............. 65 
2.2.2.3.2 Fixation and processing ...................................................................... 65 
2.2.2.3.3 Sectioning ........................................................................................... 66 
2.2.2.3.4 Immunofluorescence staining ............................................................. 66 
2.2.2.4 Isolation of cells residing in surface layer and hypoxic region of CRC 
spheroids 67 
vii 
2.2.2.5 Analysis of ALDH gene expression of CRC spheroids using qRT-PCR
 67 
2.2.2.6 Analysis of ALDH protein expression of CRC spheroids using western 
blot 68 
2.2.2.7 Immunohistochemistry staining .......................................................... 68 
2.2.2.7.1 Dewaxing and rehydration .................................................................. 68 
2.2.2.7.2 Antigen retrieval .................................................................................. 68 
2.2.2.7.3 Blocking .............................................................................................. 69 
2.2.2.7.4 Antibodies and detection .................................................................... 69 
2.2.2.7.5 Dehydration ........................................................................................ 70 
  2.2.3 The expression of ALDH in colorectal cancer xenografts .................... 70
  2.2.4 The role of HIF in the regulation of ALDH7A1 expression ................... 71
2.2.4.1 Induction of HIF using cobalt chloride (CoCl2) ................................... 71 
2.2.4.2 Knockdown of HIF-1α or HIF-2α using siRNA to evaluate their effect 
on ALDH7A1 expression ..................................................................................... 72 
2.2.4.2.1 ALDH7A1 expression ......................................................................... 72 
2.2.4.2.2 Preparation of siRNA solution ............................................................ 73 
2.2.4.2.3 Transfection with siRNA ..................................................................... 73 
2.3 Results ................................................................................................... 75 
  2.3.1 Analysis of ALDH expression in CRC cell lines ................................... 75
2.3.1.1 Gene expression using q-RT-PCR ..................................................... 75 
2.3.1.1.1 ALDH gene expression profiling of CRC cell lines under normoxic 
conditions 75 
2.3.1.1.2 ALDH genes expression profiling under hypoxic conditions .............. 76 
2.3.1.2 Analysis of ALDH protein expression using western blot .................. 80 
  2.3.2 Analysis of ALDH expression of colorectal spheroids ......................... 86
2.3.2.1 Spheroids culture ................................................................................ 86 
2.3.2.1.1 Spheroids generation.......................................................................... 86 
2.3.2.1.2 Characterisation of Spheroids ............................................................ 88 
2.3.2.1.3 Detection of the hypoxic region of MCS ............................................. 90 
2.3.2.1.4 Isolation of different layers from MCS ................................................ 91 
2.3.2.2 Expression profiling of ALDH genes and proteins of cells residing in 
the surface layer and the hypoxic region of MCS ............................................... 91 
2.3.2.3 Evaluation of ALDH expression in colorectal cancer MCS and tumour 
xenograft models ................................................................................................. 95 
2.3.2.4 Detection of hypoxia in MCS and xenograft models ........................ 104 
  2.3.3 Regulation of ALDH7A1 expression by HIF ...................................... 105
2.3.3.1 HIF-1α induction using CoCl2 treatment........................................... 105 
viii 
2.3.3.2 Knockdown of HIFs and their effect on ALDH7A1 expression ........ 106 
2.4 Discussion ............................................................................................ 110 
Chapter 3: Probing the functional roles of selected ALDH isoforms in 
colorectal cancer using siRNA knockdown ................................................ 121 
3.1 Introduction .......................................................................................... 122 
3.2 Material and Methods ........................................................................... 128 
  3.2.1 Target mRNA knockdown using siRNA ............................................ 128
3.2.1.1 Cell seeding ...................................................................................... 128 
3.2.1.2 Preparation of siRNAs ...................................................................... 128 
3.2.1.3 Transfection with siRNA ................................................................... 128 
3.2.1.4 Cells harvesting ................................................................................ 130 
  3.2.2 ALDH gene expression analysis after knockdown ............................ 130
  3.2.3 ALDH protein expression analysis after knockdown ......................... 131
  3.2.4 Cell proliferation and viability ............................................................ 131
  3.2.5 Cell cycle analysis ............................................................................ 131
  3.2.6 Detection of reactive oxygen species (ROS) ..................................... 132
  3.2.7 Detection of double strand DNA breaks ............................................ 134
  3.2.8 Cell migration ................................................................................... 134
  3.2.9 Drug cytotoxicity ............................................................................... 135
  3.2.10 Statistical data analysis .................................................................... 135
3.3 Results ................................................................................................. 136 
 3.3.1 Phenotypic appearance of DLD-1 cells after siRNA transfection and 
 culture under normoxic conditions ................................................................ 136
 3.3.2 Evaluation of ALDH mRNAs and protein expression after siRNA 
 transfection and culture under normoxic conditions ...................................... 139
 3.3.3 Phenotypic appearance of co-transfected DLD-1 cells cultured under 
 normoxic conditions ..................................................................................... 143
 3.3.4 Evaluation of ALDH mRNA and protein expression in co-transfected 
 cells cultured under normoxic conditions ...................................................... 143
 3.3.5 Phenotypic appearance after RNAi and culture of cells under hypoxic 
 conditions ..................................................................................................... 145
 3.3.6 Evaluation of ALDH mRNA and protein levels after siRNA transfection 
 and culture under hypoxic conditions ........................................................... 145
  3.3.7 The role of ALDH isoforms in cell proliferation .................................. 154
  3.3.8 Effects of ALDH isoforms on the cell cycle ....................................... 156
  3.3.9 The role of ALDH isoforms in ROS generation ................................. 157
ix 
  3.3.10 The role of ALDH in cell migration .................................................... 161
  3.3.11 Impact of ALDH expression on cell sensitivity to colon cancer drugs 163
3.4 Discussion ............................................................................................ 167 
Chapter 4: Towards identifying small molecules to clarify the functional role 
of ALDH7A1 ............................................................................................... 175 
4.1 Introduction .......................................................................................... 176 
4.2 Material and Methods ........................................................................... 179 
  4.2.1 Cell culture ....................................................................................... 179
  4.2.2 Evaluation of ALDH gene expression ............................................... 179
  4.2.3 Evaluation of ALDH7A1 protein expression ...................................... 180
  4.2.4 Evaluation of ALDH activity using the ALDEFLUOR assay ............... 180
  4.2.5 Effect of ALDH7A1 overexpression on cell proliferation .................... 181
  4.2.6 Effect of ALDH7A1 overexpression on cell migration ........................ 182
 4.2.7 Effect of ALDH7A1 overexpression on reactive oxygen species (ROS) 
 generation .................................................................................................... 182
  4.2.8 Effect of ALDH7A1 overexpression on double strand DNA damage . 183
  4.2.9 Effect of ALDH7A1 overexpression on osmoregulation .................... 183
  4.2.10 Effect of ALDH7A1 overexpression on spheroids formation .............. 184
  4.2.11 Effect of ALDH7A1 overexpression on spheroids invasion ............... 184
 4.2.12 Effect of ALDH7A1 overexpression on the anti-proliferative activity of 
 anticancer drugs .......................................................................................... 185
4.2.12.1 Drug stock solution ....................................................................... 185 
4.2.12.2 Drug treatment using the MTT assay ........................................... 187 
  4.2.13 Effect of Maybridge compounds on ROS generation ........................ 187
  4.2.14 Effect of Maybridge compounds on cell migration ............................. 188
  4.2.15 Statistical data analysis .................................................................... 188
4.3 Results ................................................................................................. 189 
  4.3.1 ALDH expression analysis ................................................................ 189
  4.3.2 ALDH activity .................................................................................... 189
  4.3.3 Effects of ALDH7A1 overexpression on cell proliferation .................. 192
  4.3.4 Effects of ALDH7A1 overexpression on cell migration ...................... 193
 4.3.5 Effect of ALDH7A1 overexpression on reactive oxygen species (ROS) 
 generation and DNA damage ....................................................................... 194
  4.3.6 Effect of ALDH7A1 overexpression on osmoregulation .................... 195
 4.3.7 Effect of ALDH7A1 overexpression on spheroids formation and invasion
  196
x 
  4.3.8 Effect of ALDH7A1 overexpression on anticancer drugs sensitivity .. 198
 4.3.9 H1299 cell survival upon treatment with non- specific ALDH inhibitors
  198
  4.3.10 Targeting ALDH7A1 activity using Maybridge compounds ................ 202
4.3.10.1 H1299 cell survival using the MTT assay .................................... 202 
4.3.10.2 The effect of Maybridge compounds on ROS generation ........... 204 
4.3.10.3 The effect of Maybridge compounds on cell migration ................ 207 
4.4 Discussion ............................................................................................ 210 
Chapter 5: General discussion, conclusion and future work ...................... 219 
Chapter 6: References ............................................................................... 234 
Appendix .................................................................................................... 262 
Appendix I: Composition and storage of cell culture media (Storage in brackets).
 ........................................................................................................................ 263 
Appendix II: Composition and storage of MTT assay solutions. ....................... 264 
Appendix III: qRT-PCR primers ........................................................................ 265 
Appendix IV: Solutions for molecular biology (Western blot) ............................ 266 
Appendix V: Primary and secondary antibodies for western blot ...................... 268 
Appendix VI: Buffers and antibodies for histology (IHC) ................................... 269 
Appendix VII: siRNAs information .................................................................... 270 
Appendix VIII: Solutions for spheroids formation and invasion ......................... 272 
Appendix IX: Raw data for ∆Ct values from qRT-PCR of ALDH1A1, 1A2, 1A3, 
1B1, 2, 3A1 and 7A1 in DLD-1 cells. ................................................................ 273 
Appendix X: Raw data for geometric mean values of area under the curve from 
ROS detection in DLD-1 cells after knockdown under normoxic and hypoxic 
conditions ........................................................................................................ 273 
Appendix XI: Raw data for geometric mean values of area under the curve from 
ROS detection in H1299 cells .......................................................................... 275 
Appendix XII: Abstracts presented to attended conferences ............................ 276 
  
xi 
List of Figures 
Figure 1 The Hallmarks of Cancer. .......................................................................... 3 
Figure 2 Diagram showing the principal differences between the vasculature of normal and 
malignant tissues. ............................................................................................... 5 
Figure 3 Regulation of HIF-1 activity by oncoproteins (red) and tumor suppressors (green).. . 8 
Figure 4 HIF target genes that encode proteins involved in crucial aspects of cancer 
progression. ..................................................................................................... 10 
Figure 5 Mechanism of cyclophosphamide drug resistance by the activity of ALDH. .......... 24 
Figure 6 The basis of the ALDEFLUOR assay. ......................................................... 31 
Figure 7 The Aldefluor and AldeRed-588-A substrates. .............................................. 35 
Figure 8 Colorectal cancer growth. ........................................................................ 43 
Figure 9 Expression profiling of ALDH1A1, 1A2, 1A3, 1B1, 2, 3A1 and 7A1 mRNAs in CRC 
monolayer cells. ................................................................................................ 76 
Figure 10 Histology of DLD-1 (A-D), HCT116 (E-H), HT29 (I-L) and SW480 (M-P) CRC 
monolayer cells. ................................................................................................ 78 
Figure 12 Influence of hypoxia on the expression of ALDH mRNA in HCT116 cells............ 79 
Figure 13 Influence of hypoxia on the expression of ALDH mRNA in HT29 cells. .............. 79 
Figure 14 Influence of hypoxia on the expression of ALDH mRNA in SW480 cells. ........... 80 
Figure 15 Western blot analysis of ALDH in DLD-1 cell line under normoxic (N) and hypoxic 
conditions (H) (48h exposure to 0.1% O2). .............................................................. 81 
Figure 16 Western blot analysis of ALDH in HCT116 cell line under normoxic (N) and hypoxic 
conditions (H) (48h exposure to 0.1% O2). .............................................................. 82 
Figure 17 Western blot analysis of ALDH in HT29 cell line under normoxic (N) and hypoxic 
conditions (H) (48h exposure to 0.1% O2). .............................................................. 83 
xii 
Figure 18 Western blot analysis of ALDH in SW480 cell line under normoxic (N) and hypoxic 
conditions (H) (48h exposure to 0.1% O2). .............................................................. 84 
Figure 19 HT29 spheroids growth using spinner flasks. .............................................. 86 
Figure 20 DLD-1 spheroids growth using spinner flasks. ............................................. 87 
Figure 21 Histology of HT29 spheroids.. ................................................................. 88 
Figure 22 Histology of DLD-1 spheroids. ................................................................. 89 
Figure 23 Hypoxia detection in HT29 (A) and DLD-1 (B) MCS. ..................................... 91 
Figure 25 The expression of ALDH mRNA in HT29 MCS. ........................................... 92 
Figure 26 ALDH protein expression profiling of HT29 MCS.. ........................................ 93 
Figure 27 ALDH protein expression profiling of DLD-1 MCS.. ...................................... 94 
Figure 28 The expression of ALDH mRNA in DLD-1 MCS. .......................................... 94 
Figure 29 Immunohistochemistry of ALDH1A1 in HT29 (A) and DLD-1 (B) MCS. .............. 95 
Figure 30 Immunohistochemistry of ALDH1A1 in colon cancer xenografts. ..................... 97 
Figure 31 Immunohistochemistry of ALDH1A3 in HT29 (A) and DLD-1 (B) MCS. .............. 98 
Figure 32 Immunohistochemistry of ALDH1A3 in colon cancer xenografts. ..................... 99 
Figure 33 Immunohistochemistry of ALDH3A1 in HT29 (A) and DLD-1 (B) MCS. ............ 100 
Figure 34 Immunohistochemistry of ALDH3A1 in colon cancer xenografts. ................... 101 
Figure 35 Immunohistochemistry of ALDH7A1 in HT29 (A) and DLD-1 (B) MCS. ............ 102 
Figure 36 Immunohistochemistry of ALDH7A1 in colon cancer xenografts. ................... 103 
Figure 37 Immunohistochemistry of CAIX in HT29 MCS. .......................................... 104 
Figure 38 Dose response curve of 24h CoCl2 treatment in HT29 and DLD-1 cell lines using 
the MTT assay. ............................................................................................... 105 
Figure 39 Western blot analysis of HIF-1α and ALDH7A1 protein expression upon treatment 
with CoCl2 in HT29 cells (A,B) and DLD-1 cells (C,D). .............................................. 106 
xiii 
Figure 40 ALDH7A1 expression in DLD-1 cells upon exposure to hypoxia for 24h, 48h and 
72h. ............................................................................................................. 107 
Figure 41 The expression of HIF1-α and HIF2-α mRNA in DLD-1 cells using qRT-PCR upon 
HIFs knockdown. ............................................................................................ 108 
Figure 42 The expression of ALDH7A1 after HIF knockdown. .................................... 109 
Figure 43 RNAi mechanism. Differences between siRNA, shRNA, and miRNA. ............. 125 
Figure 44 Phenotypic appearance of DLD-1 cells after ALDH Knockdown. .................... 136 
Figure 45 ALDH1A3 mRNA expression in ALDH1A3 siRNA transfected DLD-1 cells after 24h, 
48h and 72h of transfection. .............................................................................. 139 
Figure 46 ALDH3A1 mRNA and protein expression in ALDH3A1 siRNA transfected DLD-1 
cells after 24h, 48h and 72h of transfection. ........................................................... 140 
Figure 47 ALDH7A1 gene and protein expression in ALDH7A1 siRNA transfected DLD-1 cells 
after 24h, 48h and 72h of transfection. ................................................................. 141 
Figure 48 ALDH 1A3, 3A1 and 7A1 expression in ALDH (1A3, 3A1 or 7A1) siRNAs 
transfected DLD-1 cells after 24h, 48h and 72h of transfection. .................................. 142 
Figure 49 Phenotypic appearance of DLD-1 cells after ALDH3A1 and 7A1 co-knockdown. 143 
Figure 50 ALDH7A1 and ALDH3A1 expression in co-transfected DLD-1 cells (ALDH3A1&7A1 
siRNAs) after 24h, 48h and 72h of transfection.. ..................................................... 144 
Figure 51 Phenotypic appearance of DLD-1 cells after ALDH Knockdown under hypoxic 
conditions. ..................................................................................................... 146 
Figure 52 ALDH1A3 mRNA expression in ALDH1A3 siRNA transfected DLD-1 cells after 24h, 
48h and 72h of transfection under hypoxic conditions. ............................................. 149 
Figure 53 ALDH3A1 mRNA and protein expression in ALDH3A1 siRNA transfected DLD-1 
cells after 24h, 48h and 72h of transfection under hypoxic conditions. .......................... 149 
xiv 
Figure 54 ALDH7A1 mRNA and protein expression in ALDH7A1 siRNA transfected DLD-1 
cells after 24h, 48h and 72h of transfection under hypoxic conditions. .......................... 150 
Figure 55 ALDH1A3, 3A1 and 7A1 expression in ALDH1A3, 3A1 or 7A1 siRNAs transfected 
DLD-1 cells after 24h, 48h and 72h of transfection under hypoxic conditions. ................ 152 
Figure 56 ALDH7A1 and ALDH3A1 expression in co-transfected DLD-1 cells (ALDH3A1&7A1 
siRNAs) after 24h, 48h and 72h of transfection under hypoxic conditions.. .................... 153 
Figure 57 Live cells number using trypan blue assay after ALDH knockdown under normoxic 
conditions (A) or hypoxic conditions (B). ............................................................... 155 
Figure 58 Cell cycle analysis in ALDH7A1 or ALDH1A3 siRNAs transfected DLD-1 cells after 
24h, 48h, and 72h of transfection. ....................................................................... 156 
Figure 59 Detection of reactive oxygen species (ROS) generation in DLD-1 siRNA transfected 
cells after 72h of transfection under normoxic conditions. ......................................... 158 
Figure 60 Detection of reactive oxygen species (ROS) generation in DLD-1 siRNA transfected 
cells after 72h of transfection under hypoxic conditions. ........................................... 160 
Figure 61 DLD-1 cell migration after 72h of ALDH knockdown using scratch assay. Initial 
scratch (0h) and after 24h of migration (A), Migration rate after 24h (B). ....................... 162 
Figure 62 DLD-1 cell migration under normoxic (A) or hypoxic conditions (B) using scratch 
assay. .......................................................................................................... 163 
Figure 63 The cell survival of DLD-1 knockdown cells upon drug treatment under normoxic 
conditions using the trypan blue assay. ................................................................ 164 
Figure 64 The cell survival of DLD-1 knockdown cells upon drug treatment under hypoxic 
conditions using the trypan blue assay. ................................................................ 166 
Figure 65 The optimised binding model of HAN00316 compound to ALDH7A1. ............. 177 
Figure 66 The expression of ALDH in H1299/RFP and H1299/ALDH7A1 cells. .............. 190 
xv 
Figure 67 ALDH activity detection in H1299 isogenic cell pair using the ALDEFLUOR assay.
 ................................................................................................................... 191 
Figure 68 The effect of ALDH7A1 overexpression on H1299 cell proliferation using the MTT 
assay. .......................................................................................................... 192 
Figure 69 The effect of ALDH7A1 overexpression on H1299 cell migration using the scratch 
assay.. ......................................................................................................... 193 
Figure 70 The antioxidant properties of ALDH7A1 in H1299 isogenic cell pair. ............... 194 
Figure 71 Evaluation of phosphorylated H2AX as a marker of dsDNA damage in H1299/RFP 
and H1299/ALDH7A1 cells. ............................................................................... 195 
Figure 72 Cell survival of H1299 cell lines using the MTT assay after 24h of treatment with 
NaCl (A) or Sucrose (B). ................................................................................... 195 
Figure 73 H1299 spheroids using the hanging drop technique after 48h of cell seeding. ... 196 
Figure 74 Analysis of spheroids invasion............................................................... 197 
Figure 75 H1299 spheroids invasion after 48h of embedding in collagen matrix.............. 197 
Figure 76 The cell survival of H1299 isogenic cell pair after 96h exposure to conventional 
anticancer drugs using the MTT assay.. ............................................................... 199 
Figure 77 The cell survival of H1299 isogenic cell pair after 96h exposure to targeted 
anticancer drugs (TKIs) using the MTT assay......................................................... 200 
Figure 78 The cell survival of H1299 isogenic cell pair after 96h exposure to Disulfiram (A), 
Salinomycin (B) and Pargyline (C) using the MTT assay. .......................................... 201 
Figure 79 The cell survival of H1299 isogenic cell pair after 96h treatment with Maybridge 
compounds using the MTT assay. ....................................................................... 203 
Figure 80 The cell survival of H1299 isogenic cell pair after 24h treatment with DEAB (A), 
HAN00316 (B), KM06288 (C) and DSHS00561 (D) using the MTT assay. .................... 204 
Figure 81 The effect of Maybridge compounds on ROS generation in H1299/RFP cells. .. 205 
xvi 
Figure 82 The effect of Maybridge compounds on ROS generation in H1299/ALDH7A1 cells.
 ................................................................................................................... 206 
Figure 83 The migration rate of H1299/RFP and H1299/ALDH7A1 cells after treatment with 
DMSO, DEAB, DSHS00561, HAN00316 and KM06288 using the scratch assay. ........... 207 
Figure 84 The cell migration of H1299/RFP cells using the scratch assay. .................... 208 
Figure 85 The cell migration of H1299/ALDH7A1 cells using the scratch assay. ............. 209 
Figure 86 ALDH expression in a panel of 150 CRC cell lines. .................................... 223 
Figure 87 Catabolism of L-pipecolic acid.. ............................................................. 230 
 
  
xvii 
List of Tables 
Table 1 Invasive and non-invasive methods to measure tumour hypoxia. ......................... 6 
Table 2 Mechanisms of resistance (and sensitivity) of hypoxic cells to cytotoxic therapy. .... 11 
Table 3 ALDH superfamily, Tissue/Organ Distribution and Cellular Localisation. .............. 14 
Table 4 ALDH superfamily, Major substrates and Pathologies associated with altered 
expression. ...................................................................................................... 17 
Table 5 Cancers with identified stem cells and cells surface markers expressed.. ............. 28 
Table 6 TNM staging system of colorectal cancer. .................................................... 44 
Table 7 The number staging system of colorectal cancer.. .......................................... 44 
Table 8 Culture of colorectal cancer cell lines. .......................................................... 51 
Table 9 Cycling conditions of cDNA synthesis. ......................................................... 55 
Table 10 Q-RT-PCR cycling conditions. .................................................................. 57 
Table 11 Summary of ALDH1A1, 1A2, 1A3. 3A1 and 7A1 expression at the mRNA and 
protein levels upon exposure to 0.1% O2 for 48h. ...................................................... 85 
Table 12 Maintenance of H1299 cell lines. ............................................................ 179 
Table 13 Drug category, examples and mode of action. ........................................... 186 
Table 14 qRT-PCR primers. .............................................................................. 265 
Table 15 Primary and secondary antibodies for western blot. ..................................... 268 
Table 16 Primary and secondary antibodies for IHC. ............................................... 269 
 
  
xviii 
List of Abbreviations 
AASA: alpha-aminoadipic semialdehyde 
ABC: ATP binding cassette 
Ago-2: Argonaute-2 
AhR: aryl hydrocarbon receptor 
ALDHs: Aldehyde dehydrogenases 
AML: Acute myeloid leukaemia 
Amps: plural for ampere, a unit of electric current 
APC: Adenomatous polyposis coli 
APES: aminopropyltriethoxysilane 
AraC: 1-β-D-arabinofuranosylcytosine 
ARNT: Aryl hydrocarbon receptor nuclear translocator 
ATCC: American Type Culture Collection 
ATRA: All-trans retinoic acid 
AV: arteriovenous shunt 
BAA: BODIPY aminoacetate 
BAAA: BODIPY aminoacetaldehyde 
BAAA-DA: Bodipy-aminoacetaldehyde diethyl acetal 
BCAT1: Branched Chain Amino-Acid Transaminase 1 
BODIPY: Boron-dipyrromethene 
bps: base pairs 
BSA: bovine serum albumin 
˚C: Celsius 
CAIX: carbonic anhydrase IX 
cDNA: Complementary DNA 
c-Kit: proto-oncogene c-Kit 
cm: centimetre  
CO2: Carbon dioxide 
CoCl2: cobalt chloride 
CPA: Cyclophosphamide 
CCNG1: Cyclin-G1 
CRC: colorectal carcinoma 
CSCs: Cancer stem cells 
CYPs: Cytochromes P450 
d: Day 
2D: two dimensional 
3D: three dimensional 
DAB: 3,3-diaminobenzidine 
DAC: Decitabine 
DCIS: ductal carcinoma in situ 
DEAB: Diethylaminobenzaldehyde 
DMEs: Drug metabolising enzymes 
DMSO: Dimethyl sulfoxide 
DNA: Deoxyribonucleic acid 
dNTPs: Deoxynucleotide triphosphate 
dsDNA: double-stranded DNA 
dsRNA: double-stranded RNA 
EBV: Epstein-Barr virus  
ECM: extracellular matrix 
EDTA: Ethylene diaminetetracetic acid 
EGF: epidermal growth factor  
EGFR: epidermal growth factor receptor 
ELISA: enzyme-linked immunosorbent assay. 
EMT: epithelial-to-mesenchymal transition 
EPAS1: Endothelial PAS-domain protein 1 
ERK: extracellular-signal-regulated kinases 
FACS: Flurescence activated cell sorting 
xix 
FBS: foetal bovine serum 
FGFR: fibroblast growth factor receptor 
5-FU: 5-Fluoro Uracil 
g: gram 
G1 phase: Gap 1 phase 
G2 phase: Gap 2 phase 
GFP: green fluorescent protein 
h: hours 
HCl: hydrochloric acid 
H2AX: histone family, member X 
H2DCFDA: dichlorodihydrofluorescein 
H2O2: hydrogen peroxide 
HB-EGF: heparin-binding EGF-like factor 
HBV: hepatitis B virus 
4-HCPA: 4–hydroperoxycyclophosphamide 
H & E: Haematoxylin and Eosin 
HIFs: Hypoxia inducible factors 
HIF1: Hypoxia inducible factor 1 
4HNE: 4-Hydroxynonenal 
HPV: human papilloma virus 
HR: hypoxic region 
HSC: haematopoietic SC 
JNK: c-Jun N-terminal kinases 
KSHV: Kaposi sarcoma herpesvirus 
ICT: Institute of Cancer Therapeutics 
IHC: immunohistochemistry 
KIT: v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
l: litre 
LDH-A: lactate dehydrogenase A  
LPO: lipid peroxidation 
m: milli 
m: meter 
M: Molar 
MAPK: Mitogen-activated protein kinases 
MAO: monoamine oxidase 
MCS: Multicellular spheroids 
MDR: Multidrug resistance 
MET: Met proto-oncogene 
min: minutes 
miRNA: microRNA 
MgCl2: magnesium chloride 
ml: milli litre  
ML: monolayer 
MMP: matrix metalloproteinases 
M phase: Mitosis phase 
MRI: Magnetic resonance image 
mRNA: Messenger Ribonucleic acid 
MRS: Magnetic resonance spectroscopy 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
n: nano 
NaCl: sodium chloride 
NAD
+
: Nicotinamide adenine dinucleotide 
NADP
+
: Nicotinamide adenine dinucleotide phosphate 
NaOH: Sodium hydroxide 
N-BPs: nitrogen-containing bisphosphonates N-BPs 
NM: nodular melanoma 
NSCLC: non-small cell lung cancer 
O2: oxygen 
PAX: Paclitaxel 
xx 
PBS: Phosphate buffered saline 
PBST: PBS Tween 20 
PDE: pyridoxine-dependent epilepsy 
PDGFRA: Platelet-derived growth factor receptor, alpha polypeptide 
PET: Positron emission tomography 
PPARG: Peroxisome proliferator-activated receptor gamma 
PTEN: Phosphatase and tensin homolog 
Q-RT-PCR: quantitative real time polymerase chain reaction 
RA: retinoic acid 
rcf: relative centrifugal force 
RET: proto-oncogene encodes a receptor tyrosine kinase  
RFP: red fluorescent protein 
RISC: RNA-induced silencing complex 
RNA: Ribonucleic acid 
RNAi- RNA interference 
rpm: Revolutions per minute 
ROS: Reactive oxygen species 
RQ: Relative quantity 
s: second 
SCID: Severe combined immunodeficient 
SD: Standard deviation 
SDS: sodium dodecyl sulfate 
shRNAs: short hairpin RNAs 
siRNAs: small interfering RNAs 
SL: surface layer 
SPECT: Single photon emission computed tomography 
S phase: Synthesis phase 
Src: Proto-oncogene tyrosine-protein kinase 
SSM: superficial spreading melanoma 
t; time 
t: test 
TEMED: Tetramethylethylenediamine 
TICs: tumour-initiating cells 
TKIs: tyrosine kinase inhibitors 
TNM: tumour, node and metastasis 
TP53: Tumour suppressor p53 
TRBP: TAR-RNA-binding protein 
TSG: Tumour suppresser gene 
UK: United Kingdom 
UV: Ultraviolet 
v:volume 
VEGFA: Vascular endothelial growth factor A 
VEGFR: Vascular endothelial growth factor receptor 
VHL: Von Hippel–Lindau 
Volt: voltage 
XREs: xenobiotic response element 
ZOL: zoledronic acid 
µ: micro 
 
 
 
1 
 
 Chapter 1: Introduction 
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1.1 Cancer definition and epidemiology 
Cancer is considered as the foremost cause of death in developed countries 
and the second cause of death in developing countries with more than 200 
different types of cancer registered to date (Jemal et al., 2011). Worldwide, 
prostate cancer is the most common type in male and breast cancer in 
female. In 2008, about 12.7 million new cases and 7.6 million cancer deaths 
were reported with the most common cause of death being breast cancer 
and lung cancer in females and males, respectively (Jemal et al., 2011). 
Colorectal cancer (CRC) is the second leading cause of cancer deaths 
worldwide and is described in greater detail in Chapters 2 and 3 of this 
thesis. 
Cancer is defined as a condition where certain cells in the body have lost the 
ability to control their growth and started to replicate in a limitless manner. 
Such cells may also have acquired the ability to invade and destroy the local 
healthy tissues. In addition, they can spread to another part of the body away 
from their primary location in a process known as metastasis. 
1.2 Hallmarks of cancer 
The hallmarks of cancer were early described to comprise six biological 
capabilities acquired during the multistep development of human tumours, 
which have essential roles in contributing to tumour complexity. They include 
sustaining proliferative signalling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis (Figure 1A) (Hanahan and Weinberg, 2000). In 2011 
Hanahan and Weinberg described two enabling characteristics underlying 
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these hallmarks including genome instability and inflammation (Hanahan and 
Weinberg, 2011). In addition, advances in cancer research during the last 
decade have added two emerging hallmarks of potential generality to this list 
including reprogramming of energy metabolism and evading immune 
destruction (Hanahan and Weinberg, 2011) (Figure 1B).  
A 
B 
Figure 1 The Hallmarks of Cancer. The six hallmark capabilities originally proposed in 
Hanahan and Weinberg, 2000 review (A), Emerging Hallmarks and Enabling 
Characteristics described in Hanahan and Weinberg, 2011 review. Adopted from 
Hanahan and Weinberg, 2011 with License Number: 3833250420363. 
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Tumours exhibit another dimension of complexity relating to the presence of 
unique tumour microenvironments, which are less easily assayed but have 
profound effects on cancer progression (Semenza, 2016). The tumour 
microenvironment can be subdivided into the cellular microenvironment and 
the chemical microenvironments. The former includes tumour cells, stromal 
cells, and the extracellular matrix (ECM) produced by these cells. The 
chemical microenvironment encompasses pH, PO2 and the concentration of 
other small molecules (e.g. NO) and metabolites (e.g. glucose, glutamine, 
lactate) (Semenza, 2016). Tumour hypoxia (low PO2) contributes to the 
foundation of chemical tumour microenvironment, which has biological and 
therapeutic implications such as stimulating tumour proliferation, 
aggressiveness and drug resistance (Mathonnet et al., 2014). Here, the role 
of hypoxia in cancer progression will be discussed further. 
1.3 Tumour hypoxia 
Human cells require adequate oxygen supply for their proliferation, survival, 
metabolism and other biological functions (Dachs and Tozer, 2000, 
Semenza, 2012). In normal cells, both the delivery and consumption of O2 
are highly regulated processes. In contrast, these processes are altered 
during tumour pathogenesis and therefore most solid tumours larger than 1 
mm3 contain regions of low oxygen tension (hypoxia) due to imbalances 
between O2 supply and consumption (Hockel and Vaupel, 2001, Dachs and 
Tozer, 2000).  
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 Causes of hypoxia 1.3.1
The tumour hypoxia initially arises due to limitations in oxygen diffusion in the 
primary or metastatic tumours (Wilson and Hay, 2011). Cells that are located 
next to the perfused blood vessel are exposed to relatively high O2 
concentrations, which decline steeply as distance from the vessel increases 
(Semenza, 2010). As a consequence, cells at low oxygen level respond by 
generating new vessel growth from the existing vasculature structure 
surrounding the tumour in a process known as angiogenesis (Liao and 
Johnson, 2007, Semenza, 2010, Dachs and Tozer, 2000). However, the new 
vasculature is often structurally and functionally abnormal and therefore, 
does not adequately or consistently supply the whole tumour with oxygen 
and nutrients (Wilson and Hay, 2011). As a result of chaotic vasculature, 
irregular blood and oxygen flow cancer cells experience hypoxia (Semenza, 
2010) (Figure 2). 
Figure 2 Diagram showing the principal differences between the vasculature of normal and 
malignant tissues. AV: arteriovenous shunt. Adopted from (Brown and Giaccia, 1998) with License 
Number: 3833250840650. 
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 Measuring tumour hypoxia  1.3.2
Many invasive and non-invasive methods are currently available to measure 
the oxygen levels of tumours in both animal models and humans (Hockel and 
Vaupel, 2001). Hypoxia in human tumours has been measured by oxygen 
sensitive electrodes and by hypoxia marker techniques using various labels 
that can be detected by different methods such as positron emission 
tomography (PET), single photon emission computed tomography (SPECT), 
magnetic resonance spectroscopy (MRS), autoradiography, and 
immunohistochemistry (Sutherland, 1998, Hockel and Vaupel, 2001) (Table 
1). 
  Methods to measure tumour hypoxia 
1. Invasive microsensor techniques for direct tissue pO2 measurements 
• Polarographic O2 sensors  
• Luminescence-based optical sensors  
2. Electron paramagnetic resonance oximetry 
3.Techniques for intravascular O
2
 detection 
• Cryospectrophotometry [HbO
2
 saturation] 
• Near-infrared spectroscopy [HbO
2
 saturation] 
• Phosphorescence imaging  
4. Nuclear magnetic resonance spectroscopy and imaging techniques 
• 1H-MRI, BOLD effect  
• 19F-magnetic resonance relaxometry 
5. Non-invasive detection of sensitizer adducts 
• [18F]Fluoromisonidazole [PET] 
• [123I]Iodoazomycin-arabinoside [SPECT] 
6. Invasive immunohistochemical hypoxia marker techniques 
• Misonidazole [3H-labeled] 
• Pimonidazole 
• Etanidazole 
• Nitroimidazole-theophylline 
• Carbonic anhydrase IX (CAIX) 
• Glucose transporter (Glut-1) 
Table 1 Invasive and non-invasive methods to measure tumour hypoxia. Adopted from 
(Hockel and Vaupel, 2001) with License Number: 3833260663039. 
7 
 
 Hypoxia-inducible factors 1.3.3
The major mechanism mediating adaptive responses to reduced O2 
availability (hypoxia) is the regulation of transcription by hypoxia-inducible 
factors (HIFs) (Carroll and Ashcroft, 2005, Poon et al., 2009, Rohwer et al., 
2013). In the process of doing so, hypoxic cancer cells acquire invasive and 
metastatic properties as well as resistance to certain chemotherapeutic 
agents and radiation therapy, which together constitute lethal cancer 
phenotypes that ultimately lead to patient mortality (Dachs and Tozer, 2000, 
Semenza, 2010). 
The HIF transcriptional complex exists as heterodimers, consisting of alpha 
and beta subunits. There are three isoforms of the alpha subunit which are 
tightly regulated at the protein level by changes in cellular oxygen tension: 
HIF-1α, HIF-2α (also known as endothelial PAS-domain protein 1, EPAS1), 
and HIF-3α (Bárdos and Ashcroft, 2005). The HIF-β isoforms, also known as 
aryl hydrocarbon receptor nuclear translocator (ARNT), are constitutively and 
ubiquitously expressed across many cell types and are not sensitive to 
oxygen levels (Dachs and Tozer, 2000, Heddleston et al., 2010). 
The majority of primary human cancers and their metastases are 
characterised by increased levels of HIF-1α or HIF-2α protein (or both) 
compared to normal tissues, with intra-tumoural hypoxia being the major 
cause of their upregulation (Carroll and Ashcroft, 2005, Semenza, 2010, 
Rohwer et al., 2013). Little is known about the third isoform, HIF-3α. Some 
evidence indicates HIF-3α to be involved in the negative feedback regulation 
of HIF-1 because its expression is transcriptionally regulated by the latter 
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(Bárdos and Ashcroft, 2005, Semenza, 2010). However, the primary function 
and regulatory mechanism of HIF-3α is still to be elucidated (Heddleston et 
al., 2010, Balamurugan, 2016). 
In addition to intra-tumoural hypoxia, genetic and epigenetic alterations 
resulting in oncogene gain of function or tumour suppressor gene (TSG) loss 
of function (most notably, von Hippel–Lindau, VHL) also affect HIF levels 
either by increasing HIF-1α synthesis or by reducing HIF-1α degradation 
(Bárdos and Ashcroft, 2004, Bárdos and Ashcroft, 2005, Asby et al., 2014) 
(Figure 3). This results in HIF-1α upregulation even under normoxic 
conditions (Bárdos and Ashcroft, 2005). In addition, a large number of 
proteins encoded by transforming viruses that cause tumours in humans also 
induce HIF-1 activity (Nakamura et al., 2009). For example, herpes virus 
which causes Kaposi sarcoma, encodes three different proteins that together 
increase HIF-1α protein half-life, nuclear localisation, and transactivation 
under non-hypoxic conditions, thereby mimicking the effect of hypoxia 
(Semenza, 2010, Semenza, 2012). 
Figure 3 Regulation of HIF-1 activity by oncoproteins (red) and tumor suppressors (green). Transforming 
proteins encoded by Epstein-Barr virus (EBV), hepatitis B virus (HBV), human papilloma virus (HPV), and Kaposi 
sarcoma herpesvirus (KSHV) also activate HIF-1. Adopted from (Semenza, 2012) with License Number: 
3833251190781. 
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 Hypoxia-inducible factors in cancer progression 1.3.4
Many biologic parameters that affect the malignant potential of a neoplasm 
have been found to be affected by hypoxia (Hockel and Vaupel, 2001, 
Semenza, 2012) (Figure 4). These include the selection of genotypes that 
can survive hypoxia-reoxygenation injury (Verduzco et al., 2015), pro-
survival changes in gene expression that suppress apoptosis (Carroll and 
Ashcroft, 2005) and support autophagy (Bellot et al., 2009) and the anabolic 
switch in energy metabolism (Weljie and Jirik, 2011, Song et al., 2009, Yang 
et al., 2012, Zeng et al., 2015). In addition, hypoxia enhances autocrine 
growth factor signalling that results in increased cell proliferation (Barr et al., 
2008), tumour angiogenesis (Koukourakis et al., 2002), the epithelial-to-
mesenchymal transition (EMT) (Jiang et al., 2011), stem cell maintenance 
(Heddleston et al., 2010, Li et al., 2013), invasiveness and metastasis 
(Gruber et al., 2004), as well as suppression of the immune response 
(Doedens et al., 2010, Ruan et al., 2009, Semenza, 2012). 
Hypoxia also contributes to loss of genomic stability through the increased 
generation of reactive oxygen species (ROS) (Kondoh et al., 2013) and the 
downregulation of DNA repair pathways (Wilson and Hay, 2011, Luoto et al., 
2013, Zeng et al., 2015). Furthermore, hypoxia has been found to be 
implicated in cancer cell resistance to radiotherapy and certain 
chemotherapeutic agents through multiple mechanisms (Wilson and Hay, 
2011, Warfel and El-Deiry, 2014) (Table 2). 
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Figure 4 HIF target genes that encode proteins involved in crucial aspects of cancer progression. 
Adopted from (Semenza, 2012) with License Number: 3833251190781.. 
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Table 2 Mechanisms of resistance (and sensitivity) of hypoxic cells to cytotoxic therapy. BCL2-associated X 
protein (BAX), BH3 interacting domain death agonist (BID), dihydrofolate reductase (DHFR), double strand break 
(DSB), hypoxia-inducible factor 1 (HIF1), homologous recombination (HR), multidrug resistance protein 1 (MDR1), 
mismatch repair (MMR), nucleotide excision repair (NER), non-homologous end joining (NHEJ), poly(ADP-ribose) 
polymerase (PARP). Adopted from (Wilson and Hay, 2011) with License Number: 3833260919909. 
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1.4 Aldehyde dehydrogenase superfamily 
Although the effect of hypoxia on drug sensitivity is well known, the impact of 
low oxygen tension on drug metabolising enzymes that also play a role in 
signalling pathways, such as aldehyde dehydrogenases (ALDH), is still to be 
elucidated. Accordingly, the main focus of this project is to study the impact 
of hypoxia on the expression of ALDH. 
 Aldehyde compounds 1.4.1
Aldehyde-containing agents are considered as highly reactive electrophilic 
molecules that originated from various internal and external sources during 
multiple physiological processes. Endogenous aldehydes can be generated 
from the metabolism of many agents including neurotransmitters, amino 
acids, lipids, and carbohydrates, as well as through metabolism of vitamins 
(retinoic acid biosynthesis) and steroids (Marchitti et al., 2008, Elizondo et 
al., 2000). Among the external sources of aldehydes, the metabolism of 
some xenobiotics and drugs including ethanol and anticancer prodrugs (e.g. 
cyclophosphamide (CPA) and ifosfamide) contribute to aldehyde production. 
In addition, many industrial applications such as resins, polyurethane and 
polyester plastics manufacturing use or generate aldehydes. Many 
aldehydes are also present in food either as naturally occurring or approved 
additives to enhance flavour and odour. Moreover, many aldehydes are 
present in the environment as a result of cigarette smoke and motor vehicle 
exhaust (Marchitti et al., 2008). 
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 ALDH in normal physiological processes 1.4.2
Aldehydes have important contribution to normal physiological processes, 
such as embryonic development, vision and neurotransmission. However, 
many of them are very harmful and have been shown to elicit both cytotoxic 
and carcinogenic effects (Vasiliou and Nebert, 2005). Aldehydes react with 
cellular components including nucleic acids and amino acids, which have 
direct or indirect effects on cellular homeostasis, enzyme inactivation, DNA 
damage, and cell death (Marchitti et al., 2008). 
The aldehyde dehydrogenase (ALDH) superfamily belongs to phase 1 drug 
metabolising enzymes (DMEs) and plays an important role in the metabolism 
of a wide range of aliphatic and aromatic aldehydes (Sládek, 2003). These 
enzymes catalyse the irreversible oxidation and conversion of aldehydes into 
their corresponding carboxylic acids through pyridine nucleotide-dependent 
reaction (Vasiliou et al., 2004). The hydrogen acceptor in this reaction is 
usually NAD+, however, NADP+ has also been shown to serve as a cofactor 
in certain cases of some of these enzymes (Sládek, 2003). 
The ALDH superfamily is represented in all three taxonomic domains 
(Archaea, Eubacteria and Eukarya), suggesting a vital role throughout 
evolutionary history (Jackson et al., 2011). Mammalian ALDH activity was 
first detected in ox liver more than five decades ago (Farres et al., 1989), 
after which many types of ALDH have been identified based on their physico-
chemical characteristics, enzymological properties, subcellular localisation, 
and tissue distribution (Yoshida et al., 1998) (Table 3). 
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ALDH Tissue/Organ Distribution 
Cellular 
Localisation 
1A1 
Liver, kidney, erythrocytes, skeletal muscle, lung, breast, 
lens, stomach mucosa, brain, pancreas, testis, prostate, 
ovary 
Cytosol 
1A2 Testis, small amounts in liver, kidney Cytosol 
1A3 
Kidney, skeletal muscle, lung, breast, testis, stomach 
mucosa, salivary,  glands 
Cytosol 
1B1 
Liver, kidney, heart, skeletal muscle, brain, prostate, lung, 
testis, placenta, more 
Mitochondria 
1L1 Liver, kidney, skeletal muscle Cytosol 
1L2 Pancreas, heart, brain Mitochondria 
2 
Liver, kidney, heart, skeletal muscle, lung, lens, brain, 
pancreas, prostate, spleen 
Mitochondria 
3A1 
Stomach mucosa, cornea, breast, lung, lens, esophagus, 
salivary glands, skin 
Cytosol 
3A2 
Liver, kidney, heart, skeletal muscle, lung, brain, 
pancreas, placenta, most tissues 
Endoplasmic reticulum 
3B1 Kidney, lung, pancreas, placenta 
Cytosol and  
Endoplasmic reticulum 
3B2 Parotid gland 
Cytosol and 
Endoplasmic reticulum   
4A1 
Liver, kidney, heart, skeletal muscle, brain, placenta, lung, 
pancreas, spleen 
Mitochondria 
5A1 Liver, kidney, heart, skeletal muscle, brain Mitochondria 
6A1 Liver, kidney, heart, skeletal muscle Mitochondria 
7A1 
Fetal liver, kidney, heart, lung, brain, ovary, eye, cochlea, 
spleen, adult spiral cord 
Cytosol, Mitochondria 
and nucleus  
8A1 Liver, kidney, brain, breast, testis Cytosol 
9A1 
Liver, kidney, heart, skeletal muscle, brain, pancreas, 
adrenal gland, spinal cord 
Cytosol 
16A1 Neuronal cells Cytosol  
18A1 
Kidney, heart, skeletal muscle, pancreas, testis, prostate, 
spleen, ovary, thymus 
Mitochondria 
Table 3 ALDH superfamily, Tissue/Organ Distribution and Cellular Localisation. Adopted from (Ma and Allan, 
2011) with License Number: 3833601253515. 
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The standardised gene nomenclature system for the ALDH superfamily was 
established in 1998 based on divergent evolution and amino acid identity 
(Marchitti et al., 2008), in which the families within the superfamily shared 
more than 40% sequence identity and members of the same subfamily 
shared more than 60% sequence identity. To date, the human genome 
contains 19 known functional ALDH genes, divided into 11 families and 4 
subfamilies, and three pseudogenes (Black et al., 2009, Vasiliou et al., 
2004). 
ALDH isoforms are characterised by a wide tissue distribution, with the 
highest expression most often occurring in the liver and/or kidney (Sládek, 
2003). Furthermore, they are found in all cellular regions such as cytosol, 
endoplasmic reticulum, nucleus and mitochondria with many of them located 
in more than one organelle (Jackson et al., 2011). It has been shown that 
ALDH isoforms located in regions other than the cytosol have leader or 
signal sequences that allow their translocation to specific cellular locations 
(Braun et al., 1987). In addition, ALDH enzymes that are present in the 
nucleus have been suggested to have effects on gene expression and 
cellular proliferation (Marchitti et al., 2008, Chan et al., 2011). ALDH 
enzymes have also been shown to have broad substrate specificity (Yoshida 
et al., 1998) although the preferred substrates have been identified for most 
of them (Sládek, 2003).  
The physiological role of several of the human ALDH isoforms is yet to be 
elucidated, however, the activity of certain ALDH has been shown to be 
critical in the detoxification of specific endogenous and exogenous aldehyde 
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substrates and in the prevention of their accumulation (Jackson et al., 2011). 
This capacity has a critical role in the protection of cellular homeostasis and 
organismal functions against toxic effects of the aldehydes (Jackson et al., 
2011). The ALDH activity, through aldehyde metabolism, has also been 
found to be essential for the synthesis of vital molecules such as retinoic acid 
(RA), betaine and gamma-aminobutyric acid that are important for cell 
proliferation, differentiation and survival (Jackson et al., 2011). 
Apart from their importance in aldehyde metabolism, members of ALDH 
superfamily also have other catalytic functions, although many of these are 
yet to be clearly defined, including ester hydrolysis (ALDH1A1, ALDH2, 
ALDH4A1), nitrate reductase activity (ALDH2) and drug bioactivation 
(ALDH2) (Marchitti et al., 2008, Vasiliou and Nebert, 2005). In addition, some 
members of ALDH superfamily have the capacity for non-catalytic functions 
such as, antioxidant functionalities (ALDH1A1, ALDH3A1, ALDH7A1), 
osmoregulation (ALDH7A1) and the absorption of ultraviolet (UV) light 
(ALDH1A1, ALDH3A1). In addition, some enzymes (ALDH1A1, ALDH1L1, 
ALDH2) have been found to act as binding proteins for many endogenous 
(e.g., androgen, cholesterol and thyroid hormone) and exogenous (e.g., 
acetaminophen) compounds (Black et al., 2009, Jackson et al., 2011). 
The clinical importance of ALDH superfamily is supported by the fact that 
mutations and polymorphism in ALDH genes, leading to failure of aldehyde 
metabolism, are considered as the molecular basis of several disease 
conditions and metabolic anomalies (Ma and Allan, 2011) (Table 4).  
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ALDH Major substrates 
Pathologies associated with altered 
expression 
1A1 
Retinal, aldophosphamide, acetaldehyde, 
lipidperoxidation-derived aldehydes 
Drug resistance, alcohol sensitivity 
1A2 Retinal Tumours 
1A3 Retinal Perinatal lethality 
1B1 
Acetaldehyde, lipid peroxidation-derived 
aldehydes 
Various phenotypes 
1L1 10-Formyltetrahydrofolate Tumours 
1L2 10-Formyltetrahydrofolate - 
2 Acetaldehyde, nitroglycerin 
Ethanol-induced cancers, 
Hypertension, Alcohol sensitivity 
3A1 
Medium-chain aliphatic and aromatic 
aldehydes 
Tumours 
3A2 Long-chain aliphatic aldehydes Sjögren–Larsson syndrome 
3B1 Lipid peroxidation-derived aldehydes Paranoid schizophrenia 
3B2 Unknown - 
4A1 Proline metabolism Type II hyperprolinemia 
5A1 Succinic semialdehyde Neurological disorders 
6A1 Methylmalonate semialdehyde 
Elevated levels in urine of β-alanine, 
3-hydroxypropionicacid, 3-amino 
acids, and 3-hydroxyisobutyric acids 
7A1 
Betaine aldehyde, lipid peroxidation-
derived aldehydes 
Hyperosmotic stress 
8A1 Retinal - 
9A1 γ-Aminobutyraldehyde, aminoaldehydes - 
16A1 Unknown - 
18A1 Glutamatic γ-semialdehyde 
Hypoprolinemia, hypoornithinemia, 
hypocitrullinemia,hypoargininemia, 
hyperammonemia with cataract 
formation, neurodegeneration, 
connective tissue anomalies 
Table 4 ALDH superfamily, Major substrates and Pathologies associated with altered expression. 
Adopted from (Ma and Allan, 2011) with License Number: 3833601253515 and (Muzio et al., 2012) with License 
Number: 3833601442994 . 
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 ALDH in cancer 1.4.3
ALDH isoforms play important physiological functions as mentioned earlier, 
however their presence has implications in drug sensitivity and clinical 
prognosis while also being employed as a cancer stem cell marker (Pors and 
Moreb, 2014). In the following sections, the most prominent ALDH isoforms 
will be described. 
ALDH1A2 is a cytoplasmic enzyme that is involved in retinoic acid (RA) 
synthesis, which is known to enhance cell differentiation, growth arrest and 
apoptosis (De Luca, 1991). ALDH1A2 has been found to be downregulated 
in prostate cancer compared to normal prostate tissues (Kim et al., 2005). In 
addition, suppression of colony growth has been observed after transfection-
mediated re-expression of ALDH1A2 in DU145 prostate cancer cells, 
indicating ALDH1A2 acts as a tumour suppressor gene (TSG) in prostate 
cancer (Kim et al., 2005). 
The expression of ALDH1L1, 10-formyltetrahydrofolate dehydrogenase, has 
also been found to be associated with suppression of cancer cell 
proliferation. This cytoplasmic enzyme was found to be downregulated in 
several types of cancer including liver, lung, prostate, pancreas and ovarian 
cancers (Krupenko and Oleinik, 2002). In addition, transient expression of 
ALDH1L1 in many human cancer cell lines including prostate, hepato-
carcinoma, and lung cancer cell lines resulted in the suppression of cell 
proliferation and increased cytotoxicity (Krupenko and Oleinik, 2002) through 
induction of G1 cell cycle arrest and caspase dependent apoptosis (Oleinik 
and Krupenko, 2003). It is known that 10-formyltetrahydrofolate is required 
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for de novo purine biosynthesis and therefore, the ultimate impact of the 
depletion of intracellular 10-formyltetrahydrofolate by ALDH1L1 activity is 
diminished DNA/RNA biosynthesis. Hence, downregulation of ALDH1L1 in 
tumours has been proposed to be one of the cellular mechanisms that 
enhance cancer cell proliferation (Krupenko and Oleinik, 2002). 
In contrast to ALDH1A2 and ALDHL1, several other ALDH isoforms have 
been suggested to be associated with malignant transformation (Ucar et al., 
2009). ALDH1A1 is a cytosolic isoform that is crucial in regulating RA 
signalling and is expressed in tissues during vertebrate development 
(Yanagawa et al., 1995). Its expression in non-small cell lung cancer 
(NSCLC) was found to gradually increase during the transition from normal 
to adenocarcinoma (Patel et al., 2008). In addition, its expression in primary 
colon cancer samples was found to be significantly associated with shorter 
overall survival rates, suggesting its clinical relevance as a prognostic or 
predictive marker in colorectal carcinoma (CRC) (Kahlert et al., 2012). 
ALDH1A3, a cytoplasmic enzyme that is also involved in RA synthesis, has 
been found to be downregulated in many tumour types including breast, 
gastric and colon cancers (Okamura et al., 1999, Yamashita et al., 2006, 
Rexer et al., 2001). In contrast, its expression has been found to be 
upregulated in mice that are resistant to induced mammary tumours 
suggesting that it might have tumour suppression properties (Kuperwasser et 
al., 2000). Conflicting information on ALDH1A3 has however been reported 
as more recent studies support a role for this enzyme in cancer malignancy 
as it correlates significantly with tumour grade, metastasis, and cancer stage 
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in breast cancer patients (Marcato et al., 2011b). In addition, a recent 
investigation revealed that ALDH1A3 is overexpressed in clinical high grade 
glioma tissues compared to low grade glioma or normal brain (Mao et al., 
2013). ALDH1A3 was also found to be closely associated with clinical 
pathological behaviours, poor prognosis and decreased overall survival in 
patients with gallbladder cancer as it is associated with lymph node 
metastasis and invasion (Yang et al., 2013). Furthermore, ALDH1A3 appears 
to be highly expressed in cancer stem cells (CSCs) of the breast, 
gallbladder, glioma, melanoma and prostate and hence could be a 
contributing factor to cancer and malignancy (Pors and Moreb, 2014). 
ALDH1B1 is a mitochondrial isoform that is catalytically active towards a 
wide range of aldehyde substrates, including aliphatic and aromatic 
aldehydes and the products of lipid peroxidation (LPO). 
Immunohistochemical studies have shown approximately 5-fold higher 
expression of ALDH1B1 compared to ALDH1A1 in some cancer tissues 
(breast, lung, ovarian and colon cancer). Furthermore, 98% of colon cancer 
samples (39/40) were stained positive for ALDH1B1 using 
immunohistochemistry (Chen et al., 2011). 
The ALDH2 isoform is a mitochondrial enzyme and predominantly linked with 
acetaldehyde detoxification in alcohol metabolism (Yokoyama et al., 1998). 
Diminished activity of ALDH2 enzyme caused by a mutant allele has been 
found to dramatically increase the risk for oesophageal cancer (Yokoyama et 
al., 1998). However, its expression in leukaemia and lung cancer has been 
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associated with higher cancer cell proliferation rates and higher clonal 
efficiency (Moreb et al., 2012). 
ALDH3A1 is a cytoplasmic enzyme and plays an important role in cellular 
homeostasis through protection from ROS generated under oxidative stress 
(Pappa et al., 2003a, Pappa et al., 2003b). Chang et al. reported the 
increased expression of ALDH3A1 in hepatocellular carcinoma tissues 
derived from 50% of patients, while no detectable level was observed in 
normal liver (Chang et al., 1998). ALDH3A1 inhibition or deficiency has also 
been shown to strongly inhibit hepatoma cellular growth (Muzio et al., 2003). 
In addition, ALDH3A1 has been shown to be among the genes that were 
highly upregulated in mechanically-induced colon cancer cell population and 
correlated with cancer cell migration and invasion in athymic nude mice 
(Tang et al., 2014). 
In NSCLC, ALDH3A1 together with ALDH1A1 were found to be highly 
expressed in both cancer cell lines and primary tumour samples (Patel et al., 
2008). In addition, the expression of both enzymes has been observed to 
gradually increase during the transition from normal to atypical pneumocyte, 
carcinoma in situ and adenocarcinoma (Patel et al., 2008). Moreover, 
elevation in their expression in normal pneumocytes has been shown to be 
induced by cigarette smoking (Patel et al., 2008). ALDH3A1 has been 
suggested as a potential diagnostic marker for NSCLC (Kim et al., 2007) and 
it might serve as a candidate biomarker in the pathogenesis of oesophageal 
squamous cell carcinoma (Huang et al., 2000). 
22 
 
ALDH3B1 is a cytosolic isoform whose enzymatic activity is directed towards 
various aldehyde substrates including 4-Hydroxynonenal (4HNE), one of the 
most reactive and cytotoxic aldehydes formed during LPO. Marchitti et al. 
reported high expression of ALDH3B1 in a high percentage of human 
tumours (lung > breast = ovarian > colon) where it was shown to play an 
important physiological role against oxidative stress (Marchitti et al., 2010). 
ALDH4A1 is a mitochondrial enzyme catalysing the second step of the 
proline degradation pathway. Expression of ALDH4 mRNA was found to be 
upregulated in HCT116 colon cancer cells in response to DNA damage 
caused by adriamycin treatment (Yoon et al., 2004). In addition, induction of 
overexpression of ALDH4 in H1299, a NSCLC cell line, showed lower 
intracellular ROS levels than parental or control cells after treatment with 
hydrogen peroxide (H2O2) or UV. These findings suggest that it has 
protective role against oxidative stress (Yoon et al., 2004).  
ALDH5, a mitochondrial enzyme involved in glutamate metabolism, has been 
found to be highly expressed in a human hepatoma (Stewart et al., 1995). In 
addition, it has been shown to be overexpressed in breast ductal carcinoma 
in situ (DCIS) at both the mRNA and protein levels. Treatment using 
disulfiram and valproic acid, which are known to inhibit ALDH5A1, resulted in 
significant inhibition of net proliferation of DCIS three dimensional spheroids, 
suggesting that ALDH5A1 may play an important role in DCIS and potentially 
serve as a novel molecular therapeutic target  (Kaur et al., 2012). 
ALDH7A1 was found to be expressed in the cytoplasm, mitochondria and 
nucleus (Chan et al., 2011). It is known to be involved in protection against 
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hyperosmotic stress presumably through the generation of betaine, an 
important cellular osmolyte, formed from betaine aldehyde (Brocker et al., 
2010). In addition, it was found to attenuate reactive aldehyde and oxidative 
stress induced cytotoxicity through its antioxidant activity (Brocker et al., 
2011). Abnormally high expression of ALDH7A1 has been found in ovarian 
cancer (Saw et al., 2012). In addition, it is upregulated in prostate cancer and 
matched bone metastasis samples, where it is associated with increased 
colony formation and cell migration (van den Hoogen et al., 2010, van den 
Hoogen et al., 2011), while its expression in NSCLC patients has been linked 
with increased incidence of cancer recurrence (Giacalone et al., 2013). 
 ALDH and drug resistance 1.4.4
The increased expression and activity of certain ALDH isoforms in tumour 
tissues has been found to be associated with drug resistance and cancer 
relapse (Su et al., 2010, Januchowski et al., 2013). ALDH1A1 has a 
regulatory and metabolic role in cancer, which can confer resistance to 
selected anticancer agents by metabolic inactivation (Moreb et al., 2007). In 
a retrospective study conducted by Sladek et al., the cellular levels of 
ALDH1A1 have been reported to be predictors of treatment responses to 
cyclophosphamide (CPA) based therapy (Sladek et al., 2002). Breast cancer 
patients with low levels of this enzyme have been shown to respond better to 
CPA-based treatment compared with those patients possessing high 
ALDH1A1 levels (Sladek et al., 2002). In breast cancer, a direct correlation 
between ALDH3A1 activity and resistance to oxazaphosphorines has also 
been reported (Sreerama and Sladek, 1993). Drug resistance can be 
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reversed using the ALDH inhibitor, diethylaminobenzaldehyde (DEAB) 
(Sreerama and Sladek, 1997). In addition, Moreb et al. have shown that RNA 
interference (RNAi)-mediated knockdown of ALDH1A1 and ALDH3A1 
resulted in increased cellular sensitivity of lung cancer cell lines to CPA and 
its metabolite, 4–hydroperoxycyclophosphamide (4-HCPA) (Moreb et al., 
2007) (Figure 5). Accordingly, the expression level of these isoforms has 
been suggested to serve as predictors of therapeutic responses to 
oxazaphosphorines (Moreb et al., 2007). More recently, selective inhibition of 
ALDH3A1 in ALDH3A1-expressing lung adenocarcinoma and glioblastoma 
cell lines (A549 and SF767, respectively) caused re-sensitisation of these 
cells toward mafosfamide (Parajuli et al., 2014). 
Figure 5 Mechanism of cyclophosphamide drug resistance by the 
activity of ALDH. Adopted from (Emadi et al., 2009) with License 
Number: 3833251467327. 
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Apart from the reported role of ALDH1A1 and ALDH3A1 in the metabolic 
inactivation of aldehyde drugs (e.g. CPA and 4-HCPA), recent studies 
described the involvement of ALDH in resistance to conventional cytotoxic 
drugs that do not contain aldehydes. Sun et al. demonstrated using 
proteomic analysis that ALDH1 was among the proteins that were 
upregulated in paclitaxel resistant human lung adenocarcinoma (A549) 
compared to sensitive cells (Sun et al., 2011). In addition, when analysing 
cisplatin resistant ovarian tumours and NSCLC cell lines, ALDH1 was found 
to be upregulated compared to their parental cells (Le Moguen et al., 2007, 
Barr et al., 2013). Recent investigations by Croker and Allan have also 
shown that breast cancer cell lines that overexpressed ALDH1 demonstrated 
significant resistance to doxorubicin, paclitaxel and radiotherapy compared to 
cells with low ALDH1 expression (Croker and Allan, 2012). Furthermore, 
inhibiting ALDH activity through RA or DEAB re-sensitised resistant cells 
(Croker and Allan, 2012). The ALDH1 isoform, however, was not specified in 
the aforementioned studies. ALDH1A2 was found to be associated with 
acquired resistance of leukaemic cells exposed to 1-β-D-
arabinofuranosylcytosine (AraC) while ALDH1A2 knockdown induced 
sensitivity to AraC treatment (Kawasoe et al., 2013). 
Recent studies have shown that ALDH2 expression is also associated with 
increased drug resistance to CPA and doxorubicin in leukaemia and lung 
cancer cell lines (Moreb et al., 2012). Moreover, Touil et al. reported the 
upregulation of ALDH1A3 in 5-Fluorouracil (5-FU) resistant cells compared to 
the parental HT29 cells, perhaps indicating that colon cancer cells escape 5-
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FU chemotherapy-induced cell death by entering stemness state (Touil et al., 
2014). 
Recently, ALDH has also been shown to be involved in drug resistance to 
molecularly-targeted therapeutics. Raha et al. showed that ALDH1 is highly 
expressed in gastric carcinoma cell lines that are resistant to the MET kinase 
inhibitor, crizotinib (Raha et al., 2014). A more recent study using proteomics 
analysis revealed high expression of ALDH7A1 in DU145, a prostate cancer 
cell line resistant to zoledronic acid (ZOL), a nitrogen-containing 
bisphosphonates (N-BPs) (Milone et al., 2015). 
These novel findings suggest a much broader role for ALDH in treatment 
response than previously reported (Croker and Allan, 2012). Therefore, it has 
been suggested that a patient’s ALDH genotype should be taken into 
consideration in order to design the most efficacious treatment strategy 
(Croker and Allan, 2012). 
 ALDH in cancer stem cells (CSCs) 1.4.5
Growing evidence suggests that the cells responsible for initiating, 
maintaining and the spread of cancer are “cancer stem cells” (CSCs) or 
tumour-initiating cells (TICs) (Ma and Allan, 2011). These cells are 
characterised by limitless proliferation potential, ability to self-renew, and 
capacity to produce a progeny of differentiated cells that form the major 
tumour population (Clevers, 2011). CSCs can divide asymmetrically, 
generating an identical daughter cell and a more differentiated cell, which 
during subsequent divisions produces most of the tumour bulk (Clevers, 
2005). 
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CSCs were first identified in acute myeloid leukaemia (AML) by Dr. John 
Dick’s group in 1994 (Lapidot et al., 1994). They observed that CD34+/CD38- 
leukaemia-initiating cells were able to engraft into severe combined immune-
deficient (SCID) mice and recapitulate the original tumour population as seen 
in AML patients (Lapidot et al., 1994). 
Characteristically, CSCs are resistant to radiotherapy and chemotherapy. In 
comparison to differentiated tumour cells, CSCs are relatively quiescent and 
have a slow cycling rate. These features protect them against conventional  
chemotherapeutic agents that target rapidly proliferating cells (Zhou et al., 
2009). Their resistance to radiotherapy and chemotherapy results also from 
the presence of an arsenal of defence mechanisms such as the expression 
of ABC transporters (Hirschmann-Jax et al., 2004) and strong responses to 
DNA damage compared with their progeny (Viale et al., 2009).  
The evolution of a CSC theory has provided a paradigm shift in our 
understanding of carcinogenesis, metastasis, and tumour biology (van den 
Hoogen et al., 2010). As a consequence, the identification of normal SCs 
and CSCs has important implications in the way cancer treatment should be 
conceived and future therapeutic approaches will be designed (van den 
Hoogen et al., 2010). 
CSCs are most commonly identified by expression of cell surface markers 
(Table 5). However, not all tumour cells that are isolated by certain markers 
are necessarily CSCs. In addition, as solid cancers are characterised by their 
heterogeneity, the prospective isolation of CSCs depending on the 
expression of certain cell surface markers such as CD44+, integrin α2β1, and 
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CD133+ alone remains controversial and an unfeasible way to identify all 
putative stem or progenitor cell types (van den Hoogen et al., 2010). 
Accordingly, there is a real need to identify novel markers that can be utilised 
to refine the CSC population (Marcato et al., 2011a). 
 
   
Table 5 Cancers with identified stem cells and cells surface markers expressed. Adopted from (Ebben et 
al., 2010) and perrmission is not required for reuse in thesis. 
Cancer type Cell Surface Markers References 
Leukaemia CD34+, CD38−, CD19+ (Kong et al., 2008) 
Breast CD44+, CD24−, Lin−, ALDH1+ (Ginestier et al., 2007, Al-Hajj 
et al., 2003) 
Brain CD133+ (Hemmati et al., 2003) 
Melanoma CD20+, ABCB5+ (Fang et al., 2005, Schatton 
et al., 2008) 
Colorectal CD133+, EpCAM+, CD44+, 
CD166+, ALDH1+ 
(O/'Brien et al., 2007, Ricci-
Vitiani et al., 2007, Dalerba et 
al., 2007, Huang et al., 2009) 
Lung CD24+, CD44+, CD133+ (Ho et al., 2007, Eramo et al., 
2007) 
Sarcomas CD105+, CD44+, Stro1+ (Parker Gibbs, 2005) 
Head and Neck 
Squamous 
Cell Carcinoma 
CD44+ (Prince et al., 2007) 
Liver CD133+, CD90+, CD44+ (Ma et al., 2007, Yang et al., 
2008) 
Pancreatic CD44+, CD24+, ESA+, 
CD133+ 
(Li et al., 2007, Hermann et 
al., 2007) 
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Currently, the increased activity of certain ALDHs has been considered as a 
hallmark of CSCs and appears as a novel marker for stem cell isolation 
(Marcato et al., 2011a). In fact, the role of certain isoforms of ALDHs 
(ALDH1A1, ALDH1A2, ALDH1A3 and ALDH8A1) in RA cell signalling has 
been suggested to contribute to “stemness” characteristics of CSCs (Marcato 
et al., 2011a). In addition, as ALDH enzymes are frequently involved in the 
detoxification of endogenous or exogenous compounds, this provides a 
mechanism for SC protection and maintenance of cellular integrity (van den 
Hoogen et al., 2010). Furthermore, the role of ALDH enzymes in the 
metabolism and inactivation of certain anticancer drugs as discussed before 
has been considered as one of the suggested mechanisms for the apparent 
resistance of CSCs to current anti-cancer therapies (Marcato et al., 2011a, 
Dylla et al., 2008). Tanei et al. showed that ALDH1 positive breast CSCs are 
valuable predictors of resistance to chemotherapeutic drugs such as taxanes 
(Tanei et al., 2009). 
The isolation of CSCs based on increased ALDH activity was first reported in 
haematopoietic cancers (acute myeloid leukaemia) in a study conducted by 
Cheung et al. (Cheung et al., 2007) The team showed that the ALDH+ AML 
cells were associated with adverse prognosis and engrafted significantly 
better than ALDH- AML cells in immunocompromised mice (Cheung et al., 
2007). The same year, the pioneering work of Ginestier and co-workers 
showed the potential applicability of using ALDH activity to isolate CSCs in 
solid tumours (Ginestier et al., 2007). ALDH1 has been shown to act as a 
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marker of breast CSCs and has been linked with poor clinical outcome 
(Ginestier et al., 2007). 
ALDH activity has also been used successfully to isolate CSCs in many solid 
cancers including lung (Ucar et al., 2009), liver (Ma et al., 2007), colon 
(Huang et al., 2009), pancreatic (Hermann et al., 2007), prostate (van den 
Hoogen et al., 2010), head and neck (Prince et al., 2007), bladder (Su et al., 
2010), thyroid (Todaro et al., 2010), brain (Corti et al., 2006, Mao et al., 
2013), melanoma (Boonyaratanakornkit et al., 2010), ovarian (Silva et al., 
2011) and renal (Wang et al., 2015) carcinomas. These studies provide 
evidence regarding ALDH activity as a universal CSC marker (Marcato et al., 
2011a). 
1.4.5.1 The use of ALDH to isolate CSCs 
The activity of ALDH is now recognised as a universal marker for both 
normal and cancer SCs. Different assays have been described to study and 
measure the activity of ALDH including a spectrophotometric assay used to 
study the enzyme kinetics, where the rate of conversion of NAD+ substrate to 
NADH by the activity of ALDH in the cell lysates can be measured at 37°C 
and a wavelength of 340 nm (Moreb et al., 1998). Western blot analysis has 
also been used to study ALDH in normal and cancer SCs (Giorgianni et al., 
2000 ), although a limitation in the protein detection approach is that their 
enzymatic activity was not measured (Ma and Allan, 2011). Currently, the 
gold standard of studying the activity of ALDH in viable cells is the use of 
flow cytometry in combination with ALDH-specific fluorescent substrates as 
described below (Ma and Allan, 2011). 
31 
 
1.4.5.1.1 The ALDEFLUOR assay 
The ALDEFLUOR assay has been shown to be an efficient strategy to 
isolate primitive haematopoietic SC (HSCs). This assay is based on the use 
of a fluorescent substrate, BODIPY aminoacetaldehyde (BAAA), which can 
passively diffuse into cells where it is converted by ALDH1 activity into a 
fluorescent green molecule (negatively-charged BODIPY aminoacetate 
(BAA-)). This fluorescent product accumulates in cells due to the presence of 
verapamil, an MDR1 inhibitor included in the assay buffer, which prevent 
active efflux of converted BAA-, allowing cells with high ALDH activity to be 
identified by flow cytometry (Alison et al., 2010). The addition of DEAB, an 
inhibitor of ALDH activity, which significantly reduces the fluorescence signal 
is used as a negative control to confirm that the isolated cells are ALDH+ 
cells (Marcato et al., 2011a) (Figure 6). 
Figure 6 The basis of the ALDEFLUOR assay. Cells are incubated with BAAA in the presence of the 
MDR1 inhibitor, verapamil, enabling ALDH+ cells to be detected (bottom left). When cells are treated with 
DEAB, ALDH activity is inhibited and no fluorescent subpopulation can be identified (bottom right). Adopted 
from (Alison et al., 2010) with License Number: 3833260321984. 
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1.4.5.1.2 The selectivity of the ALDEFLUOR assay 
The ALDEFLUOR assay is a commercially available assay used to identify 
SCs. It is highly sensitive, reproducible, nontoxic, and easy to use. In 
addition, it does not involve antibody recognition or the use of DNA-
intercalating dyes; hence it is a valuable method for live single cell isolation 
as the cytoplasmic enzyme activity detection is less likely to be damaged by 
enzymatic digestion and processing of the tissues (Minn et al., 2014, Dollé et 
al., 2015). 
The ALDEFLUOR assay has been successfully employed for the isolation of 
viable haematopoietic SCs isolated from human umbilical cord blood cells 
(Storms et al., 1999, Hess et al., 2004). This assay has been reported to be 
specific to ALDH1A1 (Marcato et al., 2011a), however, recent information 
suggest it is not so specific, which may have implication for SC isolation (Levi 
et al., 2009, Marcato et al., 2011b). In a study conducted by Levi et al., it was 
found that ALDH1A1 deficiency did not affect the haematopoietic and neural 
stem cell function, while no reduction in ALDEFLUOR activity was observed. 
Other ALDH isoforms (ALDH2, ALDH3A1 and ALDH9A1) have been 
detected and suggested to contribute to ALDEFLUOR activity (Levi et al., 
2009). In a recent study conducted by Van den Hoogen et al. (van den 
Hoogen et al., 2010), the ALDEFLUOR assay was used to identify prostate 
CSCs. The study reported high expression of other ALDH isoforms and only 
low ALDH1A1 expression. In this study, ALDH7A1 was highly expressed in 
prostate cancer cells lines, prostate cancer tissue and matched bone 
metastasis samples, suggesting that ALDH7A1 might contribute to the ALDH 
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activity of these cells (van den Hoogen et al., 2010, van den Hoogen et al., 
2011). 
Marcato et al. also showed that at least for breast cancer, ALDH1A1 
expression is not the primary determinant of ALDH activity. Instead, a better 
correlation has been suggested with ALDH1A3, ALDH2, ALDH4A1, 
ALDH5A1, ALDH6A1 and ALDH7A1. However, knockdown studies showed 
that only reduction in ALDH1A3 expression resulted in the reduction of ALDH 
activity in ALDEFLUOR positive cells (Marcato et al., 2011b). Moreb et al. 
also reported that the enzymatic activity of ALDH1A2 and ALDH2 was 
detected by ALDEFLUOR assay (Moreb et al., 2012). 
Based on the aforementioned studies, it is becoming increasingly clear that 
the ALDH isoform(s) responsible for ALDEFLUOR activity is/are likely to vary 
depending on cancer type and tissue or cell origin. In addition, the tissue 
specificity of the ALDH isoforms may determine their pattern of expression in 
cancers, which may have potential to be used as biomarkers (Marcato et al., 
2011a). 
There is also a technical limitation for detection of ALDH activity using the 
ALDEFLUOR assay and a fluorescent green emission. Some organs (such 
as the liver) are rich in endogenous fluorophores (flavins and NADPH for 
example) that auto-fluoresce in the green wavelength (480 –580 nm). In 
addition, green emission reduces considerably the choice of combining 
fluorescently labelled antibodies to further fractionate the ALDH+ population 
and preclude its use for cell isolation in tissues from green fluorescent 
protein (GFP) transgenic mice. An inevitable overlapping of green 
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fluorescence emission into other channels is also problematic, and therefore 
“contamination” of ALDH expressing cells in other lineages can be high 
(Minn et al., 2014, Dollé et al., 2015). 
1.4.5.1.3 AldeRed-588-A: New red substrate for detecting ALDH activity 
Recently, Minn and co-workers have described a new red-shifted fluorescent 
ALDH substrate (AldeRed-588-A) for labelling of viable ALDH+ cells. The 
authors demonstrated that Aldefluor and AldeRed-588-A essentially have the 
same efficacy and efficiency for identifying ALDH+ cells as both have a 
common substrate moiety; acetaldehyde (Figure 7A). In addition, by 
successfully mixing the two substrates, Minn and colleagues proved that the 
labelling technique does not impede the structural recognition of the 
substrate by ALDH enzyme and that cell isolation of ALDH expressing cells 
is feasible by a single-step isolation method (Aldefluor and AldeRed-588-A 
are incubated simultaneously), thus avoiding additional purification or 
enrichment steps in which cells can be lost or damaged. This technical 
innovation opens new avenues for stem cell research by offering a greater 
flexibility for ALDH+ cell isolations (Minn et al., 2014, Dollé et al., 2015). 
Minn and co-workers also proposed a protocol for using AldeRed-588-A to 
overcome the above mentioned problems associated with the ALDEFLUOR 
assay. In addition, the authors showed the possibility of synthesising 
functional substrates for ALDH enzymes (Figure 7B). One could thus 
generate a library of fluorescently distinct substrates able to discriminate and 
fractionate stem cell populations by flow cytometry based on expression of 
specific ALDH isoenzymes (Minn et al., 2014, Dollé et al., 2015). However, 
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ALDH selectivity of these chemical probes still appears to be an issue and 
therefore the true value of using such probes to isolate CSCs remains 
unclear. 
  
Figure 7 The Aldefluor and AldeRed-588-A substrates. Aldefluor and AldeRed-588-A have the same capacity to 
isolate an ALDHbright cell population enriched in stem cells from a heterogeneous mixture of cells (A). Emerging 
opportunities in generating preferred labeled substrates with different fluorescent probes (B). ALDHbright, cells with high 
ALDH activity; ALDHdim, low-ALDH-activity fraction. Adopted from (Dollé et al., 2015) and permission is not required 
for reuse in thesis. 
36 
 
1.5 The role of hypoxia in the regulation of ALDH expression  
 Hypoxia, oxidative stress and ALDH 1.5.1
Oxidative stress is defined as an imbalance between the production of free 
radicals and reactive metabolites, so-called oxidants or reactive oxygen 
species (ROS), and their elimination by protective mechanisms, referred to 
as antioxidants (Reuter et al., 2010). It is well known that high levels of ROS 
can occur in cancer cells as a result of increased basal metabolic activity, 
peroxisome activity, uncontrolled growth caused by cytokine signalling and 
oncogene activity (Fiaschi and Chiarugi, 2012). Enhanced activity of known 
ROS sources including NADPH oxidase or lipoxygenases were also 
described in cancer (Edderkaoui et al., 2005, Ushio-Fukai and Nakamura, 
2008). In addition, low oxygen tension and hypoxia has been reported to be 
associated with an increase in ROS and oxidative stress that promotes 
tumour progression (Kondoh et al., 2013, Fiaschi and Chiarugi, 2012). The 
consequences of the production of oxygen radicals on cancer biology are 
pleiotropic and complex. ROS are reported to be tumorigenic by virtue of 
their ability to increase cell proliferation, survival and cellular migration 
(Reuter et al., 2010). Paradoxically high concentrations of ROS can trigger 
apoptotic or necrotic cell death (Reuter et al., 2010). ROS can initiate the 
oxidative degradation of biological membranes, known as lipid peroxidation 
(LPO) (Bartsch and Nair, 2006). In addition, it can attack DNA and proteins 
resulting in DNA strand breakage and enzyme inactivation, respectively 
(Fiaschi and Chiarugi, 2012). LPO is a self-perpetuating process and 
produces different types of aldehydes which can covalently bind biological 
37 
 
macromolecules producing similar damage such as caused by ROS (Bartsch 
and Nair, 2004). Aldehydes can also bind glutathione (GSH) causing 
depletion in GSH pools and as oxidative stress persists, cellular and 
intracellular redox balance becomes impaired (Brocker et al., 2011). 
Unhindered, the combined effects of ROS and LPO-derived aldehydes can 
significantly upset cellular homeostasis leading to apoptosis, cell cycle arrest 
and cellular senescence (Storz, 2005). Whether ROS promote tumour cell 
survival or are anti-proliferative depends on the cell and tissues, the location 
of ROS production, and the concentration of ROS produced (Storz, 2005). 
Mounting evidence indicates that hypoxic cancer cells undergoing exposure 
to oxidative stress develop adaptive strategies to survive to the hostile milieu. 
These are indeed antioxidant responses that may result in increased 
aggressiveness (Fiaschi and Chiarugi, 2012). Examples of antioxidant 
systems that were found to be elevated in cancer include 
glutathione/glutathione peroxidase (GSH/GPX) (Fan et al., 2008), superoxide 
dismutase (SOD) and catalase enzymes (Hileman et al., 2004). These 
antioxidant mechanisms might also provide protection of cells against 
radiotherapy and chemotherapeutic drugs with activity mediated by 
production of ROS such as cisplatin, doxorubicin, and etoposide (Reuter et 
al., 2010, Balendiran et al., 2004, Storz, 2005). Genomic analysis showed 
that certain genes in the ALDH superfamily are also upregulated due to 
oxidative stress (Vasiliou and Nebert, 2005), which can explain the increased 
protection of the cell against oxidative insult by environmental chemicals and 
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drugs (Pappa et al., 2003a). Therefore, a possible link between ALDH and 
hypoxia signalling has been suggested (Kim et al., 2013). 
 Hypoxia and ALDH expression  1.5.2
Reisdorph and Lindahl studied the effects of hypoxia on constitutive and 
inducible ALDH3 gene expression (Reisdorph and Lindahl, 1998). It is known 
that ALDH3 gene is expressed differentially in a tissue-specific manner and 
occurring constitutively in some tissues like corneal epithelial cells. In 
addition, it is upregulated in tumours like hepatoma as a result of xenobiotic 
induction via the aryl hydrocarbon receptor (AhR)/ARNT pathway (Reisdorph 
and Lindahl, 1998). The results of this investigation showed that both 
constitutive and inducible ALDH3 expression can be downregulated by 
hypoxia. It has been speculated that this is due to limiting levels of ARNT 
(HIF-1β) being shared by two pathways, which under hypoxic condition forms 
heterodimers with HIF-1α and thus is not available to interact with critical 
xenobiotic response element (XREs) required for ALDH3 expression. 
Nonetheless, in a later study done by the same group, it was shown that 
ARNT is not the limiting transcription factor (Reisdorph and Lindahl, 2001). 
Therefore, further investigations are needed to explain the mechanism 
behind the down-regulation of ALDH3 under hypoxic conditions. 
Recently, a link between ALDHs and hypoxia in CSCs has also been 
reported by Nagano et al. who showed that elevated ALDH activity may 
affect the proliferation and differentiation of mesenchymal SCs during 
hypoxia (Nagano et al., 2010). However, Hasmim et al. have examined the 
effect of hypoxia exposure of IGR-Heu, a NSCLC cell line on the expression 
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of ALDH1 and found that ALDH1 levels were not influenced by exposure to 
hypoxic stress (Hasmim et al., 2011). In a recent study conducted by Kim et 
al. the link between ALDH and hypoxia signalling was investigated in breast 
cancer (Kim et al., 2013). Exposure of breast cancer cells to hypoxia did not 
affect expansion of ALDEFLUOR+ cells. In contrast, a robust increase in HIF-
2α was reported in ALDEFLUOR+ cells grown under normoxia. This elevation 
in expression was also observed under hypoxic conditions compared with 
ALDEFLUOR- cells. Further investigations showed that ALDH was highly 
correlated with the HIF-2α expression in breast cancer cell lines and primary 
tissues. Treatment of 4T1, a breast cancer cell line, with DEAB 
downregulated the expression of HIF-2α, leading to suppressed in vitro self-
renewal ability and in vivo tumour initiation of ALDEFLUOR+ cancer cells 
(Kim et al., 2013). Based on these results it was suggested that ALDH 
activity promotes cancer stemness through a novel mechanism that involves 
the upregulation of HIF-2α (Kim et al., 2013). 
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1.6 Aims and objectives 
As reviewed in the preceding sections, much is to be understood about the 
impact of hypoxia on cancer aggressiveness and treatment outcome, which 
include identification and characterisation of TICs/CSCs that gives better 
understanding of drug resistance. ALDHs are emerging as a class of 
enzymes that appear to play a number of roles within the tumour 
microenvironment, but their expression and regulation is not well understood. 
The purpose of this study was to unravel the impact of hypoxia on ALDH 
expression and lay the foundation for future exploration of these enzymes in 
the stem cell component associated with CRC. The hypothesis is the 
expression of ALDH in cancer cell lines is modulated by hypoxia and may 
contribute to cell proliferation and migration. Specifically, the objectives of 
this research were: 
1. To study the gene and protein expression of ALDH isoforms in CRC 
2D/3D cancer models and xenograft tissues (Chapter 2). 
2. To carry out siRNA knockdown studies of selected ALDH isoforms 
(ALDH1A3, 3A1 and 7A1) using both normoxic and hypoxic 
conditions, in an attempt for better understanding of their functional 
roles in CRC and drug treatment (Chapter 3). 
3. To explore ALDH7A1 function using an isogenic lung cancer cell line 
pair (H1299/RFP and H1299/ALDH7A1-transfected) and identify small 
molecules that can be used to interrogate ALDH7A1 functional role 
(Chapter4). 
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 Chapter 2: The impact of hypoxia on 
the expression of aldehyde 
dehydrogenases in 2D and 3D 
colorectal cancer models 
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2.1 Introduction  
Colorectal cancer (CRC) is the second leading cause of cancer deaths with a 
worldwide cumulative incidence rate of 9.4%. In the UK, it is the third most 
common diagnosed type of cancer, with around 40,000 new cases 
diagnosed every year (Botchkina, 2013). 
The colon (large intestine) refers to that part of the digestive system that is 
responsible for water absorption as the digested food passes through it and 
is divided into 5 parts; ascending, transverse, descending, sigmoid colon and 
the rectum (American Cancer Society, 2014). Cancer can occur in any part 
of the colon and starts in the innermost layer where most of the cancerous 
cells begin as a small growth on the lining wall called polyps or adenomas 
(Figure 8). These polyps are premalignant and if left untreated may become 
cancerous and grow into the muscle layers and penetrate the colon wall (Lee 
et al., 2006). The cancer can then invade into adjacent organs such as the 
bladder or prostate gland or it can spread through the lymphatic system to 
the lymph nodes such as the abdominal lymph nodes. CRC can also spread 
to other parts of the body through the bloodstream with the liver being the 
most common site of metastasis (Fidler, 2003).  
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More than 95% of CRCs are adenocarcinomas that have originated in the 
glandular cells of the wall lining, although other types of cancer can also 
occur such as squamous cell carcinoma, carcinoid or sarcoma (Cuffy et al., 
2006). TNM is the most common staging system used for CRC and stands 
for tumour, node and metastasis, respectively (Quirke et al., 2007). This 
staging system describes the size of a primary tumour (T), whether any 
lymph nodes contain cancer cells (N), and whether the cancer has spread to 
another part of the body (M) (Table 6). The number staging system is usually 
used by doctors to group CRC and contains 5 main stages (Puppa et al., 
2010) (Table 7). 
  
Figure 8 Colorectal cancer growth. Taken from the patient information 
website of Cancer Research UK with permission: 
http://www.cancerresearchuk.org/about-cancer/ (Cancer Research UK, 2016).  
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Table 6 TNM staging system of colorectal cancer. Taken from the patient information website of Cancer 
Research UK with permission: http://www.cancerresearchuk.org/about-cancer/ (Cancer Research UK, 2016). 
Stage Description 
0 Carcinoma in situ. 
1 The cancer has grown through the inner lining of the bowel, or into the muscle wall, 
but no further. There is no cancer in the lymph nodes (T1, N0, M0 or T2, N0, M0). 
2 2a: the cancer has grown into the outer covering of the bowel wall but there are no 
cancer cells in the lymph nodes (T3, N0, M0). 
2b: the cancer has grown through the outer covering of the bowel wall and into 
tissues or organs next to the bowel (T4). No lymph nodes are affected (N0) and the 
cancer has not spread to another area of the body (M0). 
3 3a: the cancer is still in the inner layer of the bowel wall or has grown into the 
muscle layer. Between 1 and 3 nearby lymph nodes contain cancer cells (T1, N1, 
M0 or T2, N1, M0). 
3b: the cancer has grown into the outer lining of the bowel wall or into surrounding 
body tissues or organs. Between 1 and 3 nearby lymph nodes contain cancer cells 
(T3, N1, M0 or T4, N1, M0). 
3c: the cancer can be any size and has spread to 4 or more nearby lymph nodes. 
The cancer has not spread to any other part of the body (any T, N2, M0). 
4 The cancer has spread to other parts of the body (such as the liver or lungs) 
through the lymphatic system or bloodstream (any T, any N, M1). 
Table 7 The number staging system of colorectal cancer. Taken from the patient information website of 
Cancer Research UK with permission: http://www.cancerresearchuk.org/about-cancer/ (Cancer Research UK, 
2016). 
. 
  T Describes the size of the tumour 
T1 The tumour is only in the inner layer of the bowel. 
T2 The tumour has grown into the muscle layer of the bowel wall. 
T3 The tumour has grown into the outer lining of the bowel wall. 
T4 The tumour has grown through the outer lining of the bowel wall. It may have grown 
into another part of the bowel, or other nearby organs or structures. Or it may have 
broken through the membrane covering the outside of the bowel (the peritoneum). 
N Describes whether cancer cells are in the lymph nodes 
N0 There are no lymph nodes containing cancer cells. 
N1 1 to 3 lymph nodes close to the bowel contain cancer cells. 
N2 There are cancer cells in 4 or more nearby lymph nodes. 
M Describes the presence of metastasis 
M0 The cancer has not spread to other organs. 
M1 The cancer has spread to other parts of the body. 
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Treatment of CRC relies mainly on the excision of the colon with the adjacent 
lymph nodes. However, neoadjuvant or adjuvant chemotherapy with or 
without radiotherapy are often required depending on the location of the 
tumour and its stage. Laparoscopic colectomy is the treatment of choice for 
patients with early stages (I or II) of CRC (Lacy et al., 2002). However, the 
benefit of including adjuvant therapy in stage II disease remains unclear and 
controversial but might be considered in patients at high risk. Patients 
presenting with regional or distal metastasis (stage III and IV), are usually 
treated with a combination of surgical and other therapeutic modalities 
(Kozovska et al., 2014). 
When a chemotherapeutic regimen is indicated, a combination of 
conventional cytotoxic drugs including 5-Fluorouracil (5-FU)/ leucovorin with 
oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) is usually used (de Gramont et 
al., 2000, Douillard et al., 2000). Recently, targeted therapy has also been 
shown to be effective for CRC treatment. For example, cetuximab and 
panitumumab, two monoclonal antibodies that target the epidermal growth 
factor receptor (EGFR), have been shown to be effective in combination with 
chemotherapy or as single agents in patients with wild-type KRAS-CRC 
tumours (Lièvre et al., 2006). In addition, antiangiogenic therapy targeting 
vascular endothelial growth factor (VEGF) (e.g. bevacizumab) confers a 
benefit when used in combination with chemotherapy (Giantonio et al., 
2007). 
FOLFOX, FOLFIRI and the newer molecularly-targeted therapies only offer a 
modest improvement in overall survival rates in patients with 
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advanced/metastatic CRC. In part, this is due to the emergence of drug 
resistance and in part due to insufficient and/or selective delivery of the 
drugs. The failure rate in the adjuvant setting is 30% for high-risk stage II and 
stage III patients, and overall response rate is 60% for patients with stage IV 
CRC (Langan et al., 2013). In addition, nearly 50% of CRC patients develop 
recurrent disease, and patients with advanced and metastatic CRC still 
succumb to this disease. The major reason is ascribed to the heterogeneity 
of CRC and the presence of cancer stem cells (CSCs) in the tumour mass; 
the latter are essentially resistant to current therapeutic strategies due to 
their infrequent capacity to divide (Kumar et al., 2014). Therefore, significant 
advance in the treatment care of CRC patients could be realised by (i) the 
use of biomarkers that can accurately identify patients at-risk for disease 
recurrence and dissemination, along with those that fail to respond to 
systemic therapy (Langan et al., 2013), (ii) the development of highly 
selective therapies targeting oncogenic drivers such as BRAF and KRAS 
(Lièvre et al., 2006) and/or the CSC population (Pors and Moreb, 2014) and 
(iii) a better understanding of how and when to use the various treatment 
modalities in combination (Soreide et al., 2011). 
There is accumulating evidence for the existence of CSCs in human CRC. 
Identification and isolation of CSCs in CRC is usually based on cell surface 
marker such as CD133 and CD44, though they are not specific (Horst et al., 
2009, Shmelkov et al., 2008). Two transcription factors, Oct-4 and Sox2, may 
be more promising CSC markers as they have been found to be elevated in 
CRC, correlating with increased CSC proliferation and poor prognosis 
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(Saigusa et al., 2009). Recently, aldehyde dehydrogenase 1 (ALDH1) has 
been shown to be a specific marker for identifying, isolating, and tracking 
human colonic SCs during CRC development (Huang et al., 2009). 
Immunostaining showed that ALDH1+ cells are sparse and limited to the 
bottom of normal crypts, where SCs reside. However, during progression 
from normal epithelium to mutant adenomatous polyposis coli (APC) 
epithelium to adenoma, ALDH1+ cells increased in number and became 
distributed further up the crypt. In addition, flow cytometric isolation of cancer 
cells based on enzymatic activity of ALDH (ALDEFLUOR assay) and 
implantation of these cells in non-obese diabetic–severe combined 
immunodeficient mice resulted in the generation of xenograft tumours even 
after implantation of as few as 25 cells (Huang et al., 2009). Carpentino et al. 
showed that ALDH1 can be used as a marker for tumour-initiating cells 
(TICs) not only from colon cancer but also from colitis (Carpentino et al., 
2009). Cells were isolated from patients with chronic ulcerative colitis using 
FACS and showed both their transition to cancer stem-like cells in xenograft 
studies as well as their ability to generate three-dimensional spheres in vitro 
(Carpentino et al., 2009).  
Proteomic analysis of the secretomes of CSCs isolated from three distinct 
metastasised colon tumours has also shown that these cells secrete high 
levels of drug-metabolising enzymes, including ALDH1A1 (Emmink et al., 
2013). This isoform has been shown to be involved in causing resistance to a 
number of anticancer agents (Chapter 1, Introduction, section 1.4.4) and 
extracellular detoxification of prodrugs of alkyating agents such as 
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maphosphamide and thus contributes to CSC-intrinsic drug-resistance 
(Emmink et al., 2013). 
Most of these and other studies used the ALDEFLUOR assay and confirmed 
it as an effective method for detection and isolation of CSCs (Guo et al., 
2014) (Chapter 1 Introduction, sections 1.4.5.1.1-2). In addition, the 
metabolic function of ALDH1A1 was proposed to confer the ‘‘stemness’’ 
properties of normal and cancer SCs. However, the identity of ALDH 
isoforms that contribute to the enhanced ALDH activity were not identified. 
Chen et al. examined the expression profile of ALDH1A1 and ALDH1B1 in 
human adenocarcinomas of colon and other cancer tissues (Chen et al., 
2011). The immunohistochemical expression of ALDH1A1 or ALDH1B1 
showed approximately a 5-fold higher expression score for ALDH1B1 in 
cancerous tissues than that for ALDH1A1 and 39/40 colonic cancer 
specimens were stained positive for ALDH1B1. The study demonstrated that 
ALDH1B1 rather than ALDH1A1 is a potential biomarker for human colon 
cancer (Chen et al., 2011). 
In addition to the potential role of ALDH isoforms as a biomarker for CRC 
and stem cell isolation, recent studies also described the role of ALDH in 
CRC drug resistance and cancer recurrence. Touil et al. reported the 
upregulation of ALDH1A3 in 5-FU resistant cells compared to the parental 
HT29 cells (Touil et al., 2014), indicating that colon cancer cells may escape 
5-FU chemotherapy-induced cell death by entering a stemness state. Deng 
et al. 2014 showed that ALDH1 is an independent prognostic factor for 
patients with stages II–III rectal cancer after receiving radio-chemotherapy. 
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Specifically, preoperative treatment of rectal cancer upregulated the 
expression of ALDH1, while high ALDH1 expression post-treatment 
predicted poor prognosis for patients after neoadjuvant therapy; 40% of the 
patients with high ALDH expression suffered recurrence during the follow-up 
compared to no recurrence in the patients with low ALDH expression (Deng 
et al., 2014). 
ALDH has also been described to be involved in CRC metastases. 
Mechanically-induced colon cancer cells with increased metastatic potential 
revealed that ALDH3A1 but not ALDH1 was among the genes that were 
highly upregulated, correlating with cancer cell migration and invasion (Tang 
et al., 2014). 
The tumour microenvironment, including stromal component, is a key player 
in stimulating tumour proliferation, aggressiveness and drug resistance 
(Mathonnet et al., 2014). The dynamic interactions between CSCs and the 
microenvironment result in a continuous remodelling of both compartments, 
promoting metastasis and development of chemoresistance (Maugeri-Saccà 
et al., 2011). Increasing reports indicate that hypoxia may serve as a critical 
regulator of the CSCs pool. It is well known that hypoxia activates hypoxia-
inducible factors (HIFs), which trigger adaptive changes at multiple levels, 
including angiogenesis. However, the neovasculature is chaotic and 
dysfunctional and thus prohibits the accrual of optimal concentrations of 
chemotherapeutic agents within the tumour (Wilson and Hay, 2011). Besides 
this mechanistic hypoxia-mediated drug resistance, direct evidence also 
connects HIF and CSCs. Cancer cells cultured under low oxygen conditions 
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or low pH express higher levels of stem cell markers, which acquire a stem-
like phenotype and overexpress stemness-related genes (Heddleston et al., 
2010). Furthermore, it has been proposed that hypoxic areas within a tumour 
act as niche for CSCs (Maugeri-Saccà et al., 2011). Therefore, targeting 
these effectors will more effectively deplete the CSC pool and contribute to 
increased chemotherapeutic response (Maugeri-Saccà et al., 2011). 
Given the importance of hypoxia on tumourigenesis and resistance, 
information about how selective ALDHs adapt to hypoxia and oxidative 
stress within the tumour microenvironment could have a profound impact on 
the understanding of drug resistance and the identification and 
characterisation of TICs/CSCs in CRC. The hypothesis of this Chapter is 
ALDH expression is modulated by tumour hypoxia and the objectives were: 
1. To study the gene and protein expression of ALDH isoforms in a panel 
of CRC cell lines. 
2. To evaluate the impact of hypoxia on the expression of ALDH in CRC 
monolayer cells. 
3. To evaluate the expression of ALDH in CRC multicellular spheroids 
(MCS). 
4. To evaluate the expression of ALDH in CRC xenografts. 
5. To assess if HIF-1 or HIF-2 is responsible for inducing the expression 
of ALDH. 
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2.2 Materials and Methods 
 The expression of ALDH in a panel of colorectal cancer cell 2.2.1
lines 
2.2.1.1 Cell culture 
Mammalian cancer cell lines were obtained from the American Type Culture 
Collection (ATCC). Cells were at passage 0 and grown in complete RPMI 
1640 medium (Sigma) at 37oC, 5% CO2 and 100% humidity (Table 8). 
Passaging of these cells was carried out when the cells were 75% confluent. 
See Appendix I for the composition of the cell culture media. 
2.2.1.1.1 Passaging of mammalian cells 
Prior to passaging the cells, the old medium was removed and discarded 
from each 75 cm2 flask. The cells were washed twice with 10 ml of 
phosphate buffered saline (PBS) (Sigma), which was removed and 
discarded. A brief pre-treatment of the cells with 1 ml of 0.25% trypsin/EDTA 
(Sigma) was carried out when flasks were 75% confluent. In order to 
degrade the protein attachments between the cells and flask surface, a 
Cell line Origin of cell line Culture 
medium 
Frequency 
of 
subculture 
Dilution 
upon 
subculture 
DLD-1 Dukes' type C, colorectal 
adenocarcinoma, adult male. 
RPMI 1640 4-5 days 1:10 - 2:10 
HCT116 Primary colorectal carcinoma, adult 
male. 
RPMI 1640 3-4 days 1:8 - 1:10 
HT29 Primary colorectal adenocarcinoma, 44 
years adult female, Caucasian. 
RPMI 1640 4-5 days 1:10 
SW480 Dukes' type B, colorectal 
adenocarcinoma, 50 years male, 
Caucasian 
RPMI 1640 3-4 days 1:8 - 1:10 
Table 8 Culture of colorectal cancer cell lines. 
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further 2 ml of trypsin/EDTA was added to the flask and allowed to cover the 
cell surface to cause cell detachment. Flasks were incubated at 37oC for 
about 5 min before the cells were checked under a light microscope to 
confirm that they were detached. Trypsin was inhibited by the addition of 8 
ml complete RPMI medium to the flask. After gentle pipetting up and down 
several times, the content of the flask was added to a 20 ml universal tube 
and the cells were centrifuged at 1,000 rcf for 5 min. The medium was 
carefully discarded to prevent the loss of cell pellets and 10 ml of fresh 
medium was added and mixed vigorously by vortexing to re-suspend the 
cells. The required amount of cell suspension was added to 10 ml of fresh 
medium in a new 75 cm2 flask before incubation at 37oC, 5% CO2 and 100% 
humidity. 
2.2.1.1.2 Determination of the cell concentration 
To determine the cell concentration, the live cell number was counted using 
a haemocytometer. 100 µl of 0.4% Trypan Blue Stain (Sigma) and 100 µl of 
cell suspension were added to a 1.5 ml microcentrifuge tube and mixed 
vigorously by vortexing. 10 µl of cell /Trypan mixture was transferred to each 
chamber of the haemocytometer by pipetting under the cover slip and 
allowing the chamber to be filled by capillary action. Under the light 
microscope, using the 10× objective lens and focusing on the gridlines of the 
chamber, the live cells (not blue) were counted in the central and the four 
squares of the corners of each chamber. Cells that were on the lines were 
counted only if they lied on the top and right-hand lines of each square. 
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Cell concentration was calculated using this formula: 
Cells/ml = Average number of cells in one large square × dilution factor* × 
104**. 
*Dilution factor was 2 (1 volume cell suspension: 1 volume of Trypan blue). 
**104 is the conversion factor to convert 10-4 ml (volume of one large square) 
to 1 ml. 
2.2.1.2 Exposure of CRC cell lines to hypoxia 
The CRC cell lines were seeded at a concentration of 2 × 105 cells in 75 cm2 
flasks and incubated at normoxic conditions (37ºC, 5% CO2 and 100% 
humidity). Subsequently, cells were incubated either at normoxic conditions 
(control) or exposed to hypoxia (0.1% O2, 95% N2, 5% CO2 and 100% 
humidity) for 6h, 24h or 48h prior to cell harvesting for gene extraction and 
protein extraction. The medium was replaced with fresh RPMI, which had 
been adapted to hypoxic conditions overnight using a hypoxic chamber 
(Whitley H35 hypoxystation). Cell harvesting was done on day 5 when the 
cells were ≈ 75% confluent. 
To see whether the cells were alive after exposure to hypoxia, cells in flasks 
were stained with haematoxylin. In brief, medium was removed and cells 
were fixed with 70% ethanol (1-2 min). Cells were then stained with Harris’ 
haematoxylin (Sigma) for 5 min and washed in running tap water for 5 min. 
Photos were taken using 10 × objective lens on an inverted microscope 
(Nikon ECLIPSE TE2000-U). 
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2.2.1.3 Analysis of ALDH gene expression of CRC cell lines using 
quantitative real time polymerase chain reaction (qRT-PCR) 
2.2.1.3.1 Cell harvesting 
The CRC cell lines which were exposed to normoxic or hypoxic conditions 
were washed with PBS and detached from the flask surface after 
trypsinisation. 2 × 106 cells were collected in 20 ml universal tube and 
centrifuged at 1,000 rcf for 5 min. Medium was discarded and 1 ml of PBS 
was added to the cell pellet, mixed with cells by pipetting before the cells 
were collected in 1.5 ml microcentrifuge tube and centrifuged for 5 min at 
3,000 rcf. After centrifugation, PBS was discarded and the dry pellet was 
then processed for RNA extraction. 
2.2.1.3.2 RNA extraction and quantification 
Total RNA was extracted from the pellets isolated from CRC cell lines 
(exposed to normoxic or hypoxic conditions) using RNeasy Mini Kit 
(QIAGEN) according to the manufacturer’s instructions. In brief, cells were 
disrupted in the lysis buffer and homogenised using motor and pestle. 70% 
ethanol was added to the homogenised lysate and mixed well by pipetting. 
The supernatant was transferred to an RNeasy spin column (QIAGEN) 
placed in a 2 ml collection tube (QIAGEN) and centrifuged for 15 seconds (s) 
at 8,000 rcf. The spin column membrane was washed one time with RW1 
buffer before doing on-column DNase digestion with the RNase-Free DNase 
set (QIAGEN). In brief, DNase I incubation mix was prepared from DNase I 
stock solution according to the manufacturer’s instructions. The DNase I 
incubation mix was added directly to the RNeasy spin column membrane 
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and placed on the benchtop for 15 min. Next, the spin column membrane 
was washed several times to avoid carry over of ethanol. Finally RNA was 
eluted by adding 30 µl of RNase-free water and centrifuged for 1 min at 
8,000 rcf. The quantity and quality of RNA was evaluated by measuring the 
absorbance of UV light and calculating the 260/280 ratio using NanoDropTM 
1000 spectrophotometer (Thermo Scientific). Subsequently, samples were 
used for complementary DNA (cDNA) synthesis and stored at -80ºC until 
required. 
2.2.1.3.3 Complementary DNA synthesis 
Single stranded cDNA was synthesised from total RNA in 20 µl reaction 
volumes using AffinityScript QPCR cDNA Synthesis Kit (Agilent 
Technologies) by adding the following component in order: RNase-free 
water, 10 µl first strand master mix (2x) containing optimised buffer, MgCl2 
and dNTPs, 3 µl of random primer (0.1 µg/µl), 1 µl AffinityScript reverse 
transcriptase/ RNase Block enzyme mixture and 1 µg of specimen RNA. 
Reactions were carried out in a MJ Research PTC-200 Peltier thermal cycler 
using the conditions listed in Table 9. The completed first-strand cDNA 
synthesis reaction was stored at -20ºC until required. 
Step Time Temperature 
Incubation/ primer annealing 5 min 25ºC 
cDNA synthesis 15 min 42ºC 
Enzyme inactivation 5 min 95ºC 
                            Table 9 Cycling conditions of cDNA synthesis. 
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2.2.1.3.4 QRT-PCR primers design 
QRT-PCR assays were designed by PrimerDesign Ltd. PrimerDesign 
provides custom designed qRT-PCR assays for human, mouse, rat and 
other species genes in addition to high quality qRT-PCR assays for 
housekeeping genes. Assays are available with PerfectProbe, Double-Dye 
(Taqman style) probe or as primer only kits for use with SYBR Green 
chemistry. Every assay was individually designed to custom requirements 
and after synthesis they were fully validated on relevant biologically derived 
cDNA for priming specificity and amplification efficiency at optimal 
concentrations to ensure that the kit worked to the highest standards. Here, 
custom designed homo sapiens qRT-PCR assays for use with SYBR Green 
were used. Detailed information of the qRT-PCR assays is listed in Appendix 
III. 
2.2.1.3.5 QRT-PCR method 
QRT-PCR was set up in 96-well plate (MicroAmpTM) in triplicate for each 
gene of interest in a UV- irradiated hood on 7500 RT-PCR System (Applied 
Biosystem). The assay was performed using 20 µl reactions consisting of 1 
µl of forward and reverse primers mix for the target genes ALDH1A1, 1A2, 
1A3, 1B1, 2, 3A1, 7A1, VEGFA and β-actin (working concentration of primers 
= 300 nM), 10 µl of PrimerDesign 2x PrecisionTM Mastermix, 4 µl of 
RNAse/DNAse free water (all from PrimerDesign) and 5 µl of diluted cDNA 
[cDNA reactions were diluted 1:10 (10μl of cDNA and 90μl of water)]. 
VEGFA was used as a positive control gene for hypoxic conditions and β-
actin was used as a housekeeping gene for the normalisation of the reaction. 
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For each assay, “no reverse transcription” controls and “no template” 
controls were included as negative controls. For the cycling conditions, see 
Table 10. A post PCR run melt curve (dissociation curve) was used to prove 
the specificity of the primers. 
Stage Repetition Step Time Temperature 
1 1 Enzyme activation 10 min 95ºC 
2 50 Denaturation 15s 95°C 
Data collection 60s 60°C 
3 1 
 
Melt curve 
 
15s 95°C 
60s 60°C 
15s 95°C 
                       Table 10 Q-RT-PCR cycling conditions. 
2.2.1.3.6 Data analysis 
The qRT-PCR assay chosen in this study is based on measuring 
fluorescence using fluorescent reporter molecule such as SYBR Green. The 
fluorescence intensity increases proportionally with each amplification cycle 
in response to the increased target concentration, with the RT-PCR 
instrument systems (7500 Applied Biosystem) collecting data for each 
sample during each PCR cycle. The first cycle at which the amplification 
generated fluorescence can be detected as being above the ambient 
background signal is called the “Ct” or threshold cycle. The numerical value 
of the Ct is inversely related to the amount of target in the reaction (i.e., the 
lower the Ct, the greater the amount of target) (Schmittgen et al., 2008). 
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Relative quantification was used to evaluate the expression of the gene of 
interest in comparison to the housekeeping gene β-actin. ∆Ct method was 
used to calculate the relative expression of the gene of interest. This method 
uses Ct values and inversely correlates with gene expression (the highest 
∆Ct value is the lowest expression). The ∆Ct values were calculated using 
the following equation and these values were compared between samples 
being analysed: 
∆Ct (sample) = Ct gene of interest - Ct internal control gene 
2-∆∆Ct method was used to compare the fold change of gene expression 
between cells exposed to hypoxic conditions and cells exposed to normoxic 
conditions (control cells). ∆Ct value was firstly calculated for each sample or 
control cells using the following equation: 
∆Ct (sample) = Ct gene of interest - Ct internal control gene 
∆Ct (control cells) = Ct gene of interest - Ct internal control gene. 
Next, the ∆∆Ct value for each sample was calculated using the following 
equation:  
∆∆Ct = ∆Ct (sample) - ∆Ct (control cells) 
Finally the ∆∆Ct formula was used to estimate the normalised fold 
differences between hypoxia and normoxia exposed cells (Fold change = 2-
∆∆Ct). 
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2.2.1.3.7 Statistical analysis 
The significance of results was assessed through a comparison of means 
using two-tailed student t-test. Results were expressed as the mean ± 
standard deviation. P values were calculated to determine statistical 
significance of the results. 
2.2.1.4 Analysis of ALDH protein expression of CRC cell lines using 
western blot 
2.2.1.4.1 Sample preparation 
The selected CRC cell lines were cultured and exposed to hypoxia as 
outlined in section 2.2.1.2. After exposure to hypoxia, cells were harvested 
as described in section 2.2.1.3.1. The supernatant was removed and cells 
were resuspended in 300 µl RIPA lysis buffer (see Appendix IV for western 
blot buffers and solutions). Cell suspensions were kept on ice under constant 
agitation for 15-20 min, followed by sonication (10s, 3 cycles at power 10) 
twice; between the two sonication steps, samples were kept on ice for 30s. 
Next, samples were centrifuged at 13,200 rcf for 15 min at 4ºC. Supernatants 
were removed to new microcentrifuge tubes. The protein concentration was 
determined using BCA protein assay kit (Thermo Scientific Pierce). Samples 
were then resuspended in 4x Laemmli’s loading buffer [Appendix IV, (2:3, 
sample: total volume)] containing β-mercapto ethanol (6 % v/v) and 
subsequently denatured at 95ºC for 5 min. Finally, the samples were allowed 
to cool down at room temperature and kept at -20ºC for later use. 
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2.2.1.4.2 Determination of protein concentration 
Protein standards ranging from 0 mg/ml to 2 mg/ml were prepared by serial 
dilution of bovine serum albumin standard (BSA, 2 mg/ml) (Thermo Scientific 
Pierce) in distilled water. 10 µl of BSA dilutions were added to the standard 
wells of 96 well plates (Nure 96-well collection plates), 10 µl of distilled water 
were added to the blank wells and 2 µl of the cell lysate were added to the 
sample wells. 50 parts of reagent A and 1 part reagent B (both provided in 
Thermo Scientific Pierce BCA kit) were mixed vigorously and 200 µl of this 
mixture was added to each well. The plate was incubated for 30 min at room 
temperature before the absorbance was measured using a 
spectrophotometer. A standard curve was created for protein standards 
using SkanIt Software 2.4.4 RE for Multiskan Spectrum and the protein 
concentration of the samples in loading buffer was calculated. 
2.2.1.4.3 Polyacrylamide gel preparation 
The gel loading assembly (Bio-Rad) was cleaned with 70% ethanol and 
assembled as directed by the manufacturer’s instructions. A 12% resolving 
gel was prepared and pipetted into the assembled apparatus (Appendix IV). 
0.5 ml of 0.1% (w/v) sodium dodecyl sulphate (SDS) was added above the 
resolving gel which was allowed to set at room temperature for at least 1 h. 
After discarding the SDS, a 5% stacking gel was prepared and pipetted 
above the resolving gel (Appendix IV). A gel comb was inserted and the gel 
was allowed to set at room temperature for at least 30 min. The comb was 
then removed and the gel apparatus was transferred to an electrophoresis 
buffer tank (Bio-Rad) filled with 1x running buffer (Appendix IV). The 
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denatured samples containing 50 µg of protein were loaded in the gel wells 
as well as 8 µl of pre-stained protein ladder (Fermentas PageRuler™ Plus, 
Thermo Scientific Pierce). The gel was run at 70 volt for 1h followed by 120 
volt for 1:30h. 
2.2.1.4.4 Protein transfer to nitrocellulose membrane 
Following electrophoresis, wet blotting was carried out using nitrocellulose 
membrane (GE health care Life Sciences) soaked up in 1x transfer buffer 
(Appendix IV). Transfer was carried out at 35 amps overnight. 
2.2.1.4.5 Immunodetection of electrophoresed proteins after transfer to 
nitrocellulose membrane 
Nitrocellulose membrane was placed over clean tissue and allowed to dry at 
room temperature (3 × 15 min) then washed in PBS Tween 20 (PBST, 
Appendix IV) for 10 min on a shaker (20 rpm). The membrane was then 
placed in 25 ml of 5% blocking solution (5% w/v non-fat milk:PBST, 
(Appendix IV) on a shaker. The blocking solution was discarded and 
replaced with 20 ml of 5% blocking solution containing one of the 
unconjugated primary antibodies (1A1, 1A2, 1A3, 3A1, 7A1 and LDH-A) 
(Table 15, Appendix V). 
The membrane with the primary antibody was incubated at 4ºC on a shaker 
overnight. Next, the membrane was washed with PBST (3 × 5 min) and 
subsequently incubated with 20 ml of 5% blocking solution containing 
horseradish peroxidase (HRP) based secondary antibody (Table 15, 
Appendix V) for 1h on a shaker. Finally, the membrane was washed with 
PBST (3 × 5 min) and then prepared for the detection of the bands. 
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2.2.1.4.6 Enhanced chemiluminescent detection 
The membrane was developed using the enhanced chemiluminescent 
system (Roche). The detection solution was prepared according to the 
manufacturer’s instructions. The excess washing buffer was drained off and 
the prepared detection solution was pipetted on the membrane with the 
surface protein side up. After incubation at room temperature for 1 min, 
excess of detection reagent was removed and the membrane was placed on 
X ray film (Amersham hyperfilmTM ECL, GE Healthcare) processor before 
being developed using Ilford developer and fixer solutions (Developing: 2 
min, d.H2O wash, Fixation: 2 min and final d.H2O wash) (Appendix IV). The 
same membrane was washed with PBST (3 × 5 min) and re-blotted with 
primary and secondary antibodies to detect actin protein (Table 15, Appendix 
V). 
2.2.1.4.7 Data analysis 
Image J software was used to measure the intensity of detected bands. The 
expression level of a target protein was normalised to the actin protein of the 
same sample. In order to calculate the fold change in the expression of the 
target protein upon exposure to hypoxia, the expression level in hypoxic 
samples was normalised to normoxic controls. 
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 The expression of ALDH in colorectal cancer spheroids 2.2.2
2.2.2.1 Spheroids culture 
2.2.2.1.1 Spheroids formation 
Three-dimension (3D) multicellular spheroids were generated from HT29 and 
DLD-1 CRC cell lines using the spinner flask culture technique (O'Connor, 
1999). HT29 or DLD-1 cells were seeded in 250 ml spinner flasks at a 
concentration of 4×106 cells in 100 ml complete RPMI, incubated at 37ºC on 
a magnetic stirrer plate (Techne, Bibby Scientific Limited, Stafford, UK) and 
stirred at 60 rpm. Medium was added to make up 250 ml and renewed every 
two days. Photos were taken at 10 × objective lens on an inverted 
microscope (Nikon ECLIPSE TE2000-U). 
2.2.2.1.2 Spheroids growth curve 
The diameter of HT29 and DLD-1 spheroids was measured from day 3 and 
every other day during the culture period using calibrated graticule fixed to 
the light microscope at 10 × objective lens. Results were plotted as a graph 
with the mean of the diameters of at least 20 spheroids on the Y-axis and 
time (day) on the X-axis. 
2.2.2.2 Histology of spheroids 
2.2.2.2.1 Fixation 
DLD-1 and HT29 spheroids were transferred from spinner flasks to a 20 ml 
universal tube. All medium was removed and replaced with the fixative agent 
Bouin’s solution (Sigma). The spheroids were incubated in Bouin’s solution 
for 75 min at room temperature and then washed in 70% ethanol to remove 
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excess fixative. The spheroids were left in 70% ethanol at room temperature 
until processing. 
2.2.2.2.2 Processing 
The 70% ethanol was replaced with 90% ethanol for 60 min at room 
temperature, which was discarded and replaced with 100% ethanol for 30 
min (100% ethanol wash was repeated twice). Ethanol was then removed 
and replaced with xylene for 30 min (xylene wash was repeated one more 
time). The spheroids were transferred from the universal tube to an 
embedding mould. Any excess xylene was removed and the mould was filled 
with paraffin wax. The spheroids were allowed to settle down in the wax and 
incubated for 30 min at 68ºC in the warming oven. The waste wax was 
pipetted off and replaced with fresh wax and returned to the warming oven 
for another 30 min (repeated twice). The mould was then allowed to set on a 
cold stage. 
2.2.2.2.3 Sectioning 
The wax blocks were stored at -20ºC overnight. Sections (5 µm thick) of 
paraffin embedded spheroid blocks were cut using a microtome and 
mounted on Superfrost Plus slides (BDH, Poole, UK). Slides were allowed to 
dry on a heated stage at 37ºC for at least 2h. This was done to ensure that 
sections were fully attached to the slide surface to reduce the risk of sections 
dislodgement during subsequent use. 
2.2.2.2.4 Haematoxylin and Eosin Staining 
Sections were de-paraffinised with xylene (2 × 5 min) and 50% 
xylene/ethanol (1 × 5 min) then rehydrated using 100% ethanol (1 × 5 min, 
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1× 2 min), 90% ethanol (1 × 2 min) and 70% ethanol (1 × 2 min). Sections 
were then stained with Harris’ haematoxylin (Sigma) for 10 min and washed 
in running tap water for 5 min. Excess stain was removed from the section by 
soaking in acid alcohol (0.5% HCl in 70% ethanol) for a few seconds before 
rinsing in running tap water for 5 min and immersing in Scott’s Tap Water for 
2 min to allow the colour to develop. Sections were counterstained in Eosin 
for 1 min before a final wash in running tap water. Finally, the sections were 
dehydrated using sequential ethanol (1 x 1 min, 1 x 3 min), 50% 
xylene/ethanol (1 × 3 min), xylene (1 × 3 min, 1 × 5 min) and mounted using 
diphenylxylene (BDH) 
2.2.2.3 Hypoxia detection 
2.2.2.3.1 Spheroids treatment with the hypoxic marker pimonidazole 
Hypoxia detection was performed using Hypoxyprobe™-1 Green kit (HPI). 
Pimonidazole, the active compound of Hypoxyprobe, forms stable adducts 
with proteins in hypoxic cells. HT29 (day 10) and DLD-1 (day 15) spheroids 
were transferred to 1.5 ml microcentrifuge tubes. Spheroids were treated 
with pimonidazole dissolved in the culture media (100 μM) for 2h at 37°C.  
2.2.2.3.2 Fixation and processing 
After pimonidazole treatment, all medium was removed and spheroids were 
washed with PBS and transferred to an embedding mould. PBS was 
removed and spheroids were frozen using Cryo-Freeze Aerosol (Agar 
Scientific). Spheroids were embedded in OTC embedding matrix form 
(Cryoteck), sprayed with Cryo-Freeze Aerosol and then kept at -80ºC. 
Negative control samples (no pimonidazole treatment) were also processed. 
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2.2.2.3.3 Sectioning 
Frozen blocks were transferred to -20ºC at least 1 day before sectioning. 
Spheroids were cryosectioned to 5 µm thickness using a microtome 
(LEICA1100). Sections were collected on APES coated slides. 
2.2.2.3.3.1 APES coated slides 
Superfrost Plus slides were immersed in clean acetone for 2 min and allowed 
to drain then immersed in a freshly prepared 4% (v/v) solution of 3-
aminopropyltriethoxysilane (APES) (Sigma) in acetone for 2 min. Slides were 
then drained, washed twice in running tap water for 2 min. Finally, the slides 
were dried overnight and stored at room temperature.  
2.2.2.3.4 Immunofluorescence staining 
Frozen sections (5 µm thick) from the central regions of spheroids were fixed 
for 10 min in acetone at 4°C then washed with PBS for 10 min. Slides were 
blocked for 30 min in 4% (v/v) FBS, 5% (w/v)  non-fat milk, and 0.1% (v/v) 
Triton X-100 (Sigma) in PBS. Pimonidazole adducts were detected by 
incubating sections with FITC conjugated MAb1 (monoclonal mouse 
antibody provided in the Hypoxyprobe™-1 Green kit, 1/150 dilution) for 2h at 
37°C. After PBS washes (3 × 3 min), DNA was stained using DAPI 
(VECTASHIELD Mounting Medium with DAPI, Vector). FITC (green) and 
DAPI (blue) fluorescent signals for spheroids sections were acquired on a 
Leica microscope. 
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2.2.2.4 Isolation of cells residing in surface layer and hypoxic region of 
CRC spheroids 
Cells from different depths within HT29 or DLD-1 spheroids were harvested 
by sequential trypsinisation techniques (Phillips et al., 1994). Spheroids were 
washed with PBS and treated with trypsin-EDTA for 2 min at room 
temperature under constant gentle agitation. After the sample was 
trypsinised, 10 ml of complete growth medium was added, and cells in 
suspension were separated from spheroids by sedimentation. Spheroids 
were washed again with medium, and free floating cells were recovered by 
centrifugation. Pellets of cells were immediately frozen in a dry ice bath and 
stored at -80ºC until required for RNA or protein extraction. This process was 
repeated several times until spheroids were completely stripped of the 
numerous cell layers. After each cell layer was stripped from the spheroid, 
the diameter remaining was measured using calibrated graticule fixed to the 
light microscope at 10 × objective lens. 
2.2.2.5 Analysis of ALDH gene expression of CRC spheroids using 
qRT-PCR 
RNA extraction, cDNA synthesis and qRT-PCR techniques for cells residing 
in the surface layer (SL) and hypoxic region (HR) of the spheroids were 
carried out as described in section 2.2.1.3. The cells of the SL of HT29 and 
DLD-1 MCS were at (0-10.8 µm) and (0-21 µm) depth, respectively, while the 
cell of the HR were at depth of (132-186 µm) and (133-150.7 µm), 
respectively. 
68 
 
2.2.2.6 Analysis of ALDH protein expression of CRC spheroids using 
western blot 
Protein extraction and western blot analysis for cells residing in SL and HR of 
the spheroids were carried out as described in section 2.2.1.4. Image J 
software was used to measure the intensity of detected bands. The 
expression level of a target protein was normalised to the actin protein of the 
same sample. In order to calculate the fold change in the expression of the 
target protein in the SL or HR, the expression level in these samples was 
normalised to normoxic monolayer cells. 
2.2.2.7 Immunohistochemistry staining 
Paraffin embedded spheroids were sectioned and collected on APES coated 
slides as previously described in section 2.2.2.2.3. Slides were processed for 
the detection of ALDH1A1, 1A3, 3A1 and 7A1 and the hypoxic marker, 
carbonic anhydrase IX (CAIX). 
2.2.2.7.1 Dewaxing and rehydration 
Sections were de-paraffinised with xylene (2 x 5 min) and rehydrated using 
absolute ethanol (1 x 5 min, 1 x 2 min), 90% ethanol (2 min) and 70% 
ethanol (2 min) before being washed in distilled water (5 min). 
2.2.2.7.2 Antigen retrieval 
Heat induced antigen retrieval was carried out using citrate buffer (10 mM, 
pH 6.0, see Appendix VI) at medium-high power of microwave for 
appropriate time (Table 16, Appendix VI), after which slides were allowed to 
cool for 30 min at room temperature. Slides were rinsed in PBS (pH 7.4) for 
10 min. 
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2.2.2.7.3 Blocking 
Endogenous peroxidase activity was then blocked using 3% (v/v) H2O2 
(Sigma) in 100% methanol (Sigma) for 15 min at room temperature and 
slides were washed in PBS for 10 min. Afterwards, slides were incubated 
with normal blocking serum (Table 16, Appendix VI) for 30 min at room 
temperature to block the non-specific binding. The blocking serum was 
chosen from species where the biotinylated secondary antibody was raised 
(Table 16, Appendix VI). 
2.2.2.7.4 Antibodies and detection 
The sections were incubated in a humidified chamber with 100 µl of the 
primary antibody at optimum dilution (diluted in blocking serum) for the 
optimised time and incubation conditions (Table 16, Appendix VI). Slides 
were washed in PBS (2 x 5 min) before the addition of 100 µl of the vector 
biotinylated secondary antibody (1:200, 30 min) at room temperature. 
Following this, slides were again washed in PBS (2 x 5 min) and sections 
were incubated with Avidin/Biotin Complex (ABC, Vectastain peroxidase 
standard kit) for 30 min at room temperature. This was followed by PBS 
wash (2 x 5 min) before sections were incubated with 3,3-diaminobenzidine 
(DAB, Vector Laboratories) for 2-10 min at room temperature, enabling the 
ABC reagent to break down the DAB to a brown precipitate at the location of 
the antigen. Sections were washed in running tap water for 5 min before 
being counterstained using Harris’ haematoxylin for 20s, rinsed in tap water 
for 60s, and Scott’s tap water for 2 min. 
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2.2.2.7.5 Dehydration  
Sections were dehydrated using 70% ethanol (1 × 5 min), 90% ethanol (1 × 5 
min), 100% ethanol (2 × 2 min), 50% xylene/ ethanol (1 × 2 min) and xylene 
(1 × 2 min, 1 × 5 min) series and finally mounted using diphenylxylene 
(BDH). 
 The expression of ALDH in colorectal cancer xenografts 2.2.3
The xenografts were previously prepared by Mrs Patricia Cooper at the 
Institute of Cancer Therapeutics. In brief, immunodeficient mice (aged six to 
eight weeks), were obtained from Harlan (Loughborough, UK), and injected 
subcutaneously with human CRC cell lines (HT29, HCT116, DLD-1, SW620 
and COLO205). When the tumour size reached 500 mm3, mice were 
sacrificed. The tumours were then excised, fixed in 10% formalin for 24h and 
processed for embedding in paraffin wax. All animal procedures were 
performed according to a protocol approved by the UK Home Office and in 
accordance with the UK National Cancer Research Institute Guidelines for 
the Welfare of Animals (Workman et al. 2010). 
Paraffin embedded xenografts were sectioned, processed and stained 
according to the immunohistochemistry (IHC) protocol used to detect ALDH 
expression as previously described in section 2.2.2.7. The endogenous 
hypoxic marker, CAIX was used to detect hypoxic areas as previously 
described in section 2.2.2.7. 
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 The role of HIF in the regulation of ALDH7A1 expression 2.2.4
2.2.4.1 Induction of HIF using cobalt chloride (CoCl2) 
Cobalt chloride (CoCl2) is known as a chemical inducer of HIF-1α under 
normoxic conditions (Law et al., 2012) and in an attempt to evaluate whether 
the expression of ALDH is induced by HIF-1α, CoCl2 treatment was carried 
out. To determine the non-toxic concentration that was required to induce 
HIF-1α, DLD-1 and HT29 cells were seeded into 96 well plates by adding 
180 µl of cell suspension containing 2 × 103 cells to each well followed by 
incubation for 24h at 37ºC, 5% CO2 and 100% humidity. Cells were treated 
with CoCl2 (concentration range 10 µM to 500 µM) for 24h before the media 
was replaced with fresh media and the cells were incubated for further 72h, 
after which the anti-proliferative activity was evaluated using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
(Sieuwerts et al., 1995). See Appendix II for the composition of MTT assay 
solutions. 
The medium was replaced with 200 µl MTT solution (0.5 mg/ml) and the cells 
were incubated for an additional 4h. The supernatant was removed and 150 
µl of DMSO was added to each well and gently pipetted up and down to 
dissolve the blue formazan crystals. The absorbance of samples was 
measured in a microplate reader (Thermo Electron Corporation) at 540 nm. 
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Microsoft Excel 2010 was used for data analysis and the percentage of cell 
survival was calculated as follows: 
Mean absorbance for wells containing cells (control or treated) or no cells 
(blank) was calculated. The true absorbance from the microplate reading 
was calculated from the following formula:  
True absorbance = Mean absorbance (each drug concentration or control 
wells) – mean absorbance of blank wells. 
Percentage of cell survival = (true absorbance of treated / true absorbance of 
control) × 100% 
To induce HIF-1α expression, DLD-1 and HT29 cells were seeded into 75 
cm2 flasks at concentration of 2 × 105 cells/flask. Cells were incubated at 
37ºC, 5% CO2 and 100% humidity. Based on the results of the MTT assay, 
DLD-1 (100 and 150 µM CoCl2) and HT29 cells (200 and 300 µM CoCl2) 
were treated for 24h before being harvested for protein extraction. Western 
blot was carried out as previously described in section 2.2.1.4 using HIF-1α 
and ALDH7A1 antibodies (Table 15, Appendix V). 
2.2.4.2 Knockdown of HIF-1α or HIF-2α using siRNA to evaluate their 
effect on ALDH7A1 expression 
2.2.4.2.1 ALDH7A1 expression 
The expression of ALDH7A1 was revaluated in DLD-1 cells upon incubation 
at normoxic or hypoxic conditions, as a part of optimising the conditions for 
knockdown experiments (see below). In brief, DLD-1 cells were seeded at a 
73 
 
concentration of 2.75 × 105 cells/25 cm2 flask in 5 ml complete RPMI and 
incubated at 37˚C and 5% CO2 for 24h. Cells were transferred to the hypoxic 
chamber with medium being replaced with hypoxic preconditioned medium. 
The cells were incubated for a further 24h, 48h and 72h before being 
harvested for RNA and protein extraction. Normoxic cells were included as 
controls at each time point. ALDH7A1 expression was evaluated at the gene 
and protein levels as previously described (Sections 2.2.1.3-4). 
2.2.4.2.2 Preparation of siRNA solution 
siRNA duplexes against HIF-1α or HIF-2α were designed, synthesised and 
validated by Ambion/Life Technologies. See Appendix VII for siRNA 
information. 
Stock solution: 20 µM siRNA solutions of HIF-1α or HIF-2α siRNAs were 
prepared by dissolving 20 nmol of each siRNA (Ambion/Life Technologies) in 
1 ml of 1x Dharmacon siRNA re-suspension buffer. 2 µM of siRNA was also 
prepared as a working stock solution. Both concentrations of siRNA were 
stored in aliquots at -80˚C. 
2.2.4.2.3 Transfection with siRNA 
DLD-1 cells in early passage number (2-4) were seeded at a concentration of 
2.75 × 105 cells/25 cm2 flask in 5 ml complete RPMI and incubated at 37˚C 
and 5% CO2 for 24h. Cells were checked under the microscope to make sure 
that they were 20-30% confluent and evenly distributed throughout the flask 
surface. For single siRNA transfection, siRNA was prepared in 1.5 ml 
microcentrifuge tube by adding 30 µl of 2 µM siRNA stock solution into 525 µl 
Optimem (Gibco). For dual transfection, 15 µl of each siRNA (2 µM stock) 
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were added into 525 µl Optimem. 45 µl of diluted oligofectamine solution (1:5 
oligofectamine (Life Technologies) in Optimem was prepared and incubated 
for 30 min at room temperature) was added to siRNA mix (final concentration 
= 7.5% v/v) and was thoroughly mixed by pipetting (20-30 times). The mix 
was incubated for 45 min inside the cell culture safety cabinet. A control 
solution with the liposome carrier was prepared by adding 45 µl of diluted 
oligofectamine solution into 555 µl Optimem. During the incubation time, 
medium was removed from the flasks and 5 ml of Optimem was added to 
each flask for washing before being discarded. 2 ml of fresh Optimem was 
then added to each flask. After 45 min of incubation, 500 µl of siRNA mix 
was added to relevant flasks (final concentration of each siRNA in single or 
co-transfection is 20 or 10 nM respectively). For liposome control cells, 500 
µl of control solution was added to each flask. For mock-transfected cells, 
500 µl of Optimem only was added to each flask. Cells were incubated at 
37ºC and 5% CO2 for 4h before being exposed to hypoxia (0.1% O2); 2.5 ml 
preconditioned hypoxic 2x RPMI was added to each flask. Normoxic mock 
samples were also included as a control and 2.5 ml of 2x RPMI was added to 
each flask. Cells were then incubated for 48h or 72h before being harvested 
for RNA or protein extraction. The expression of HIF-1α, HIF-2α and 
ALDH7A1 was evaluated at both the gene and protein levels as previously 
described in sections 2.2.1.3-4 (Table 15, Appendix V for antibodies 
information). 
  
75 
 
2.3 Results 
 Analysis of ALDH expression in CRC cell lines 2.3.1
2.3.1.1 Gene expression using q-RT-PCR 
2.3.1.1.1 ALDH gene expression profiling of CRC cell lines under 
normoxic conditions 
ALDH gene expression levels were evaluated for seven selected ALDH 
isoforms ALDH1A1, 1A2, 1A3, 1B1, 2, 3A1 and 7A1 in four CRC cell lines 
(DLD-1, HCT116, HT29 and SW480). These isoforms were selected as they 
have been found to play various roles in cancer; ALDH1A1 and 1A3 in 
CSCs, 1A2 as TSG in prostate cancer, 1B1 as a potential biomarker for 
CRC, 2 in oesophageal carcinoma, 3A1 in drug resistance and 7A1 as a 
contributing mediator of prostate cancer metastasis (Chapter 1 Introduction, 
section 1.4.3-5). 
As shown in Figure 9A, qRT-PCR of DLD-1 cells revealed high gene 
expression of ALDH1B1, 2, 3A1 and 7A1 compared to ALDH1A3, while 
ALDH1A1 and 1A2 showed the lowest expression. Similar analysis was 
performed in HCT116 cells and revealed high endogenous levels of 
ALDH1A3, 1B1, 2 and 7A1 compared to ALDH3A1, while ALDH1A1 and 1A2 
were expressed at the lowest levels (Figure 9B). A similar pattern of 
expression was also found in SW480 (Figure 9D). In contrast to other CRC 
cell lines examined, qRT-PCR of HT29 showed that there was less 
differential expression between the ALDHs, with ALDH1A2 exhibiting the 
lowest expression (Figure 9C). 
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2.3.1.1.2 ALDH genes expression profiling under hypoxic conditions 
The CRC cell lines were exposed to hypoxic conditions and stained with 
Haematoxylin as previously described (Material and Methods, section 
2.2.1.2), which revealed cells were still viable and attached to the flask 
surface (Figure 10). 
  
A B 
C D 
Figure 9 Expression profiling of ALDH1A1, 1A2, 1A3, 1B1, 2, 3A1 and 7A1 mRNAs in CRC 
monolayer cells. DLD-1 (A), HCT116 (B), HT29 (C) and SW480 (D). Values are the mean of 3 
independent experiments and error bars are SD. ∆Ct= Ct (target gene) – Ct (actin). 
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Figure 10 Histology of DLD-1 (A-D), HCT116 (E-H), HT29 (I-L) and SW480 (M-P) CRC monolayer cells. Normoxic 
conditions (A,E,I,M), Hypoxic conditions [6h (B, F,J,N), 24h (C, G,K,O), 48h (D,H,L,P)]. Scale bar = 100 µm at 10x 
objective lens. 
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Gene expression analysis of ALDH isoforms was evaluated using qRT-PCR 
(Materials and Methods, section 2.2.1.3). 
In order to evaluate whether the selected exposure times to hypoxic 
conditions were enough to induce changes at the gene level, VEGFA gene 
expression was used as a positive control. As shown in Figure 11, VEGFA 
gene expression was induced in DLD-1 cells upon exposure to 24h and 48h 
of 0.1% O2. In contrast, only the expression of ALDH1A2 and ALDH7A1 was 
found to be upregulated about a 3-fold in response to the same hypoxic 
conditions. 
The same analysis was carried out in HCT116 cells (Figure 12). All 
examined ALDH isoforms showed similar response to hypoxia exposure: 
downregulation after transient exposure to hypoxia (6h) and an increase in 
expression after 48h with the exception of ALDH2 and ALDH7A1, which at 
the last time point had not yet recovered to normoxic expression levels. 
Figure 11 Influence of hypoxia on the expression of ALDH mRNA in DLD-1 cells. VEGFA was used as 
positive control and β-actin as internal control gene. ALDH gene expression analysis was performed under 
normoxic (control, blue bar) and hypoxic conditions (0.1% O2; 6h (red bar), 24h (green) and 48h (purple)). 
Values are the mean of 3 independent experiments and error bars are SD. P values: * p<0.05, ** p<0.01, *** 
p<0.001. For Raw data, see Appendix IX. 
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Figure 13 shows that VEGFA was upregulated in HT29 cells in response to 
hypoxia reaching 5-fold after 48h. The results of ALDH gene expression 
analysis revealed that ALDH1A1, 1A2 and 7A1 were upregulated after 48h of 
exposure to hypoxia reaching 5, 9 and 6-fold, respectively. The expression of 
ALDH1B1 was also increased, however this elevation was not correlated 
with hypoxia exposure time. 
  
Figure 12 Influence of hypoxia on the expression of ALDH mRNA in HCT116 cells. VEGFA was used as 
positive control and β-actin as internal control gene. ALDH gene expression analysis was performed under 
normoxic (control, blue bar) and hypoxic conditions (0.1% O2; 6h (red bar), 24h (green) and 48h (purple)). Values 
are the mean of 3 independent experiments and error bars are SD. P values: * p<0.05, ** p<0.01, *** p<0.001. 
 
.  
Figure 13 Influence of hypoxia on the expression of ALDH mRNA in HT29 cells. VEGFA was used as 
positive control and β-actin as internal control gene. ALDH gene expression analysis was performed under 
normoxic (control, blue bar) and hypoxic conditions (0.1% O2; 6h (red bar), 24h (green) and 48h (purple)). 
Values are the mean of 3 independent experiments and error bars are SD. P values: * p<0.05, ** p<0.01. 
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Exposure of SW480 cells to hypoxia (6h) resulted in 3-fold increase of 
ALDH1A1 and 1A2 expression, however, the upregulation was transient and 
the expression levels declined as the exposure times increased reaching the 
same levels as under normoxic conditions (Figure 14). Only ALDH1A3 was 
found to be upregulated upon 48h exposure to hypoxia, while ALDH1B1, 2 
and 7A1 were downregulated in response to low oxygen tensions. 
2.3.1.2 Analysis of ALDH protein expression using western blot 
The protein expression levels of selected ALDH isoforms 1A1, 1A2, 1A3, 
3A1 and 7A1 were evaluated in CRC cell lines 48h after exposure to 
normoxic conditions or 0.1% O2 using western blot. ALDH1B1 and 2 were 
not selected for protein analysis as these isoforms were not shown to be 
significantly affected by exposure to low oxygen tension over 48h. All cell 
lines were probed for target ALDH expression after they were loaded to the 
same gel. Here lactate dehydrogenase A (LDH-A) protein was used as a 
Figure 14 Influence of hypoxia on the expression of ALDH mRNA in SW480 cells. VEGFA was used as 
positive control and β-actin as internal control gene. ALDH gene expression analysis was performed under 
normoxic (control, blue bar) and hypoxic conditions (0.1% O2; 6h (red bar), 24h (green) and 48h (purple)). Values 
are the mean of 3 independent experiments and error bars are SD. P values: * p<0.05, ** p<0.01, *** p<0.001. 
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positive control because the VEGFA antibody was not producing clear bands 
in contrast to LDH-A that gave reliable bands.  
The expression of ALDH1A1, 1A2, and 1A3 at the protein level was not 
detectable in the DLD-1 cell line (Figure 15B-D). This observation is 
consistent with the gene expression data where these isoforms were 
expressed at low level compared to other isoforms (Figure 9, section 
2.3.1.1.1). Even after 48h exposure to hypoxia (0.1% O2), no variation in the 
expression was observed. In contrast, the positive control protein LDH-A was 
found to be upregulated 6-fold after 48h exposure to hypoxia (0.1% O2) 
(Figure 15A). ALDH3A1 was largely unaffected (Figure 15E), while 
ALDH7A1 was found to be upregulated by 25% after exposure to hypoxia 
(Figure 15F) indicating good correlation between the gene (Figure 11, 
section 2.3.1.1.2) and protein expression patterns. 
Figure 15 Western blot analysis of ALDH in DLD-1 cell line under normoxic 
(N) and hypoxic conditions (H) (48h exposure to 0.1% O2). LDH-A (A), 1A1 
(B), 1A2 (C), 1A3 (D), 3A1 (E) and 7A1 (F). 
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ALDH1A3 was observed to be increased to 1.3-fold after hypoxia exposure 
(Figure 16D) while ALDH7A1 was slightly reduced in HCT116 cells (Figure 
16F). ALDH1A1, 1A2 and 3A1 were not expressed in normoxic or hypoxic 
cells (Figure 16B, C and E respectively), which is in agreement with gene 
expression data (Figure 9 and 12, section 2.3.1.1.1-2). LDH-A was 
upregulated in hypoxia exposed cells (Figure 16A). 
  
Figure 16 Western blot analysis of ALDH in HCT116 cell line under normoxic (N) and hypoxic conditions 
(H) (48h exposure to 0.1% O2). LDH-A (A), 1A1 (B), 1A2 (C), 1A3 (D), 3A1 (E) and 7A1 (F). 
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Among the three ALDH1 isoforms examined in HT29 cells, only ALDH1A1 
was detected in normoxic cells. However, no major variation in its expression 
between normoxic and hypoxic cells was detected (Figure 17B), which was 
in contrast to LDH-A that was induced a 3-fold (Figure 17A). ALDH3A1 and 
7A1 were also expressed in cells grown under normoxic conditions (Figure 
17E and F). ALDH3A1 expression was slightly reduced in hypoxic cells 
(Figure 17E), however, ALDH7A1 was upregulated 1.34-fold (Figure 17F). 
These findings confirm the modulation of ALDH expression that was 
observed in hypoxic cells at the gene level (Figure 13, section 2.3.1.1.2). 
Figure 17 Western blot analysis of ALDH in HT29 cell line under normoxic (N) and hypoxic 
conditions (H) (48h exposure to 0.1% O2). LDH-A (A), 1A1 (B), 1A2 (C), 1A3 (D), 3A1 (E) and 7A1 (F).  
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Figure 18 shows the ALDH protein expression of SW480 cells which showed 
a similar pattern of expression as observed in HCT116 cells. LDH-A was 
upregulated 1.3-fold under hypoxic conditions (Figure 18A), however ALDH 
1A1, 1A2 and 3A1 were not detected under normoxic or hypoxic conditions 
(Figure 18B, C and E). In contrast, the ALDH1A3 protein was detected in 
normoxic cells and a 2.17-fold induction was observed upon hypoxia 
exposure (Figure 18D). ALDH7A1 was also detected in control cells and its 
level was found to be slightly downregulated under hypoxic conditions (0.85-
fold) (Figure 18F). These findings are consistent with the gene expression 
data (Figure 14, section 2.3.1.1.2). 
Figure 18 Western blot analysis of ALDH in SW480 cell line under normoxic (N) and hypoxic conditions 
(H) (48h exposure to 0.1% O2). LDH-A (A), 1A1 (B), 1A2 (C), 1A3 (D), 3A1 (E) and 7A1 (F). 
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Table 11 shows summary of the findings of ALDH expression at both the 
mRNA and protein levels upon exposure to 0.1% O2 for 48h in DLD-1, 
HCT116, HT29 and SW480 cell lines.  
 mRNA level Protein level 
ALDH1A1   
DLD-1 No major difference Not detected 
HCT116 No major difference Not detected 
HT29 Upregulated No major difference 
SW480 No major difference Not detected 
ALDH1A2   
DLD-1 Upregulated Not detected 
HCT116 Upregulated Not detected 
HT29 Upregulated Not detected 
SW480 No major difference Not detected 
ALDH1A3   
DLD-1 No major difference Not detected 
HCT116 Upregulated Upregulated 
HT29 Downregulated  Not detected 
SW480 Upregulated Upregulated 
ALDH3A1   
DLD-1 No major difference No major difference 
HCT116 No major difference Not detected 
HT29 Downregulated Downregulated  
SW480 No major difference Not detected 
ALDH7A1   
DLD-1 Upregulated Upregulated 
HCT116 Downregulated Downregulated 
HT29 Upregulated Upregulated 
SW480 Downregulated Downregulated 
Table 11 Summary of ALDH1A1, 1A2, 1A3. 3A1 and 7A1 expression at the mRNA and 
protein levels upon exposure to 0.1% O2 for 48h. 
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 Analysis of ALDH expression of colorectal spheroids 2.3.2
2.3.2.1 Spheroids culture 
2.3.2.1.1 Spheroids generation 
The DLD-1 and HT29 CRC cell lines were incubated in a spinner flask as 
previously described in Materials and Methods, section 2.2.2.1. As shown in 
Figure 19A, HT29 cells were able to form spheroids when incubated in 
spinner flasks. Small spheroids were visible after 3 days of incubation and 
their diameter was increasing as the period of incubation was prolonged.  
The growth of the spheroids was monitored by taking the average diameter 
and plotting it against the time of incubation. Figure 19B reveals the diameter 
of HT29 multicellular spheroids (MCS) increasing proportionally with the 
incubation time, reaching approximately 1200 µm after 17 days. 
A 
Figure 19 HT29 spheroids growth using spinner flasks. Photos of HT29 MCS at 10x objective lens (A). 
Growth curve of HT29 MCS (B). Points represent the average of at least 20 spheroids and error bars are 
SD.  
A B 
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Figure 20A shows that DLD1 cells were able to form small spheroids after 3 
days of incubation in a spinner flask. In addition, the diameter was increasing 
proportionally with the incubation time, albeit slower than the HT29 
spheroids. The growth curve shows that DLD-1 spheroids were growing 
exponentially reaching approximately 600 µm after 15 days of incubation 
(Figure 20B).  
  
Figure 20 DLD-1 spheroids growth using spinner flasks. Photos of DLD-1 MCS at 10x objective lens (A). 
Growth curve of DLD-1 MCS (B). Points represent the average of at least 20 spheroids and error bars are SD. 
A B 
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2.3.2.1.2 Characterisation of Spheroids 
In order to investigate the HT29 cells residing in the inner hypoxic regions 
and the outer peripheral layers, spheroids were sectioned and stained with H 
& E (Materials and Methods, section 2.2.2.2). As shown in Figure 21, the 
size of spheroids increased proportionally with incubation time. The necrotic 
(inner) core was only observed after 10 days of incubation when the 
diameter reached approximately 600 µm (Figure 21E). In addition, as the 
spheroids increased in size, the necrotic core also increased.  
Figure 21 Histology of HT29 spheroids. Spheroids were processed and stained with H & E staining (day 
3 (A), day 5 (B), day 7 (C), day 8 (D), day 10 (E), day 13 (F), day 15 (G) and day 17 (H)). Surface layer 
(SL), Necrotic core (NC). Scale bar = 100 µm at 10x objective lens.  
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Similar histology experiments were conducted using DLD-1 spheroids. As 
illustrated in Figure 22, the necrotic core was visible after 15 days of 
incubation when the spheroid diameter reached approximately 600 µm and 
this increased in size after a further 2 days of incubation. 
  
Figure 22 Histology of DLD-1 spheroids. Spheroids were processed and stained with H&E staining (day 3 (A), 
day 7 (B), day 10 (C), day 13 (D), day 15 (E), day 17 (F)). Surface layer (SL), Necrotic core (NC). Scale bar = 
100 µm at 10x objective lens.  
 
90 
 
2.3.2.1.3 Detection of the hypoxic region of MCS 
Pimonidazole, a hypoxic marker, is reductively activated in an oxygen 
dependent manner and is covalently bound to thiol-containing proteins in 
hypoxic cells (Varia et al., 1998). Pimonidazole–protein adducts can be 
detected by means of immunohistochemistry, immunofluorescence and flow 
cytometry (Varia et al., 1998). In this study, when the necrotic cores of HT29 
and DLD-1 MCS were observed for the first time they were treated with 
pimonidazole on day 10 and 15, respectively, followed by 
immunofluorescence as described in Materials and Methods, section 2.2.2.3. 
Figures 23A and B show the necrotic cores in the centre of the HT29 and 
DLD-1 spheroids, respectively. Cells directly around the necrotic core have 
very bright green fluorescence, which decreases gradually as the distance to 
the surface layer cells of the spheroids becomes smaller. The peripheral 
cells residing in the surface layer were only stained with DAPI.  
  
Figure 23 Hypoxia detection in HT29 (A) and DLD-1 (B) MCS. Hypoxic regions are stained by 
pimonidazole (green) and nuclei are stained using DAPI (blue). Surface layer (SL), Necrotic core 
(NC), Hypoxic region (HR). Scale bar = 100 μm at 10x objective lens.  
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2.3.2.1.4 Isolation of different layers from MCS 
A total of 6 layers of cells were stripped and isolated from HT29 MCS and 7 
layers were isolated from DLD-1 MCS. The change in diameter of spheroids 
for each layer of cells removed is presented in Figure 24 (HT29 (A), DLD-
1(B)). 
2.3.2.2 Expression profiling of ALDH genes and proteins of cells 
residing in the surface layer and the hypoxic region of MCS 
The gene and protein expression was analysed in cells residing in the 
surface layer (depth ≈ 0-10.8 µm) and hypoxic region (depth ≈ 132-186 µm) 
of HT29 spheroids. 
The results of qRT-PCR (Figure 25) shows that VEGFA (positive control) is 
highly upregulated in the hypoxic region (HR) compared to surface layer (SL) 
or monolayer (ML) cells. The expression of ALDH1A1 and 1A2 was 
enhanced in SL but reduced as the depth increased toward the HR. 
However, both layers showed higher expression in comparison to monolayer. 
Figure 24 Isolation of cells from different depths within MCS by sequential 
trypsinisation. HT29 (A) and DLD-1 (B) spheroid diameters after trypsinisation. 
Points represent the mean of at least 30 spheroids and error bars are SD.  
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ALDH1B1 also showed increased expression in SL compared to the HR, 
which was shown to have the same expression level as in monolayer cells. 
ALDH1A3 and 3A1 were slightly downregulated in SL and that was more 
pronounced as the depth increased toward the HR. ALDH2 showed 
upregulation in the HR compared with both the SL and the monolayer cells. 
The SL showed 5-fold upregulation of ALDH7A1 compared to monolayer and 
the expression was elevated more in the HR (7-fold). 
To evaluate whether these observations were translated to the protein level, 
western blot was carried out and protein expression was analysed in SL and 
HR cells and compared to monolayer cells. Figure 26 shows that ALDH1A1 
was upregulated in SL (1.4-fold) and HR (1.8-fold) compared to monolayer 
cells. The expression of ALDH1A2 and 1A3 was not detected in spheroids 
nor in monolayer cells. No major difference was observed in ALDH3A1 
expression in SL compared to monolayer, however, the expression was 
reduced in HR cells, which is in agreement with gene analysis results. 
ALDH7A1 showed 1.9-fold increase in SL and 4.6-fold in the HR compared 
to monolayer cells. 
Figure 25 The expression of ALDH mRNA in HT29 MCS. Gene expression analysis was carried out using 
q-RT-PCR. VEGFA was used as positive control and β-actin as internal control gene. Values are the mean of 
3 independent experiments and error bars are SD. P values: * p<0.05, ** p<0.01.  
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Similar analysis was carried out in DLD-1 spheroids. The gene and protein 
expression was analysed in cells residing in the surface layer (depth ≈ 0-21 
µm) and hypoxic region (depth ≈ 133-150.7 µm) of DLD-1 spheroids. 
Figure 27 shows the results of qRT-PCR. The positive control gene VEGFA 
was upregulated in the hypoxic region but not in the surface layer, confirming 
the presence of hypoxia in the deep layer of DLD-1 spheroids but not in the 
surface layer. Slight upregulation of ALDH1A1 was observed in SL, however 
this was significantly elevated in the HR (5-fold). No major variation was 
detected in other ALDH1 isoforms (1A2, 1A3 and 1B1). ALDH2 and 3A1 
showed elevated level of expression in the HR compared to SL, while 
ALDH7A1 was found to be elevated in both SL (2-fold) and HR (3-fold) layers 
compared to monolayer cells. 
Figure 26 ALDH protein expression profiling of HT29 MCS. Western blot (A), Fold changes of protein level 
(B). Protein expression analysis was carried out using western blot. Actin was used as internal control protein. 
Monolayer (ML), Surface layer (SL) and Hypoxic region (HR).  
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Western blot analysis was carried out to see whether these observations 
were translated to protein level (Figure 28). ALDH1 isoforms were not 
detected in SL or in HR. ALDH3A1 was found to be upregulated in HR 
compared to monolayer (ML) (1.8-fold) with no major difference in 
expression between SL and ML, while ALDH7A1 was found to be elevated in 
SL and HR compared to ML (2.7 and 3-fold, respectively).  
 Figure 27 ALDH protein expression profiling of DLD-1 MCS. Western blot (A), Fold changes of 
protein level (B). Protein expression analysis was carried out using Western blot. Actin was used 
as internal control protein. Monolayer (ML), Surface layer (SL) and Hypoxic region (HR).  
 
Figure 28 The expression of ALDH mRNA in DLD-1 MCS. Gene expression analysis was carried out using 
q-RT-PCR. VEGFA was used as positive control and β-actin as internal control gene. Values are the mean of 3 
independent experiments and error bars are SD. P values: * p<0.05.  
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2.3.2.3 Evaluation of ALDH expression in colorectal cancer MCS and 
tumour xenograft models 
To evaluate the distribution of ALDH and their cellular localisation, protein 
expression was evaluated in colon cancer MCS and tumour xenograft 
models using IHC staining as previously described in Materials and Methods, 
section 2.2.2.7.  
Figure 29A shows that ALDH1A1 is uniformly expressed in HT29 MCS with 
the main expression occurring in the cytoplasm, although some cells show 
nuclear staining as well. Furthermore, some cells residing in the necrotic 
core were also expressing ALDH1A1. DLD-1 MCS showed positive staining 
in the deeper hypoxic region, while surface layers showed faint staining 
indicating less expression compared to hypoxic region (Figure 29B). 
  
Figure 29 Immunohistochemistry of ALDH1A1 in HT29 (A) and DLD-1 (B) MCS. Brown colour 
indicates positive staining and ALDH1A1 expression. Scale bar = 100 µm at 10x and 40x objective 
lens.  
96 
 
Figure 30A shows high expression of ALDH1A1 in the HT29 xenograft with 
staining primarily in the cytoplasm and some cells showing positive nuclear 
expression. The COLO205 xenograft also had high expression of ALDH1A1 
in both cytoplasmic and nuclear compartments (Figure 30E). The DLD-1 
xenograft showed moderate cytoplasmic expression of ALDH1A1 (Figure 
30B), while the HCT116 and SW620 xenografts had the lowest cytoplasmic 
expression of ALDH1A1 amongst the xenografts models investigated (Figure 
30C and D, respectively). 
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Figure 30 Immunohistochemistry of ALDH1A1 in colon cancer 
xenografts. HT29 (A), DLD-1 (B), HCT116 (C), SW620 (D) and COLO205 
(E). Brown colour indicates positive staining and ALDH1A1 expression. 
Nuclear staining (N) and cytoplasmic staining (C). Scale bar = 100 µm at 
40x objective lens.  
N 
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Figure 31 shows that both HT29 and DLD-1 MCS do not express ALDH1A3 
confirming the results from western blot (Figure 26 and 28, section 2.3.2.2). 
IHC of xenografts are shown in Figure 32. Only stromal cells in HT29 
xenograft have weak detectable expression of ALDH1A3, while tumour cells 
were negative. The DLD-1 and SW620 xenografts showed weak, primarily 
cytoplasmic expression, while COLO205 xenografts were shown to express 
both weak cytoplasmic and nuclear ALDH1A3 expression. HCT116 showed 
the highest expression, primarily in the cytoplasm although some cells also 
showed nuclear expression.  
  
Figure 31 Immunohistochemistry of ALDH1A3 in HT29 (A) and DLD-1 (B) MCS. Both spheroids 
were negative for ALDH1A3 expression (no brown colour was detected). Scale bar = 100 µm at 10x 
and 40x objective lens.  
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Figure 32 Immunohistochemistry of ALDH1A3 in colon cancer xenografts. 
HT29 (A), DLD-1 (B), HCT116 (C), SW620 (D) and COLO205 (E). Brown colour 
indicates positive staining and ALDH1A3 expression. Nuclear staining (N), 
cytoplasmic staining (C) and stromal staining (S). Scale bar = 100 µm at 40x 
objective lens.  
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IHC staining of ALDH3A1 showed high expression in both HT29 and DLD-1 
MCS (Figure 33). The expression was mainly cytoplasmic in HT29 but both 
cytoplasmic and nuclear in DLD-1 MCS. Interestingly, cells in the necrotic 
core of both spheroids showed positive nuclear staining of ALDH3A1. 
All tested xenograft models showed weak, primarily cytoplasmic expression 
of ALDH3A1 with the exception to COLO205, which showed high nuclear 
expression as well (Figure 34). 
  
Figure 33 Immunohistochemistry of ALDH3A1 in HT29 (A) and DLD-1 (B) MCS. Brown colour indicates 
positive staining and ALDH3A1 expression. Nuclear staining (N) and cytoplasmic staining (C). Scale bar = 
100 µm at 10x and 40x objective lens.  
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Figure 34 Immunohistochemistry of ALDH3A1 in colon cancer xenografts. 
HT29 (A), DLD-1 (B), HCT116 (C), SW620 (D) and COLO205 (E). Brown colour 
indicates positive staining and ALDH3A1 expression. Nuclear staining (N) and 
cytoplasmic staining (C). Scale bar = 100 µm at 40x objective lens. 
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Figure 35 shows the expression of ALDH7A1 in MCS. Both spheroids were 
shown to possess high expression of this isoform in the hypoxic regions, 
which gradually reduced with distance to the peripheral surface layers. This 
finding confirms that ALDH7A1 is upregulated in hypoxic areas. The 
expression was both cytoplasmic and nuclear in HT29 MCS. In contrast, the 
DLD-1 surface layer cells showed only cytoplasmic staining while inner 
layers showed both cytoplasmic and nuclear. Some cells in the necrotic core 
of both MCS models were stained positive for ALDH7A1. 
Figure 36 shows that ALDH7A1 is highly expressed in all examined 
xenograft models. Its expression is mainly cytoplasmic, although some cells 
showed nuclear expression as well. 
Figure 35 Immunohistochemistry of ALDH7A1 in HT29 (A) and DLD-1 (B) MCS. Brown colour indicates 
positive staining and ALDH7A1 expression. Nuclear staining (N) and cytoplasmic staining (C). Scale bar = 
100 µm at 10x and 40x objective lens. 
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Figure 36 Immunohistochemistry of ALDH7A1 in colon cancer xenografts. 
HT29 (A), DLD-1 (B), HCT116 (C), SW620 (D) and COLO205 (E). Brown colour 
indicates positive staining and ALDH7A1 expression. Nuclear staining (N) and 
cytoplasmic staining (C). Scale bar = 100 µm at 40x objective lens.  
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2.3.2.4 Detection of hypoxia in MCS and xenograft models 
The areas of hypoxia were identified in HT29 MCS using the hypoxic marker 
carbonic anhydrase IX (CAIX). Figure 37 shows the hypoxic region of HT29 
MCS that were stained with CAIX (brown) where CAIX is mainly located in 
the cellular membrane of HT29 cells, although some cytoplasmic expression 
was also observed. In comparison, cells residing in the outer layers showed 
no expression, suggesting that these cells were not hypoxic. The expression 
of ALDH7A1 as previously described is significantly elevated in the hypoxic 
region of HT29 MCS compared to the outer viable rim, indicating that low 
oxygen tensions may modulate ALDH7A1 expression. In contrast, 
localisation of the hypoxic regions in DLD-1 MCS and xenografts were 
unsuccessful with anti-CAIX antibody, although different incubation 
conditions were carried out and HT29 spheroids were included as controls. 
  
Figure 37 Immunohistochemistry of CAIX in HT29 MCS. Brown colour indicates positive staining and  
CAIX expression. Membranous staining (M) and cytoplasmic staining (C). Scale bar = 100 µm at 10x and 
40x objective lens. 
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 Regulation of ALDH7A1 expression by HIF 2.3.3
2.3.3.1 HIF-1α induction using CoCl2 treatment 
Results from 2D and 3D experiments showed that ALDH7A1 is upregulated 
under hypoxia in both HT29 and DLD-1 cells. To understand whether the 
expression of ALDH7A1 was regulated by HIF-1α, cells were treated with 
CoCl2, which is known as an inducer of HIF-1α protein (Piret et al., 2002). 
The concentration of CoCl2 was selected based on the results of the MTT 
assay. Figure 38 shows the dose response curve of DLD-1 and HT29 cells 
that were treated with CoCl2 for 24h. 100 and 150 µM were chosen to treat 
DLD-1 cells while 200 and 300 µM were chosen to treat HT29 cells. 
CoCl2 treatment induced significant expression of HIF-1α but not ALDH7A1 
in both DLD-1 and HT29 cell lines (Figure 39), which point towards 
ALDH7A1 being independent of the HIF-1α key regulator. 
Figure 38 Dose response curve of 24h CoCl2 treatment in HT29 and 
DLD-1 cell lines using the MTT assay. Values are the mean of 3 
independent experiments and error bars are SD.  
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2.3.3.2 Knockdown of HIFs and their effect on ALDH7A1 expression 
The expression of ALDH7A1 was measured in DLD-1 cells after 24h, 48h 
and 72h exposure to hypoxia, revealing an upregulation at each time point at 
both the gene and protein levels (Figure 40). This preliminary finding 
reconfirms that ALDH7A1 was upregulated under hypoxic conditions. 
  
A B 
C D 
Figure 39 Western blot analysis of HIF-1α and ALDH7A1 protein expression upon 
treatment with CoCl2 in HT29 cells (A,B) and DLD-1 cells (C,D). Actin was used as internal 
control protein.  
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The previous experiment using CoCl2 treatment, however, showed no 
difference in ALDH7A1 expression upon induction of HIF-1α. Accordingly, to 
confirm this observation and to evaluate whether HIF-2α might have a 
regulatory role, single and dual knockdown experiments of HIF-1α and HIF-
2α were carried out under hypoxic conditions. 
Figure 41 shows the preliminary result with significant reduction in HIF-1α 
and HIF-2α gene expression was achieved after 48h and 72h of single or 
dual siRNAs transfection. However, it was not possible to confirm this at the 
protein level as no bands were detected using western blot. 
A 
B 
Figure 40 ALDH7A1 expression in DLD-1 cells upon exposure to 
hypoxia for 24h, 48h and 72h. ALDH7A1 mRNA expression using qRT-
PCR (A). ALDH7A1 protein expression using western blot (B). Results 
represent one experiment. 
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Nevertheless, gene analysis of ALDH7A1 in HIF-α knockdown cells was 
carried out. The preliminary results showed that ALDH7A1 gene expression 
was not affected after 48h or 72h of single HIF-α knockdown. On the other 
hand, dual knockdown of HIF-1α and HIF-2α after 72h resulted in 50% 
reduction of ALDH7A1 expression at the mRNA level (Figure 42A). The 
results of ALDH7A1 protein expression, however, revealed that it was not 
significantly affected upon HIF knockdown (Figure 42B). 
The aforementioned findings suggest that ALDH7A1 expression under 
hypoxic conditions is HIF1α/2α independent. 
  
Figure 41 The expression of HIF1-α and HIF2-α mRNA in DLD-1 cells 
using qRT-PCR upon HIFs knockdown. HIF1-α (A), HIF2-α (B), 
Normoxia (N), Hypoxia (H). Results represent one experiment. 
 
109 
 
  
Figure 42 The expression of ALDH7A1 after HIF knockdown. ALDH7A1 mRNA expression using qRT-PCR 
after 48h and 72h of HIF-α knockdown (A). ALDH7A1 protein expression using western blot after 72h of HIF 
knockdown (B). Results represent one experiment. 
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2.4 Discussion 
Some evidence suggests that certain ALDH isoforms may play important 
roles in the aggressiveness of colorectal cancer. ALDH1A1 has been shown 
to act as a stem cell marker (Emmink et al., 2013), while 1B1 in one study 
was shown to be highly expressed in clinical tissue and on this basis was 
suggested to be a potential colon cancer biomarker (Chen et al., 2011). In 
addition, it has been demonstrated that ALDH1A3 and 3A1 are involved in 
drug resistance and metastasis, respectively (Touil et al., 2014, Tang et al., 
2014) (for further details, see Introduction, section 2.1). 
Given the role of the tumour microenvironment and hypoxia in the 
aggressiveness of CRC and drug resistance (Mathonnet et al., 2014), this 
study was designed to explore the link between hypoxia and ALDH 
expression. Specifically, the impact of hypoxia on the expression of selected 
ALDH isoforms (1A1, 1A2, 1A3, 1B1, 2, 3A1 and 7A1) that have been linked 
to cancer pathogenesis was evaluated. ALDH7A1 was of particular interest 
due to its role in protection against oxidative stress (Brocker et al., 2011). It 
was envisaged that this line of investigation would subsequently aid in 
determining the suitability of using ALDHs as biomarker(s) and/or therapeutic 
target(s). 
To interrogate ALDH expression, a panel of CRC cell lines (DLD-1, HT29, 
HCT116 and SW480) were exposed to very low oxygen level (0.1%) and 
compared to cells grown under normoxia. Although an oxygen gradient 
exists across a solid tumour, 0.1% O2 was chosen in this study as it is a 
physiologically relevant level that is associated with induction of HIF-1 
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activation (Wilson and Hay, 2011) and likely to support an aggressive 
microenvironment. 
Gene expression profiling of ALDH was evaluated by measuring the level of 
mRNA using qRT-PCR (Ginzinger, 2002), while protein expression was 
evaluated using western blot (Mahmood and Yang, 2012). VEGFA gene was 
used as a positive control because it is known to be upregulated under 
hypoxic conditions (Bergers and Benjamin, 2003). However, the antibody of 
VEGFA for western blot did not work consistently in all experiments and 
therefore, LDH-A was also used as a positive control to validate the hypoxia-
related experiments (Firth et al., 1995). In this study, all cell lines showed 
upregulation of VEGFA gene and LDH-A protein in hypoxic samples, 
confirming that cells were exposed to hypoxic conditions capable of inducing 
changes at the gene and protein levels. 
The CSC marker ALDH1A1 was found to be expressed at low level in all 
examined normoxic cell lines except HT29 cells. Exposure of these cells to 
hypoxia resulted in upregulation of ALDH1A1 in both HCT116 and HT29 
cells. However, at the protein level, only HT29 cells showed expression of 
ALDH1A1 but without significant change upon exposure to hypoxia. This 
finding supports the result of Hasmim et al. study, where the expression of 
ALDH1 in NSCLC was found not to be affected by hypoxia (Hasmim et al., 
2011). 
ALDH1A2 gene was found to have the lowest level of expression amongst all 
seven ALDH isoforms evaluated and its expression was upregulated upon 
exposure to hypoxia in all cell lines except SW480. However, this isoform 
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was not detected at the protein level. As a previous study showed that this 
isoform act as TSG in prostate cancer, where it was found to be 
epigenetically silenced (Kim et al., 2005), it might suggest that ALDH1A2 
expression is also under epigenetic control in CRC. However, further work 
such as DNA methylation analysis in both normal and cancerous colon cells 
is required to confirm this observation. 
In the current study, ALDH1A3 was found to be highly expressed in HCT116 
and SW480 cell lines at the mRNA level. In addition, it was only detected in 
these two cell lines at the protein level. The change in expression upon 
exposure to hypoxia revealed that only the aforementioned cell lines showed 
significant upregulation of ALDH1A3. A previous study reported that 
ALDH1A3 is upregulated in 5-FU resistant cells (Touil et al., 2014). In 
addition, hypoxia has been shown to induce drug resistance against 5-FU in 
a wide panel of cells (Ahmadi et al., 2014). Therefore, the upregulation of 
ALDH1A3 might be one of the mechanisms that contribute to drug resistance 
observed in hypoxic cells. However, more experiments are needed to 
confirm this is indeed the case. 
ALDH1B1 was the last ALDH1 isoform evaluated in this study and was found 
to be highly expressed in all cell lines with the exception of HT29. However, 
as hypoxia exposure showed no major effect on ALDH1B1 gene expression, 
the protein expression was not evaluated. The abundance of ALDH1B1 is in 
agreement with immunohistochemical studies that showed expression of this 
isoform in 98% of colon cancer samples (Chen et al., 2011). Although very 
little is understood about what regulates ALDH1B1, its high and reliable 
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expression in clinical samples could be used to ascertain the presence of 
CRC. 
Little is known regarding the expression of ALDH2 in CRC. ALDH2 gene was 
found to be highly expressed in the four CRC cell lines that showed similar 
levels of expression. However, hypoxia resulted either in its downregulation 
(HCT116 and SW480) or no major changes (HT29 and DLD-1), hence the 
protein expression was not evaluated. 
The third family that was investigated was ALDH3. ALDH3A1 has been 
shown to be amongst the genes that were highly upregulated in a 
mechanically-induced colon cancer cell population, which correlated with 
cancer cell migration and invasion (Tang et al., 2014). In this study, DLD-1 
and HT29 showed similar level of 3A1 gene expression which was higher 
than what was found in HCT116 and SW480 cells. ALDH3A1 protein 
expression was only detectable in HT29 and DLD-1 cells. However, only 
HT29 showed slight, insignificant reduction of 3A1 expression at both the 
gene and protein levels. The findings presented here is in line with previously 
published data, which indicated that hypoxia exerts downregulation of both 
the constitutive and inducible ALDH3 expression and the effect is cell line 
specific (Reisdorph and Lindahl, 1998). It has been speculated that this was 
due to limiting levels of ARNT (HIF-1β) being shared by two pathways, which 
under hypoxic conditions forms heterodimers with HIF-1α and thus was not 
available to interact with critical xenobiotic response elements (XREs) 
required for ALDH3 expression (Reisdorph and Lindahl, 1998). Nonetheless, 
in a later study conducted by the same group, it was shown that ARNT was 
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not the limiting transcription factor and thus it was concluded that further 
investigations were urgently needed to explain such findings (Reisdorph and 
Lindahl, 2001). 
ALDH7A1 was the final ALDH isoform investigated in this study. Human 
ALDH7A1 protects against hyperosmotic stress presumably through the 
generation of betaine, an important cellular osmolyte, formed from betaine 
aldehyde (Brocker et al., 2010). In addition, it was found that ALDH7A1 may 
possess important antioxidant activity that attenuate reactive aldehyde and 
oxidative stress induced cytotoxicity (Brocker et al., 2011). Abnormally high 
expression of ALDH7A1 has been found in ovarian cancer (Saw et al., 2012), 
prostate cancer and matched bone metastasis samples (van den Hoogen et 
al., 2010, van den Hoogen et al., 2011), while its expression in NSCLC 
patients has been linked with increased incidence of cancer recurrence 
(Giacalone et al., 2013). However, the role of ALDH7A1 in CRC is 
unexplored. In the present study, ALDH7A1 was found to be expressed in all 
cell lines at both the gene and protein levels. Exposure of these cells to 
hypoxia resulted in significant upregulation in HT29 and DLD-1 cells at both 
the gene and protein levels. As previous studies reported the role of 
ALDH7A1 as an antioxidant enzyme (Brocker et al., 2011), it suggests that 
hypoxic cells might enhance the expression of this enzyme in order to protect 
themselves against ROS and oxidative stress. Accumulating evidence has 
shown that hypoxic cells undergoing exposure to oxidative stress develop 
adaptive responses to survive in the aggressive environment (Fan et al., 
2007) (Chapter 1 Introduction, section 1.5.1). In fact, these might include 
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antioxidant responses such as the GSH–GPX antioxidant system (Fan et al., 
2008). In the present study, one of these adaptive responses may be the 
upregulation of the antioxidant enzyme, ALDH7A1. Brocker et al. showed 
that ALDH7A1 enzyme activity is cytoprotective under oxidative conditions 
where LPO and subsequent aldehyde levels are elevated. Mechanistically, it 
has been shown that the removal of LPO-derived aldehydes by ALDH7A1 
could have multiple cytoprotective functions; ALDH7A1 metabolic activity 
could reduce the need for GSH conjugation and help maintain intracellular 
GSH levels counteracting the damaging effects of oxidative stress (Brocker 
et al., 2011).  
The data presented in this study using 2D models demonstrated that the 
selected panel of ALDHs are expressed in CRC cell lines at different levels 
but there is no clear distinction between these cells based on the ALDH 
expression pattern. To our knowledge, this is the first study to report findings 
on the role of hypoxia in modulating the aforementioned isoforms with the 
exception to ALDH1A1 and 3. The findings of the current study suggested 
that hypoxia has an impact on ALDH expression although this is cell line 
specific. In addition, the upregulation of ALDH1A3 and 7A1 upon exposure to 
hypoxia suggests that these isoforms might have important roles in cell 
survival and aggressiveness of hypoxic cells of CRC. However, more work is 
required to clarify their roles. 
The impact of hypoxia on ALDHs in 3D multicellular spheroids (MCS) models 
of DLD-1 and HT29 CRC cell lines was also explored. Although they do not 
have an existing vasculature system, MCSs are good representatives of 
116 
 
micro-metastases prior to vascularisation due to their 3D nature 
(Hirschhaeuser et al., 2010) and lack of abundant oxygen and nutrients 
(Waleh et al., 1995). Therefore, it was of great interest to study the selected 
ALDHs in cells that reside in the hypoxic region of the MCS as well as cells 
in the outer viable rim; the latter has access to molecular oxygen and 
nutrients in contrast to the former which is starved of both. To our 
knowledge, only few studies have explored the expression of ALDH in 3D 
spheroids. ALDH1 was reported to be upregulated in CRC spheroids (HT29) 
(Fan et al., 2011), while ALDH1A1 isoform was found to be highly expressed 
in ovarian cancer MCS where it was directly connected to key elements of 
the β-catenin pathway (Condello et al., 2015). However, these studies did not 
explore the expression of ALDH at different depth within MCS which may 
affect enzyme expression and function. 
Spheroids were generated using the spinner flask technique (O'Connor, 
1999) and hypoxia was detected using the hypoxic marker, pimonidazole 
(Laurent et al., 2013). It was found that cells residing in the outer layers were 
not hypoxic, while the intensity of pimonidazole staining increased toward the 
inner layers surrounding the necrotic cores. These cells were stripped from 
HT29 and DLD-1 MCSs using sequential trypsinisation technique as 
previously described (Phillips et al., 1994). Results from gene and protein 
expression of DLD-1 and HT29 MCS models, revealed that ALDH1A1 was 
upregulated in HT29 MCS compared to monolayer normoxic cells which 
supports the findings of Fan et al. study (Fan et al., 2011). However, no 
major difference in ALDH1A1 expression between peripheral layer and 
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hypoxic region of MCS was observed. In contrast, ALDH7A1 expression was 
found to be increased in the peripheral layers of both DLD-1 and HT29 
spheroids compared to normoxic monolayer cells, while hypoxic regions 
showed more pronounced upregulation. Variable responses were observed 
for other ALDH examined in this study (See Results, section 2.3.2.2). Given 
the role of ALDH7A1 in oxidative stress, the coexistence of hypoxia and 
ALDH7A1 may provide a signature of the aggressiveness of CRC. 
Immunohistochemistry (IHC) studies were also carried out to assess the 
distribution of ALDH7A1 through different depth of MCS as well as its cellular 
localisation (Schacht and Kern, 2015). Interestingly, the expression of 
ALDH7A1 was highly elevated in the hypoxic region of both MCS compared 
to the outer layer, indicating that this isoform might be an important player in 
the CRC microenvironment. In addition, cytoplasmic and nuclear expression 
was evident, suggesting that ALDH7A1 might have a role in cell cycle 
progression. Chan et al. studies showed that ALDH7A1 was upregulated and 
accumulated in the nucleus during G1/S phase transition in both the human 
embryonic kidney HEK293 cells and liver WRL68 cells. Knockdown 
experiments showed modulation in the levels of several key cell cycle-
regulating proteins .(Chan et al., 2011). For further investigation of ALDH7A1 
role in CRC, analysis of cell cycle phases upon ALDH7A1 knockdown will be 
carried out and discussed in the next chapter. 
To further evaluate the abundance of ALDH7A1 in CRC, the expression was 
explored in 5 CRC xenografts (HT29, DLD-1, SW620, HCT116 and 
COLO205) using IHC and it was found to be highly expressed in all 
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examined xenografts. IHC were also carried out to assess ALDH7A1 
distribution in correlation with hypoxia using an intrinsic marker of tumour 
hypoxia, CAIX, which is a membrane-associated zinc metalloenzyme that 
has a key role in pH regulation and one of HIF-1α targets (Loncaster et al., 
2001). In this study, the expression of CAIX was only detected in the inner 
layers of HT29 MCS confirming that these cells were hypoxic. As ALDH7A1 
was found to be highly expressed in these layers, this supports the potential 
role of hypoxia in the modulation of ALDH7A1 expression. The use of CAIX 
to locate hypoxia in DLD-1 MCS and xenograft tumour models was however, 
unsuccessful and other markers such as glucose transporter-1 (Glut-1) will 
be considered for future work (Airley et al., 2003). 
Results from 2D and 3D culture models of HT29 and DLD-1 cell lines 
strongly supports the evidence that hypoxia modulates the expression of 
ALDH7A1. It is well known that tumour cells adapt to deprivation in oxygen 
through the stabilisation of hypoxia inducible factors (Sutherland, 1998). In 
order to investigate whether HIF-1α and/or HIF-2α are involved in the 
transcriptional regulation of ALDH7A1 expression, induction of HIF-1α using 
CoCl2 and downregulation of these HIFs using knockdown experiments were 
carried out. CoCl2 is known to cause stabilisation of HIF-1α under normoxic 
conditions (Piret et al., 2002, Law et al., 2012). In this study CoCl2 was found 
to intensely induce HIF-1α protein expression in both DLD-1 and HT29 cells. 
However, no variation in the expression level of ALDH7A1 was observed. 
This suggests that the expression of ALDH7A1 under hypoxic conditions is 
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HIF-1α independent. Therefore, knockdown studies of both HIF-1α and/or 
HIF-2α were carried out to confirm this finding. 
The expression of ALDH7A1 in DLD-1 cells was revaluated after 24h, 48h 
and 72h of incubation under hypoxia and it was found to be increased at both 
the gene and protein levels. Knockdown studies using small interfering RNAs 
(siRNAs) against HIF-1α and/or HIF-2α were carried out and their effect on 
ALDH7A1 expression was evaluated. Significant and specific knockdown of 
HIF-1α and HIF-2α expression was achieved after 48h and 72h at the gene 
level. Although different incubation conditions for western blot were used, 
results were not confirmed at the protein level as no bands were detected. 
Nevertheless, the expression of ALDH7A1 was only downregulated by 50% 
after 72h of HIF-1α/2α dual knockdown at the gene level, while less than 
22% reduction occurred at the protein level. This suggests that ALDH7A1 
expression in hypoxia is HIF-1α/HIF-2α independent and might be controlled 
by another cellular mechanism. Although the major hypoxia-regulated 
transcription factor is HIF, tumour cells can also adapt to hypoxic 
microenvironment through other hypoxia inducible transcriptional factors 
such as nuclear factor ҝB (NF-ҝB), activator protein I (AP-I) and p53 (Carroll 
and Ashcroft, 2005). Therefore, these factors might be involved in the 
regulation of ALDH7A1 expression upon exposure to hypoxia, however, 
further work is needed to confirm this. 
In summary, the expression of ALDHs was assessed in CRC at both the 
gene and the protein levels using 2D and 3D models. ALDH7A1 was found 
to be highly expressed in CRC xenografts, while this isoform was found to be 
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sensitive to hypoxia exposure in HT29 and DLD-1 cell lines. In addition, this 
enzyme was highly expressed in the hypoxic region of 3D MCS models of 
these cell lines compared to surface layer cells. Given the role of hypoxia in 
mediating the adaptive strategies in cells undergoing exposure to oxidative 
stress, upregulation of ALDH7A1 as antioxidant enzyme was suggested. 
However, knockdown experiments suggested that HIF-1α/HIF-2α were not 
important for inducing ALDH7A1 expression and hence this enzyme is 
controlled by another cellular mechanism. Accordingly, ALDH7A1 was further 
explored and the data from knockdown studies and isogenic cell line pair is 
reported in Chapter 3 and 4, respectively. 
The main findings of this Chapter were: 
• ALDH1A2 is expressed at very low level in the four cell lines 
examined in this study. 
• ALDH1A3 expression was found to be upregulated upon exposure to 
hypoxia in both HCT116 and SW480 cell lines at both the mRNA and 
protein levels. 
• ALDH7A1 expression was found to be upregulated upon exposure to 
hypoxia in both HT29 and DLD-1 cell lines at both the mRNA and 
protein levels. Its expression was also increased at the hypoxic 
regions of MCS of both cell lines.  
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 Chapter 3: Probing the functional 
roles of selected ALDH isoforms in 
colorectal cancer using siRNA 
knockdown 
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3.1 Introduction 
Previous studies reported various roles for particular ALDH isoforms in CRC. 
These include ALDH1B1 as a potential biomarker (Chen et al., 2011), 
ALDH1A1 as stem cell marker (Emmink et al., 2013), ALDH1A3 associated 
with drug resistance (Touil et al., 2014) and ALDH3A1 involved in mediating 
metastasis (Tang et al., 2014). In addition, results from Chapter 2 revealed 
ALDH7A1 expression in four CRC cell lines and its expression was shown to 
increase upon exposure to hypoxia in both HT29 and DLD-1 cell lines. 
Furthermore, cells residing in the surface layer of MCS models were shown 
to possess high expression of ALDH7A1 that also increased toward the 
hypoxic region at both the gene and protein levels compared with monolayer 
cells. Paraffin-embedded sections of MCS showed clear increased staining 
for ALDH7A1 in hypoxic regions, while it was also shown that ALDH7A1 was 
expressed in 5/5 CRC xenografts. Whilst the current literature indicates a 
role for ALDH1A1, 1A3, 1B1 and 3A1 in CRC, the novel data generated in 
Chapter 2 suggests that ALDH7A1 might also play an important role in CRC 
particularly in the context of the hypoxic tumour microenvironment. 
Human ALDH7A1 plays a major role in lysine catabolism in the pipecolic acid 
pathway where it catalyses the oxidation of alpha-aminoadipic semialdehyde 
(AASA) to alphaaminoadipate. Mutation in ALDH7A1 has been linked to 
pyridoxine-dependent epilepsy (PDE) as a result of defective lysine 
catabolism (Mills et al., 2010). In addition, Broker et al. reported that human 
ALDH7A1 plays an important role in protecting cells and tissues from 
hyperosmotic stress presumably through the generation of betaine, an 
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important cellular osmolyte, formed from betaine aldehyde (Brocker et al., 
2010). Recent investigation showed that this isoform also has protective role 
against oxidative stress and lipid peroxidation (Brocker et al., 2011). 
Increased expression of ALDH7A1 has been reported in different cancer 
types. Hoogen et al. has shown high expression of ALDH7A1 in prostate 
cancer and matched bone metastasis samples, where it has been validated 
to be involved in mediating metastasis (van den Hoogen et al., 2010, van 
den Hoogen et al., 2011). In melanoma, ALDH7A1 was found to be 
expressed in nodular melanoma (NM), the most aggressive form of 
melanoma, but not in superficial spreading melanoma (SSM) (Rose et al., 
2011). Furthermore, ALDH7A1 was discovered to be upregulated in human 
papilloma virus-16 (HPV-16)-immortalised cervical epithelial cells, Ecto1 and 
E6E7, upon treatment with nicotine-derived carcinogen (Prokopczyk et al., 
2009). Prokopczyk et al. proposed that ALDH7A1 might contribute to 
malignant transformation of HPV-16-immortalised cervical cells to cervical 
carcinoma through ALDH7A1 mediated metabolism of 4-
(methylnitrosamino)-1-(3-pyridyl)- 1-butanone (Prokopczyk et al., 2009). 
Significant overexpression of ALDH7A1 has also been observed in ovarian 
tumours relative to normal ovarian tissue (Saw et al., 2012). A recent study 
also found the expression of ALDH7A1 to be associated with recurrence in 
patients with surgically resected NSCLC (Giacalone et al., 2013). More 
recently, proteomic studies showed that ALDH7A1 was upregulated in 
DU145 cells resistant to zoledronic acid, pointing to a potential role of 
ALDH7A1 in drug resistance (Milone et al., 2015). 
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The above-mentioned investigations and studies presented in Chapter 2 
concern the expression of ALDH7A1, however, relatively little is known 
regarding its biological functions and roles in mediating cancer progression. 
Therefore, in an attempt to understand the biological significance of 
ALDH7A1 in CRC, this Chapter interrogates ALDH7A1 function in vitro using 
RNA interference (RNAi). Specifically, RNAi is the process by which 
expression of a target gene can be effectively silenced or knocked down by 
the selective degradation or inhibition of translation of its corresponding 
mRNA by double-stranded RNA (dsRNA) (Rao et al., 2009, Davidson and 
McCray, 2011). RNAi is activated by dsRNA species delivered to the 
cytoplasm of cells. The silencing mechanisms can either lead to the 
degradation of a target mRNA using small interfering RNAs (siRNAs) or short 
hairpin RNAs (shRNAs), or the suppression of translation of specific mRNAs, 
as induced by microRNA (miRNA) (Davidson and McCray, 2011). This in 
turn blocks further expression/accumulation of the target protein, causing a 
decrease in its levels, and eventual knockdown at the protein level (Davidson 
and McCray, 2011). 
Two key approaches to RNAi that have gained important interest for use in 
gene silencing are the double-stranded small interfering RNAs (siRNAs) and 
the vector-based short hairpin RNAs (shRNAs) (Rao et al., 2009). While both 
siRNAs and shRNAs can be used for experimental knockdown studies, there 
are differences in their mechanisms of action (Figure 43) (Rao et al., 2009). 
siRNAs are short duplexes of about 21 base pairs (bps) that are introduced 
directly into cells where they accumulate in the cytoplasm and get 
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incorporated into the RNA-induced silencing complex (RISC), which is 
composed of endoribonuclease Argonaute-2 (Ago-2), Dicer (a dsRNA-
specific RNAse III enzyme) and TAR-RNA-binding protein (TRBP). The RNA 
duplex is separated and one strand is removed from the complex. The strand 
with the lowest duplex stability at its 5'-end is selected for stable 
incorporation into the RISC. As a moiety of the RISC, the siRNA binds to the 
target mRNA in a sequence-specific manner that is mediated by 
complementary base pairing, leading to cleavage of the target RNA 
phosphate backbone near the centre of the duplex via the action of Ago-2 
(Allison and Milner, 2014). This process is illustrated in Figure 43. 
Figure 43 RNAi mechanism. Differences between siRNA, shRNA, and miRNA. Adopted 
from Torrecilla et al. 2014 (Open access article distributed under the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited). 
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shRNAs are synthesised in the nucleus of transfected/transduced cells and 
form hairpin structures that consist of a stem region of paired antisense and 
sense strands connected by unpaired nucleotides that make up a loop. 
shRNAs are introduced into the nuclei of target cells using either bacterial or 
viral vectors that, in some cases, can stably integrate into the genome. 
shRNAs are transcribed by either RNA polymerase II or III, depending on the 
promoter driving their expression (Rao et al., 2009). These initial precursors 
are processed by Drosha and its dsRNA-binding partner DGCR8, resulting in 
species known as pre-shRNAs before being exported to the cytoplasm by 
Exportin-5. The pre-shRNA is then cleaved by Dicer and TRBP/PACT, 
removing the hairpin and creating a double-stranded siRNA with a length of 
20-25 nucleotides. This active siRNA is then loaded onto the RISC complex. 
Once loaded onto the RISC, the process of targeting mRNA recognition and 
degradation by both shRNA and siRNA is essentially the same (Rao et al., 
2009). 
shRNA has an advantage over siRNA because of the ability to use viral 
vectors for delivery to overcome the difficulty of transfecting certain cell 
types, however a drawback with shRNA is the need for it to be delivered into 
the cell nucleus to be processed (Torrecilla et al., 2014). In addition, shRNA 
can cause oversaturation of the endogenous RNAi machinery, which can 
result in non-physiological and off-target effects and induce cellular stress. 
On the other hand, siRNA oligomers can be chemically modified in order to 
reduce direct off-target effects (Rao et al., 2009). Accordingly, in this study 
ALDH7A1 siRNA was used to downregulate the expression of ALDH7A1, 
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while ALDH1A3 and ALDH3A1 siRNAs were employed as controls to help 
understand specificity of any ALDH7A1 knockdown and associated biological 
consequences. 
The hypothesis of this Chapter was that ALDH7A1 is involved in CRC cell 
proliferation, migration and reduction in ROS generation. The aims and 
objectives of this Chapter were: 
1. To carry out siRNA knockdown studies of ALDH7A1, ALDH3A1 and 
ALDH1A3 in DLD-1 cells using both normoxic and hypoxic conditions. 
2. To evaluate the effect of ALDH knockdown using the following 
endpoints: 
 Cell proliferation using the trypan blue assay. 
 Cell migration using the scratch assay. 
 Reactive oxygen species (ROS) generation. 
 DNA damage using phosphorylated H2AX as a marker of 
dsDNA breaks. 
 Drug cytotoxicity of three CRC anticancer drugs; oxaliplatin, 5-
FU and irinotecan using the trypan blue assay. 
  
128 
 
3.2 Material and Methods 
 Target mRNA knockdown using siRNA 3.2.1
3.2.1.1 Cell seeding 
DLD-1 cells in early passage number (2-4) were seeded at concentration of 
2.75 × 105 cells/ 25 cm2 flask in 5 ml complete RPMI medium (for gene and 
protein expression, cell proliferation assay, cell cycle and ROS detection 
experiments) or at concentration of 1.1× 105 cells/ well (2 ml complete RPMI) 
in 6 well plates (for migration and trypan blue cytotoxicity assays). Cells were 
incubated at 37˚C and 5% CO2 for 24h. 
3.2.1.2 Preparation of siRNAs 
siRNA duplexes against ALDH1A3, 3A1 and 7A1 were designed, 
synthesised and validated by Ambion/Life Technologies. See appendix VII 
for siRNA information. 
Stock solution: 20 µM of siRNA solution (ALDH1A3, ALDH3A1 and 
ALDH7A1 siRNAs) was prepared by dissolving 20 nmol of each siRNA 
(Ambion/Life Technologies) in 1 ml of 1x Dharmacon siRNA resuspension 
buffer. 2 µM of siRNA was also prepared as a working stock solution. Both 
concentrations of siRNA were stored in aliquots at -80˚C. 
3.2.1.3 Transfection with siRNA 
After 24h of incubation at 37˚C and 5% CO2, the cells were checked under 
the microscope to make sure that they were 20-30% confluent and evenly 
distributed on the flask surface. For single siRNA transfection, siRNA was 
prepared in 1.5 ml microcentrifuge tube by adding 30 µl of 2 µM siRNA stock 
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solution (ALDH1A3, ALDH3A1 or ALDH7A1 siRNAs) into 525 µl Optimem 
(Gibco). For ALDH3A1 and ALDH7A1 siRNAs cotransfection, 15 µl of 
ALDH3A1 siRNA (2 µM stock) and 15 µl of ALDH7A1 siRNA (2 µM stock) 
were added into 525 µl Optimem. 45 µl of diluted oligofectamine solution (1:5 
oligofectamine (Life technologies) in Optimem was prepared and incubated 
for 30 min at room temperature) was added to siRNA mix (final concentration 
= 7.5% v/v) and was mixed by pipetting 20-30 times. The mix was incubated 
for 45 min inside the cell culture safety cabinet. Control solution with the 
liposome carrier only was prepared by adding 45 µl of diluted oligofectamine 
solution into 555 µl Optimem. During the incubation time, medium was 
removed from flasks and 5 ml of Optimem was added to each flask for 
washing before it was discarded (or 2 ml of Optimem in 6 well plates). 2 ml of 
fresh Optimem was added to each flask (or 800 µl of Optimem in 6 well 
plates). After 45 min of incubation, 500 µl of siRNA mix (or 200 µl to 6 well 
plates) was added to relevant flasks (final concentration of each siRNA in 
single or cotransfection was 20 or 10 nM respectively). For liposome control 
cells, 500 µl of control solution was added to each flask (or 200 µl to 6 well 
plates). For mock transfected cells, only 500 µl of Optimem was added to 
each flask (or 200 µl to 6 well plates). Cells were incubated at 37˚C and 5% 
CO2 for 4h before 2.5 ml of 2x RPMI was added to each flask (or 1ml to 6 
well plates). Next, cells were incubated at 37˚C and 5% CO2 for 24h, 48h or 
72h before being harvested for RNA or protein extraction. For knockdown 
studies under hypoxic conditions, the same steps were carried out until the 
end of the 4h incubation, after which flasks or plates were incubated in the 
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hypoxic chamber (0.1% O2) and preconditioned hypoxic 2x RPMI was 
added. Normoxic mock samples were also included as a control. 
3.2.1.4 Cells harvesting 
To evaluate whether there were any obvious phenotypic changes due to 
transfection, bright field images were taken for flasks containing mock and 
liposome controls, ALDH1A3 siRNA, ALDH3A1 siRNA, ALDH7A1 siRNA and 
co-transfection (ALDH3A1 and ALDH7A1 siRNAs) at 24h, 48h and 72h time 
points. To harvest cells, the medium was removed into 20 ml universal tube 
and 5 ml PBS was used to wash the cells. Next, cells were trypsinised and 
detached from the flask surface before all contents were transferred to a 20 
ml universal tube and centrifuged at 1,000 rcf for 5 min. Media was then 
discarded and the cell pellet was washed with 1 ml PBS. The PBS containing 
the cells was collected in 1.5 ml microcentrifuge tube and centrifuged for 5 
min at 3,000 rcf. Finally, PBS was discarded and the cell pellet was kept at -
80˚C for RNA or protein extraction. 
 ALDH gene expression analysis after knockdown 3.2.2
RNA extraction and cDNA synthesis was carried out as previously described 
(Chapter 2, Material and Methods, section 2.2.1.3) Gene expression analysis 
was carried out using qRT-PCR (Chapter 2, Material and Methods, section 
2.2.1.3) and the fold change in the expression of the target gene was 
calculated for siRNA transfected samples and liposomes control samples in 
comparison to mock controls 
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 ALDH protein expression analysis after knockdown 3.2.3
Protein extraction was carried out as previously described (Chapter 2, 
Material and Methods, section 2.2.1.4). Protein expression analysis was 
carried out using western blot technique (Chapter 2, Material and Methods, 
section 2.2.1.4) and Image J was used to calculate the fold change in the 
expression of the target protein in siRNA transfected samples and liposomes 
control samples in comparison to mock controls. 
 Cell proliferation and viability 3.2.4
To evaluate whether ALDHs are involved in the regulation of cellular 
proliferation, cells were seeded into 25 cm2 flasks and transfected with 
siRNAs as described in sections 3.2.1.1-3. After 24h, 48h and 72h, cell 
proliferation and viability was evaluated using the trypan blue assay. In brief, 
cells were trypsinised and centrifuged to obtain the cell pellet, which was 
then re-suspended in RPMI. 100 µl of cell suspension was mixed with 100 µl 
of trypan blue dye before the total number of live cells was counted. Cell 
number on the Y-axis was then plotted against the incubation time post 
transfection on the X-axis. 
 Cell cycle analysis 3.2.5
DLD-1 cells were seeded into 25 cm2 flasks and transfected as previously 
described (Sections 3.2.1.1-3). After 24h, 48h or 72h of siRNA transfection, 
cells were harvested for ethanol fixation and cell cycle analysis. In brief, cells 
were trypsinised and both adherent and floating cells were collected. After 
centrifuge at 1,000 rcf for 5 min, the cell pellet was washed twice with ice 
cold PBS to remove serum proteins present in the culture media. Cells were 
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then re-suspended in 1 ml ice cold PBS in a 15 ml Falcon tube and vortexed 
while 4 ml of 90% -20ºC chilled ethanol was added dropwise before the 
samples were left on ice for 1h. Next, the samples were stored at 4ºC until 
processed for propidium iodide staining. The fixed cells were centrifuged at 
1,000 rcf for 5 min at 4ºC. Ethanol was then carefully aspirated and 
discarded. The cell pellet was re-suspended in 5 ml ice cold PBS and re-
centrifuged at 1,500 rcf for 5 min (this was done twice). The residual PBS 
was carefully removed and cells were gently re-suspended in 500 µl PBS (at 
room temperature) containing 20U/ml RNase (Sigma) and incubated at 37ºC 
for 15 min. 500 µl of propidium iodide (60 µg/ml diluted in PBS) (Sigma) was 
then added, mixed well by pipetting and cells left for 30 min at room 
temperature. Occasionally, tubes were flicked to keep cells in suspension. 
Subsequently, samples were incubated overnight at 4ºC after which the cell 
cycle analysis was carried out using FACS and detection of propidium iodide 
fluorescence using the FL2-A channel (red channel). 
Propidium iodide is the most commonly used dye to quantitatively assess 
DNA content of cells. It binds DNA stoichiometrically by intercalating in the 
DNA double helix, however it will also bind to dsRNA. Treatment with RNase 
is therefore necessary to degrade dsRNA (Krishan, 1975). 
 Detection of reactive oxygen species (ROS) 3.2.6
DLD-1 cells were seeded in phenol red free RPMI medium (Gibco, Appendix 
I) into 25 cm2 flasks and transfected with siRNAs to knockdown ALDH1A3, 
ALDH3A1 and ALDH7A1 as well as co-knockdown of ALDH3A1 and 
ALDH7A1 as described previously in sections 3.2.1.1-3. After 48h of 
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transfection, 1 flask with cells was treated with 250 µM H2O2 (in 5 ml phenol 
red free RPMI) and used as a positive control for ROS detection. After 72h of 
transfection, medium was transferred to 20 ml universal tube and cells were 
washed with PBS and removed to the universal tube. Trypsin was added to 
detach the cells and were inhibited by the addition of phenol red free RPMI 
and all cells were collected into the universal tube. Cells were centrifuged at 
1,000 rcf for 3 min and media was discarded. 5 ml of PBS at room 
temperature was added to wash the cell pellet and centrifuged at 1,000 rcf 
for 3 min before being discarded. Next, 2 ml of phenol red free RPMI 
containing 5 µM of 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA, Fisher scientific) was added to the cell pellet and the 
mixture was mixed gently with pipetting. The medium containing the cells 
was transferred to 1 well of a 6 well plate and incubated at 37ºC for 30 min 
with gentle shaking every 6 min to prevent cell attachment. 
Carboxy-H2DCFDA is a chemically reduced, acetylated form of fluorescein 
used as an indicator for ROS in cells. Carboxy-H2DCFDA is readily 
converted to a green-fluorescent form when the acetate and ester groups are 
removed by intracellular oxidation (e.g. by the activity of ROS). The 
carboxylated H2DCFDA has two negative charges at physiological pH and 
upon cleavage carboxydichlorofluorescein is produced, which has additional 
negative charges that impede its leakage out of the cell. Fluorescence can 
be monitored using a flow cytometer at Ex/Em: ~492–495/517–527 nm 
(Eruslanov and Kusmartsev, 2010). 
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After 30 min of incubation, cells were removed to a 20 ml universal tube and 
centrifuged at 700 rcf for 3 min. The cell pellet was then washed with 5 ml 
PBS and centrifuged at 1,000 rcf for 3 min. To enable fluorescence analysis, 
the cell pellet was re-suspended in 0.5 ml PBS and analysed with FACS 
using the FL1H channel (green channel). 
 Detection of double strand DNA breaks 3.2.7
In order to study the potential protective role of the ALDH7A1 enzyme 
against DNA damage that might be caused by ROS, the effect of ALDH 
knockdown on phosphorylated H2AX expression was evaluated. In brief, 
DLD-1 cells were seeded into 25 cm2 flasks, transfected with siRNAs for 72h 
under normoxic conditions and harvested for protein extraction as described 
previously in section 3.2.1. Western blot was carried out as described 
previously in section 3.2.3 using rabbit anti phosphorylated H2AX primary 
antibody and HRP based anti-rabbit secondary antibody (Table 15, Appendix 
V)  
 Cell migration 3.2.8
A scratch assay was used to evaluate the role of ALDH in cell migration. The 
scratch assay is an easy, low-cost and well-developed method to measure 
cell migration in vitro (Liang et al., 2007). In brief, DLD-1 cells were seeded 
and transfected in 6 well plates as described in sections 3.2.1.1-3. After 72h 
of transfection, confluent cells were scraped in a straight line to create a 
"scratch" with a p200 pipet tip. The cells were then washed to remove the 
debris and smooth the edge of the scratch using 1 ml of RPMI. Next, 2 ml of 
RPMI containing 2% FBS was added to each well. Photos were taken at time 
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0 (initial scratch before migration) as well as after 24h of incubation at 37ºC 
and 5% CO2 (24h after migration). To compare the cell migration under 
normoxic and hypoxic conditions, only mock samples were included; cells 
were incubated in the hypoxic chamber directly after the scratch had been 
created. Preconditioned hypoxic media containing 2% FBS was added 
afterwards. Image J was used for migration analysis by calculating the cell 
free area (at t = 0 and 24h) and quantifying the migration rate of the cells 
after 24h. 
 Drug cytotoxicity 3.2.9
DLD-1 cells were seeded and transfected in 6 well plates as described in 
sections 3.2.1.1-3. After 48h of transfection, cells were treated with 2 ml of 
RPMI containing oxaliplatin (75 µM), irinotecan (75 µM) or 5-FU (100 µM) for 
48h. Control cells were treated with 0.1% DMSO. The total number of live 
cells was calculated using the trypan blue assay as previously described in 
Chapter 2, Material and Methods, section 2.2.1.1.2. The same experiments 
were also carried out under hypoxic conditions using ALDH7A1 siRNA 
transfected cells. The percentage of live cells was calculated as following: 
% Live cells = Total number of live cells (treated)/ Total number of live cells 
(Control). 
 Statistical data analysis 3.2.10
The significance of results was assessed through a comparison of means 
using two-tailed student t-test. Results were expressed as the mean ± 
standard deviation. P values were calculated to determine statistical 
significance of the results. 
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3.3  Results 
 Phenotypic appearance of DLD-1 cells after siRNA 3.3.1
transfection and culture under normoxic conditions 
Cell images were taken 24h, 48h and 72h following siRNA transfection and 
this showed that there were no obvious phenotypical differences between 
siRNA transfected cells, liposome controls and mock cells (Figure 44). 
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 Evaluation of ALDH mRNAs and protein expression after 3.3.2
siRNA transfection and culture under normoxic conditions 
Gene and protein expression was evaluated using qRT-PCR and western 
blot, respectively as described previously in Materials and Methods, sections 
3.2.2-3. 
Figure 45 shows the preliminary finding that ALDH1A3 siRNA resulted in a 
60-75% reduction in ALDH1A3 mRNA levels compared to mock transfected 
cells. However, expression of ALDH1A3 protein could not be detected using 
western blot and hence the effect of the mRNA knockdown on protein levels 
could not be determined. 
Figure 46A and B shows the preliminary finding of 60-75% knockdown in the 
expression of the ALDH3A1 mRNA after ALDH3A1 siRNA transfection with 
levels most reduced at 72h post-transfection. ALDH3A1 was also reduced at 
the protein level with the decrease in protein levels correlating with the length 
of time after siRNA transfection (Figure 46C). 
A B 
Figure 45 ALDH1A3 mRNA expression in ALDH1A3 siRNA transfected DLD-1 cells after 24h, 48h and 
72h of transfection. The fold change of ALDH1A3 gene expression using qRT-PCR (A) and the percentage 
of ALDH1A3 gene expression (B). Results represent 1 experiment. 
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Figure 46 ALDH3A1 mRNA and protein expression in ALDH3A1 siRNA transfected DLD-1 cells after 24h, 
48h and 72h of transfection. Fold change of ALDH3A1 gene expression using qRT-PCR (A), the percentage of 
ALDH3A1 gene expression (B) and ALDH3A1 protein expression using western blot (C). Results represent 1 
experiment. 
A B 
C 
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Figure 47 shows that ALDH7A1 mRNA levels were reduced by 75-82% after 
ALDH7A1 siRNA transfection and ALDH7A1 protein levels by 60-90%. 
To evaluate the specificity of target siRNA and to assess whether there was 
cross talk between different ALDH isoforms, analysis of the effect of ALDH 
isoform knockdown on other selected members of the ALDH family was 
carried out. Figure 48 shows the preliminary findings that significant and 
specific knockdown of each isoform mRNA can be achieved. However, 
Figure 47 ALDH7A1 gene and protein expression in ALDH7A1 siRNA transfected DLD-1 cells after 24h, 
48h and 72h of transfection. The fold change of ALDH7A1 gene expression using qRT-PCR (A), the percentage 
of ALDH7A1 gene expression (B) and ALDH7A1 protein expression using western blot (C). Results represent 1 
experiment. 
A B 
C 
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ALDH7A1 siRNA also resulted in consistent upregulation of both ALDH3A1 
mRNA and protein. This may be a compensatory response to reduced 7A1 
levels but indicates crosstalk between different ALDH isoforms and that 7A1, 
directly or indirectly, can influence expression of 3A1 
Accordingly, co-transfection experiments were carried out to reduce the 
expression of both ALDH7A1 and ALDH3A1 in DLD-1 cells. Experiments 
were carried out as described in Materials and Methods, section 3.2.1. 
  
Figure 48 ALDH 1A3, 3A1 and 7A1 expression in ALDH (1A3, 3A1 or 7A1) siRNAs transfected DLD-1 cells 
after 24h, 48h and 72h of transfection. The fold change of ALDH (1A3, 3A1 and 7A1) gene expression using 
qRT-PCR (A), the percentage of ALDH3A1 gene expression in ALDH7A1 siRNA transfected cells (B) and 
ALDH3A1 protein expression in ALDH7A1 siRNA transfected cells (C). Results represent 1 experiment. 
A B 
C 
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 Phenotypic appearance of co-transfected DLD-1 cells 3.3.3
cultured under normoxic conditions 
Figure 49 shows that the phenotypic appearance at 10x objective lens of 
mock, liposome control and co-transfected cells 24-72h after transfection 
were similar. No morphological differences were detectable when viewing at 
higher magnification (40x or 100 x objective lens). 
 Evaluation of ALDH mRNA and protein expression in co-3.3.4
transfected cells cultured under normoxic conditions 
As ALDH7A1 knockdown resulted in upregulation of ALDH3A1 at both the 
gene and protein levels, cells were transfected with ALD3A1 and 7A1 
siRNAs in order to try and knockdown both ALDH3A1 and 7A1 isoforms. 
Figure 50A and B show the preliminary finding that the co-transfection 
resulted in a reduction of both ALDH3A1 and ALDH7A1 mRNAs by 50-60% 
Figure 49 Phenotypic appearance of DLD-1 cells after ALDH3A1 and 7A1 co-knockdown. 
Photos were taken 24h, 48h and 72h post-transfection at 10x lens and scale bar= 100 µm. 
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and 65%, respectively relative to mock-transfected cells. Figure 50C shows 
that ALDH3A1 and ALDH7A1 proteins were also significantly reduced, 
confirming that the co-transfection and mRNA knockdown resulted in effects 
at the level of protein expression. 
A 
B
Figure 50 ALDH7A1 and ALDH3A1 expression in co-transfected DLD-1 cells (ALDH3A1&7A1 
siRNAs) after 24h, 48h and 72h of transfection. The fold change of ALDH (3A1 and 7A1) gene 
expression using qRT-PCR (A), the percentage of ALDH3A1 and ALDH7A1 gene expression in co-
transfected cells (B) and the protein expression of ALDH3A1 and ALDH7A1 in co-transfected cells (C). 
Results represent 1 experiment. 
C 
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 Phenotypic appearance after RNAi and culture of cells 3.3.5
under hypoxic conditions 
The role of ALDH7A1 was also studied under hypoxic conditions and 
protocols were used as already described in Materials and Methods, section 
3.2.1. As observed under normoxic conditions, no discernible difference was 
observed on cells morphology after siRNA transfection, however, all cells 
cultured in hypoxic conditions grew more slowly compared to normoxic mock 
cells; resulting in reduced confluency which was most apparent 72h post-
transfection (Figure 51). 
 Evaluation of ALDH mRNA and protein levels after siRNA 3.3.6
transfection and culture under hypoxic conditions  
ALDH1A3, ALDH3A1 and ALDH7A1 mRNA and protein expression levels 
were determined 24h, 48h and 72h post-siRNA transfection. As shown in 
Figure 52, the preliminary result shows that ALDH1A3 mRNA levels were 
slightly lower in both mock and liposome hypoxic controls whilst ALDH1A3 
siRNA resulted in 65% reduction in ALD1A3 mRNA relative to normoxic 
mock control cells. 
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ALDH3A1 mRNA was increased under hypoxic conditions (at 48h & 72h) 
compared to normoxia (Figure 53A and B). Significant knockdown of 
ALDH3A1 mRNA and protein was also observed relative to the elevated 
levels observed in hypoxic control cells (Figure 53C).  
Figure 53 ALDH3A1 mRNA and protein expression in ALDH3A1 siRNA transfected DLD-1 cells after 24h, 
48h and 72h of transfection under hypoxic conditions. The fold change of ALDH3A1 gene expression using 
qRT-PCR (A), the percentage of ALDH3A1 gene expression (B) and ALDH3A1 protein expression using western 
blot (C). Normoxia (N), Hypoxia (H). Results represent 1 experiment. 
B A 
C
Figure 52 ALDH1A3 mRNA expression in ALDH1A3 siRNA transfected DLD-1 cells after 24h, 48h and 
72h of transfection under hypoxic conditions. The fold change of ALDH1A3 gene expression using qRT-
PCR (A), the percentage of ALDH1A3 gene expression (B). Normoxia (N), Hypoxia (H). Results represent 1 
experiment. 
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the preliminary findings revealed that ALDH7A1 mRNA and protein levels 
were increased 1.7-fold and 1.4-fold, respectively in response to prolonged 
hypoxia exposure (48h & 72h), as indicated in Figure 54. ALDH7A1 siRNA 
reduced mRNA expression by approximately 35% relative to normoxic 
controls and 60% relative to hypoxic controls after 48h and 72h transfection 
(Figure 54A and B). Protein expression was also significantly reduced at all 
time points. After 72h transfection, protein levels were reduced by 78% 
relative to normoxic controls and 85% relative to hypoxic controls (Figure 
54C).  
Figure 54 ALDH7A1 mRNA and protein expression in ALDH7A1 siRNA transfected DLD-1 cells after 
24h, 48h and 72h of transfection under hypoxic conditions. The fold change of ALDH7A1 gene 
expression using qRT-PCR (A), the percentage of ALDH7A1 gene expression (B) and ALDH7A1 protein 
expression using western blot (C). Normoxia (N), Hypoxia (H). Results represent 1 experiment. 
A B 
C 
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As indicated in Figure 48, ALDH7A1 knockdown in normoxic conditions 
resulted in increased levels of ALDH3A1. To assess whether this is also the 
case under hypoxia, the expression of ALDH3A1 following ALDH7A1 
knockdown in hypoxic DLD1 cells was evaluated. Figure 55 shows the 
preliminary findings that ALDH7A1 knockdown in hypoxic conditions also 
resulted in the upregulation of ALDH3A1, particularly after 48h and 72h of 
siRNA transfection; supporting existence of a regulatory link or crosstalk 
between these two isoforms. Accordingly, co-transfection experiments using 
both ALDH3A1 and ALDH7A1 siRNAs were carried out, as was previously 
done for cells cultured under normoxic conditions. Figure 56 shows a 
reduction in both ALDH7A1 and 3A1 mRNAs and proteins with co-
transfection. 
  
152 
 
  
Figure 55 ALDH1A3, 3A1 and 7A1 expression in ALDH1A3, 3A1 or 7A1 siRNAs transfected DLD-1 
cells after 24h, 48h and 72h of transfection under hypoxic conditions. The fold change of ALDH1A3, 
3A1 and 7A1 gene expression using qRT-PCR (A), the percentage of ALDH3A1 gene expression in 
ALDH7A1 siRNA transfected cells (B) and ALDH3A1 protein expression in ALDH7A1 siRNA transfected 
cells (C). Normoxia (N), Hypoxia (H). Results represent 1 experiment. 
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Figure 56 ALDH7A1 and ALDH3A1 expression in co-transfected DLD-1 cells (ALDH3A1&7A1 siRNAs) after 
24h, 48h and 72h of transfection under hypoxic conditions. The fold change of ALDH3A1 and 7A1 gene 
expression using qRT-PCR (A), the percentage of ALDH3A1 and 7A1 gene expression in cotransfected cells (B) 
and the protein expression of ALDH3A1 and 7A1 in cotransfected cells using western blot (C). Results represent 1 
experiment. 
A B 
C 
154 
 
 The role of ALDH isoforms in cell proliferation 3.3.7
Recent studies have reported a role of ALDH7A1 in mediating cell survival 
and proliferation in prostate cancer (van den Hoogen et al., 2011). To assess 
whether ALDH7A1 may have a similar function in CRC, cell proliferation and 
survival in ALDH7A1 knockdown cells was evaluated using the trypan blue 
exclusion assay. 
Figure 57A shows that no major difference in the total number of live cells 
was observed between mock-transfected cells, liposome control cells, or 
ALDH1A3 siRNA-transfected cells under normoxic conditions at all time 
points. ALDH3A1 siRNA-transfected cells showed less cell number only after 
24h of transfection relative to mock cells (P value= 0.007). In comparison, 
ALDH7A1 siRNA-transfected cells appeared to proliferate at a slower rate 
with fewer live cells at all time points. This was found to be statistically 
significant with P values = 0.007, 0.02 and 0.02 for 24h, 48h and 72h, 
respectively. This was also observed to a similar extent in ALDH7A1 and 
3A1 siRNAs co-transfected cells, where the reduction in cell number was 
presumed to be due to reduced ALDH7A1 expression. No clear differences 
in dead cell number was observed using positive staining for trypan blue 
indicating effects of ALDH7A1 on cell proliferation but no apparent effects on 
cell survival. 
Similar experiments were also carried out under hypoxic conditions (Figure 
57B). The rate of cell proliferation was a lot lower under hypoxia as evident 
from comparing cell number for cells cultured under hypoxia versus 
normoxia. This is consistent with many other studies showing that hypoxia 
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can significantly reduce cell proliferation (Goda et al., 2003). Nonetheless, 
total live cell number at 24h and 48h post-transfection was reduced in 
ALDH7A1 siRNA-transfected cells, compared to hypoxic mock control cells 
supporting a role for this isoform in promoting cell proliferation both under 
normoxic and hypoxic conditions in DLD-1 cells. 
Figure 57 Live cells number using trypan blue assay after ALDH knockdown under normoxic 
conditions (A) or hypoxic conditions (B). Normoxia (N), Hypoxia (H). Values are the mean of 3 
independent experiments and error bars are SD. Live cell number was compared to N mock in A and 
H mock in B. P values: * p<0.05, ** p<0.01.  
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 Effects of ALDH isoforms on the cell cycle 3.3.8
To assess whether ALDH7A1 knockdown might exert its effects on cell 
proliferation via effects on the cell cycle, cell cycle analysis were performed. 
The preliminary data revealed no obvious changes in cell cycle distribution 
with either ALDH1A3 or ALDH7A1 knockdown (Figure 58), suggesting that 
ALDH7A1 knockdown inhibited cell proliferation through mechanism other 
than cell cycle arrest.  
Figure 58 Cell cycle analysis in ALDH7A1 or ALDH1A3 siRNAs transfected DLD-1 cells after 24h, 48h, and 
72h of transfection. Cell cycle analysis was performed using FACS. Results represent 1 experiment. 
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 The role of ALDH isoforms in ROS generation 3.3.9
The literature has described the role of ALDH3A1 as an antioxidant and how 
it promotes resistance to UV and 4-HNE-induced oxidative damage in the 
cornea (Marchitti et al., 2011). Emerging evidence also points towards 
antioxidant properties of ALDH7A1, which in part offers protection to normal 
tissues from oxidative stress induced by ROS (Brocker et al., 2011). 
However, no reports are available to describe its role in the protection of 
cancer cells against cell death caused by ROS. Accordingly, DLD-1 cells 
were transfected with ALDH1A3, ALDH3A1 and ALDH7A1 siRNAs as single 
transfection and co-transfection (ALDH3A1 and ALDH7A1) and flow 
cytometry was employed to detect the generation of ROS compared to 
liposome controls as previously described in Material and Methods, section 
3.2.6. 
Hydrogen peroxide (H2O2) was used as a positive control for ROS induction 
(Figure 59A, curve shifted to right). ALDH1A3 knockdown resulted in 
reduction of ROS formation (Figure 59B, curve shifted to left) while 
ALDH3A1 knockdown had no effect on the ROS generation (Figure 59C). In 
contrast, ALDH7A1 knockdown resulted in an increase in ROS compared to 
control cells (Figure 59D), suggesting that ALDH7A1 in CRC DLD-1 cells has 
antioxidant properties; a similar finding was observed in co-transfected cells 
(Figure 59E). The fold change of ROS generation between siRNA 
transfected cells is illustrated in Figure 59F. 
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Figure 59 Detection of reactive oxygen species (ROS) generation in DLD-1 siRNA transfected cells after 
72h of transfection under normoxic conditions. ROS generation curves (A-E), Fold change of ROS generation 
using the geometric means of area under the curve (F) and phosphorylated H2AX expression in knockdown 
samples (G). Values are the mean of 3 independent experiments and error bars are SD. P values: * p<0.05, ** 
p<0.01. For raw data, see Appendix X. 
Phospho- 
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Direct effects of ROS, generally attributed to their high concentrations, 
include single strand (ss) or double strand (ds) DNA breaks that ultimately 
might cause cell death (Li et al., 1994). Accordingly, experiments were 
conducted to evaluate the effect of ROS on phosphorylated histone protein 
H2AX, which is a marker for dsDNA damage (KUO and YANG, 2008). 
However, no major difference in phosphorylated H2AX expression was 
observed for ALDH7A1 knockdown cells. ALDH1A3 knockdown cells showed  
lower levels of phosphorylated H2AX. This is consistent with the reduced 
ROS levels observed upon ALDH1A3 knockdown, suggesting that ALDH1A3 
might have pro-oxidant activity in these cells (Figure 59G). 
Similar experiments were carried out under hypoxic conditions and showed 
that H2O2 treatment (positive control) resulted in increased ROS generation 
compared to control cells (curve shifted to right, Figure 60A and B). Hypoxic 
cells were shown to have less ROS compared to normoxic samples (curve 
shifted to left, Figure 60A and C) which is in agreement with previous studies 
(Lopez-Barneo, 2001, Liu et al., 2004). Comparison between hypoxic 
knockdown samples and hypoxic liposome control, showed no major 
difference between ALDH1A3 or ALDH3A1 knockdown. However, ALDH7A1 
knockdown either alone or when combined with ALDH3A1 knockdown 
showed more formation of ROS (curve shifted to right, Figure 60A and E), 
again pointing to an antioxidant role for ALDH7A1 under both normoxic and 
hypoxic conditions. 
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Figure 60 Detection of reactive oxygen species (ROS) generation in DLD-1 siRNA transfected cells 
after 72h of transfection under hypoxic conditions. ROS generation curves (A), Fold change of ROS 
generation using the geometric means of area under the curve (B,C,D). Values are the mean of 3 
independent experiments and error bars are SD. P values: *** p<0.001.For Raw data, see Appendix X. 
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 The role of ALDH in cell migration 3.3.10
Given a role for ALDH7A1 in mediating cell migration in prostate cancer has 
recently been described (van den Hoogen et al., 2011); studies were 
performed to determine if ALDH7A1 might have a similar function in CRC. 
Accordingly, the migratory ability of ALDH-knockdown cells was evaluated. 
Figure 61 reveals that single knockdown of ALDH3A1 or ALDH7A1 resulted 
in a small reduction in DLD-1 cell migration but this was not found to be 
statistically significant (P value = 0.091 and 0.095, respectively). 
The literature has described how hypoxia often contributes to the 
aggressiveness of cancer cells, however there is controversy regarding its 
impact on cell migration (Qu et al., 2005, Fujiwara et al., 2007). Therefore, 
migration of normoxic and hypoxic mock cells were studied. Results showed 
less migratory ability of hypoxic cells compared to normoxic even after 40h 
(Figure 62). Consequently, no evaluation of migration in hypoxic knockdown 
cells was carried out. 
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Figure 61 DLD-1 cell migration after 72h of ALDH knockdown using scratch assay. Initial scratch (0h) and after 24h of 
migration (A), Migration rate after 24h (B). Values are the mean of 3 independent experiments and error bars are SD. Photos 
are at 10x lens and scale bar = 100 µm. 
A 
B 
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 Impact of ALDH expression on cell sensitivity to colon 3.3.11
cancer drugs 
The expression of ALDHs has been correlated with drug resistance to 
several anticancer drugs (Chapter 1, Introduction, section 1.4.4). 
Accordingly, it was desirable to measure the potency of oxaliplatin, 5-FU and 
irinotecan in ALDH1A3, ALDH3A1 or ALDH7A1 siRNA, single or co-
transfected DLD-1 cells. 
Figure 63A shows that oxaliplatin treatment (75 µM, 48h) of mock cells 
resulted in 70% cell kill. ALDH1A3 and ALDH7A1 knockdown resulted in the 
same level of sensitivity to oxaliplatin treatment. While ALDH3A1 and 
ALDH3A1/7A1 co-transfected cells showed a slight increase in the 
percentage of cell survival compared to mock or liposome treated cells this 
was not found to be significant (P values= 0.13 and 0.46, respectively). In 
Figure 62 DLD-1 cell migration under normoxic (A) or hypoxic conditions (B) using scratch assay. Photos 
are at 10x lens and scale bar = 100 µm. 
A 
B 
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contrast, co-transfection resulted in an insignificant increase in sensitivity to 
5-FU treatment (P value= 0.08) (Figure 63B), while all other treated samples 
showed no difference upon knockdown. Figure 63C shows that irinotecan 
caused 80% cell kill in all samples without any difference between 
knockdown, liposome or mock treated cells. 
Figure 63 The cell survival of DLD-1 knockdown cells upon drug treatment under 
normoxic conditions using the trypan blue assay. Cells were treated with oxaliplatin (A), 5-
FU (B) and irinotecan (C) for 48h. Values are the mean of 3 independent experiments and error 
bars are SD.  
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A recent study reported the role of hypoxia in mediating 5-FU drug resistance 
(Ahmadi et al., 2014). Accordingly, evaluation of drug sensitivity was also 
carried out under hypoxic conditions. ALDH7A1 knockdown experiment was 
also included to assess whether ALDH7A1 was involved in drug resistance. 
Figure 64 shows that hypoxia caused drug resistance to the three anticancer 
drugs evaluated in this study. Upon exposure to hypoxic conditions (0.1% 
O2), the percentage of cell survival was increased from 24% to 87% for 
oxaliplatin, 30% to 66% for 5-FU and 20% to 77% for irinotecan. However, 
no significant difference was observed in sensitivity of drug treated cells 
transfected with ALDH7A1 siRNA versus liposome control cells under 
hypoxic conditions (P values= 0.91, 0.23 and 0.13 for oxaliplatin, 5-FU and 
irinotecan, respectively).  
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Figure 64 The cell survival of DLD-1 knockdown cells upon drug treatment under 
hypoxic conditions using the trypan blue assay. Cells were treated with oxaliplatin (A), 5-
FU (B) and irinotecan (C) under normoxic (N) and hypoxic (H) conditions. Values are the mean 
of 3 independent experiments and error bars are SD.  
A 
B 
C 
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3.4 Discussion  
In this study, siRNA knockdown was used to assess the functional role of 
ALDH7A1 in CRC, in order to gain insight into its biological importance in 
CRC progression and drug resistance. DLD-1 cells were chosen for 
knockdown studies as they showed high expression of ALDH7A1. In 
addition, ALDH7A1 was upregulated in DLD-1 cells under hypoxic conditions 
and in the hypoxic regions of DLD-1 spheroids (Chapter 2). Similar 
observations were also found in HT29, however this cell line is not migratory 
and hence was not employed for siRNA studies. siRNAs against ALDH1A3 
and ALDH3A1 were employed as controls to help understand specificity of 
ALDH7A1 knockdown and associated biological consequences. 
Knockdown of ALDH3A1 and ALDH7A1 isozymes were successfully 
achieved resulting in abolishment of up to 70% of target ALDH expression in 
DLD-1 cells at both the gene and protein levels. The efficiency of ALDH1A3 
knockdown was only evaluated at the gene level, as it was not detectable in 
DLD-1 cells at the protein level. 
Interestingly, silencing of ALDH7A1 resulted in the upregulation of ALDH3A1 
expression, which might suggest a compensatory mechanism when 
ALDH7A1 is suppressed. Accordingly, simultaneous dual knockdown of 
ALDH3A1 and 7A1 was carried out, which resulted in knockdown of both 
targets at both the gene and protein levels. Knockdown experiments were 
also carried out under hypoxic conditions as upregulation of ALDH7A1 upon 
exposure to hypoxia in both monolayer and MCS models were observed 
(Chapter 2). Significant and specific knockdown was also achieved. In 
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addition, the role of ALDH7A1 knockdown in the upregulation of ALDH3A1 
was also observed under hypoxic conditions supporting the suggested 
compensatory mechanism or cross-talk between these two isoforms. 
ALDH7A1 has been shown to be involved in mediating cell growth and 
enhancing clonogenicity in prostate cancer (van den Hoogen et al., 2011). 
Accordingly, the effect of ALDH7A1 knockdown on cell viability and 
proliferation was assessed using the trypan blue assay. Trypan blue is a cell 
membrane impermeable molecule which only enters cells with compromised 
membranes (dead cells), binds to intracellular proteins and renders the cells 
a bluish colour. This assay allows for a direct identification and enumeration 
of live (unstained) and dead (blue) cells in a given population (Strober, 
2001). Using the trypan blue assay, marked reduction of live cell number of 
DLD-1 cells was observed upon knockdown of ALDH7A1 (P value< 0.05), 
supporting the findings of Hoogen et al. study, where ALDH7A1 knockdown 
led to significantly decreased prostate cancer cell growth and clonogenicity 
(van den Hoogen et al., 2011). Although these results suggest that ALDH7A1 
may promote CRC cell proliferation, no difference in the number of dead 
cells was observed, indicating that ALDH7A1 does not affect cell survival or 
apoptosis. To confirm this, future work will include evaluation of the effect of 
ALDH knockdown on cell proliferation using cell proliferation assays such as 
ATP bioluminescence (Crouch et al., 1993) and the effect on cell apoptosis 
using Annexin V/Propidium Iodide apoptosis assay (Rieger et al., 2011).  
Similar results were also observed when knockdown experiments were 
carried out under hypoxic conditions. All hypoxic cells had reduced live cell 
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numbers compared to normoxic cells, which is in agreement with the 
reported role of extreme hypoxia in arresting cell proliferation (Åmellem and 
Pettersen, 1991, Goda et al., 2003). Here, hypoxic cells with ALDH7A1 
knockdown had the lowest live cell number among all other samples, 
providing further support for the potential role of ALDH7A1 in cell 
proliferation. 
The role of ALDH7A1 in cell cycle progression is still not fully understood. 
Chan et al. has shown that ALDH7A1 has a role in cell cycle progression 
through its upregulation and accumulation in the nucleus during the G1/S 
phase transition in both the human embryonic kidney HEK293 cells and liver 
WRL68 cells. Knockdown studies resulted in changes in the levels of several 
key cell cycle-regulating proteins including upregulation of cyclin E, cyclin D1 
and E2F-1 while the level of cyclin A decreased (Chan et al., 2011). In this 
work, nuclear staining of ALDH7A1 in MCS and xenograft models were 
demonstrated (Chapter 2). Accordingly, to understand if ALDH7A1 mediated 
cell growth through a role in cell cycle progression, analysis of the cell cycle 
phases upon ALDH7A1 knockdown using flow cytometry was carried out. 
However, no difference was observed compared to controls. Das et al. 
showed that inhibition of cell proliferation and growth rate can be caused by 
increase in cell doubling time without being triggered by cell death or cell 
cycle arrest (Das et al., 2012). This might be the reason for the findings 
observed in this study, however, further investigations are needed to confirm 
this such as using BrdU labelling Assay (Weber et al., 2014). 
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The detoxification capacity of ALDHs has been suggested to be one of the 
important factors governing CSC longevity and protect them against 
oxidative insults that are markedly increased in cancer (Reuter et al., 2010, 
Klaunig et al., 2010, Dando et al., 2015). Oxidative stress is caused by 
increased production of reactive oxygen intermediates that in part cause 
peroxidation of lipids (Brocker et al., 2011). This in turn can increase the 
production of aldehydes which can be directly toxic through the formation of 
adducts that damage DNA and inactivate enzymes (Comporti, 1998). In this 
study, it was expected that ALDH7A1 might enhance cell growth through its 
role in the protection against oxidative stress as previously observed 
(Brocker et al., 2011). It has been shown that stable expression of ALDH7A1 
in Chinese hamster ovary (CHO) cells provides significant protection against 
treatment with the LPO-derived aldehydes hexanal and 4HNE (Brocker et al., 
2011). In addition, a significant increase in cell survival was observed when 
cells were treated with increasing concentrations of hydrogen peroxide 
(H2O2), implicating a protective function for the enzyme during oxidative 
stress (Brocker et al., 2011). However, the antioxidant properties of 7A1 
have not been investigated in cancer under normal basal growth conditions; 
in the absence of any external source of oxidative stress. Accordingly, the 
ROS levels in siRNA transfected cells was measured and compared to 
liposome control. Higher ROS levels were specifically detected in DLD-1 
cells in which 7A1 expression was reduced by siRNA silencing. This 
advocates potential antioxidant properties of ALDH7A1, at least in DLD-1 
CRC cells and supports the findings of Brocker et al. study (Brocker et al., 
2011). Although ALDH3A1 has been described as ROS scavenger (Lassen 
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et al., 2007), no difference in ROS levels was observed upon its knockdown. 
In contrast, ALDH1A3 knockdown cells showed lower levels of ROS 
suggesting that 1A3 might have a pro-oxidant role in CRC DLD-1 cells. This 
would represent a novel function for 1A3, although the mechanism for its 
apparent pro-oxidant activity is presently unclear.as this role has not been 
described before. 
ROS detection was also evaluated under hypoxic conditions as there is 
controversy regarding its level in hypoxic cells and tumour microenvironment 
(Liu et al., 2004, Kondoh et al., 2013). It is well known that oxygen pressure 
(pO2) is a critical culture parameter which can cause oxidative stress (Ross 
et al., 2001). In this study, hypoxic cells were found to generate less ROS 
compared to normoxic cells, which is in agreement with previous studies 
(Fan et al., 2007, Fan et al., 2008). Fan et al. demonstrated that hypoxia 
effectively reduced intracellular ROS levels by downregulating NADPH 
oxidase expression (Fan et al., 2007). In addition, the analysis of glutathione 
redox status and ROS products showed less superoxide and H2O2 
generation in hypoxia compared to normoxia (Fan et al., 2008). In order to 
evaluate whether the upregulation of ALDH7A1 observed upon hypoxia 
exposure (Chapter 2) also contributes to reduction of ROS generation in 
hypoxic cells, knockdown experiments were carried out. It was found that 
ALDH7A1 knockdown (single or in combination with ALDH3A1 knockdown) 
had more ROS generation. These findings support its potential role as 
antioxidant enzyme and suggest that hypoxia might reduce ROS generation, 
in part through upregulation of antioxidant enzymes such as ALDH7A1. 
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The role of ALDH7A1 in mediating prostate cancer metastasis has been 
reported (van den Hoogen et al., 2011). However, evaluation of DLD-1 cell 
migration using the scratch assay (Liang et al., 2007) showed that ALDH3A1 
or 7A1 knockdown resulted in insignificant suppression of cell migration. 
The migration ability of DLD-1 cells under normoxic and hypoxic conditions 
was also investigated as there is a controversy regarding the relation 
between hypoxia and cell migration (Turner et al., 1999, Qu et al., 2005, 
Fujiwara et al., 2007, Chen et al., 2009). It was found that DLD-1 cells 
incubated under hypoxia lost their migration ability. This might be due to 
changes in the cellular metabolism that can supress cell migration or through 
downregulation of migration-related genes, such as matrix 
metalloproteinases (MMPs) as previously reported in other studies (Turner et 
al., 1999, Qu et al., 2005). 
Finally, the effect of ALDHs on the cytotoxicity of the clinically used colon 
cancer drugs; oxaliplatin, irinotecan and 5-FU was evaluated using the 
trypan blue assay. The activity of ALDHs has been shown to have a crucial 
role in causing resistance to a number of cancer therapeutics (Chapter 1, 
Introduction, section 1.4.4). However, little is known regarding the role of 
ALDH7A1 in drug resistance. Only one recent study using proteomics 
analysis revealed, incidentally, high expression of ALDH7A1 in DU145 
prostate cancer cell line resistant to zoledronic acid (ZOL), nitrogen-
containing bisphosphonates (Milone et al., 2015). In this study, the doses of 
oxaliplatin, irinotecan and 5-FU that were used caused 70%, 80% and 60% 
cell kill, respectively. However, no significant difference in drug sensitivity 
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was observed at these doses between knockdown and control cells, 
suggesting that ALDH7A1 is not involved in mediating resistance to these 
drugs. 
The role of hypoxia in mediating drug resistance to certain conventional 
cytotoxic drugs as well as tyrosine kinase inhibitors (TKIs) is well established 
(Brown, 2002, Ahmadi et al., 2014). In this study, it was found that hypoxia 
resulted in resistance to oxaliplatin, irinotecan and 5-FU which supports 
previous reports (Luo et al., 2010, Chintala et al., 2010, Ahmadi et al., 2014). 
To evaluate whether ALDH7A1 upregulation in hypoxia might contribute to 
this observation, knockdown studies and drug treatment were carried out 
under hypoxic conditions. However, hypoxic cells with supressed ALDH7A1 
expression upon knockdown showed the same response to these drugs as in 
hypoxic control cells, suggesting that ALDH7A1 is not involved in causing 
resistance to these drugs. 
In summary, the data generated in this Chapter revealed that ALDH7A1 is 
involved in the reduction of ROS in CRC under both normoxic and hypoxic 
conditions. This is the first study to report on ALDH7A1 and hypoxia in 
cancer, indicating that the expression of ALDH7A1 in hypoxic cells might 
have an impact on CRC cell proliferation and its protection against cell death 
caused by oxidative stress. In order to further study the role of ALDH7A1, 
similar experiments will be carried out using an isogenic cell line pair and are 
described in Chapter 4. 
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The main findings of this Chapter were: 
• Significant and specific knockdown of ALDH1A3, 3A1 and 7A1 was 
achieved. 
• ALDH7A1 is involved in increased live cell number of DLD-1 cells 
under normoxic and hypoxic conditions. 
• ALDH7A1 is involved in reducing the level of ROS in DLD-1 cells 
under normoxic and hypoxic conditions. 
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 Chapter 4: Towards identifying small 
molecules to clarify the functional 
role of ALDH7A1  
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4.1 Introduction 
The work described in Chapter 2 using 2D and 3D CRC cell culture models 
showed that ALDH7A1 expression was increased upon exposure to low 
oxygen level. Recent reports in the literature have linked ALDH7A1 with 
prostate cancer and matched bone metastasis (van den Hoogen et al., 
2011), ovarian cancer (Saw et al., 2012) and recurrence in patients with non-
small-cell lung carcinoma (Giacalone et al., 2013), further confirming a role 
for this enzyme in some cancer types. The pilot study using siRNA in the 
DLD-1 colorectal cancer cell line showed that ALDH7A1 increased the live 
cell number (Chapter 3), although further RNAi studies in additional CRC cell 
lines are required. Effects observed in the DLD-1 cells revealed the first 
demonstration that ALDH7A1 is involved in the reduction of ROS level in a 
cancer setting (Chapter 3, Results, section 3.3.9), which is in agreement with 
a reported protective role against oxidative stress (Brocker et al., 2011). 
However, ALDH7A1 had no apparent effect on the DLD-1 cell sensitivity of 
oxaliplatin, 5-FU and irinotecan (Chapter 3, Results, section 3.3.11). In an 
attempt to further unravel the role of ALDH7A1 in cancer, an isogenic cell 
line pair was acquired as a gift from Professor Jan Moreb (University of 
Florida). Specifically, the H1299 NSCLC cell line was employed due to its 
low endogenous ALDH expression (Moreb et al., 2012) and hence was 
deemed a good cell line to stably transfect with ALDH7A1, enabling an 
isogenic cell line pair to be used for investigation in this chapter. 
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In collaboration with Dr Zoe Cournia (Athens Academy Biomedical Research 
Foundation), a Maybridge database consisting of 24,000 compounds were 
included in a virtual screen against the ALDH7A1 protein structure. Several 
constraints were set including filters for solubility (QPlogS> -6.5), cell 
permeability (QPCaco> 22 nm), and number of metabolites (<7) compounds 
while Lipinski’s rule of five (Lipinski, 2004) was adhered to (Maybridge UK, 
2015). Nine compounds (BTB10142, HAN00316, RJC00145, DSHS00561, 
HC00017, KM06288, BTB04710, SEW03901 and SO6259) with the highest 
binding affinity for ALDH7A1 were purchased from Maybridge and were used 
to probe ALDH7A1 activity. The optimised binding model of HAN00316 
compound is illustrated in Figure 65. 
  
Figure 65 The optimised binding model of HAN00316 compound to ALDH7A1. The binding model is 
obtained from Dr Zoe Cournia. 
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The hypothesis of this Chapter is: ALDH7A1 expression in NSCLC affects 
cell proliferation and migration and small molecule agents can be used to 
clarify its functional role. The aim of this chapter was to explore ALDH7A1 
function using lung H1299 cancer cell lines. The specific objectives were: 
1. To study the role of ALDH7A1 in mediating cell proliferation, 
migration, spheroid formation and invasion. 
2. To evaluate the effect of ALDH7A1 overexpression on ROS level. 
3. To evaluate ALDH7A1 role in osmoregulation. 
4. To evaluate ALDH7A1 effect on the sensitivity of conventional 
cytotoxic drugs and molecularly-targeted agents. 
5. To evaluate computationally designed compounds with potential of 
inhibiting ALDH7A1 activity to find a compound that might act as a 
starting point for further chemical tool discovery to study the role of 
ALDH7A1 in cancer.  
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4.2 Material and Methods 
 Cell culture 4.2.1
The human non-small cell lung carcinoma cell line, H1299, derived from the 
metastatic lesion in the lymph node was originally obtained from ATCC. 
These are known to have no significant ALDH activity by the ALDEFLUOR 
assay and western blot (Moreb et al., 2012). Cells were transduced with 
lentiviral vectors containing the full cDNA for ALDH7A1 or red fluorescent 
protein RFP (used as a control) (Personal communication, Prof Jan Moreb). 
The cells were cultured and maintained in complete RPMI 1640 culture 
medium (Table 12) containing 1x penicillin/streptomycin antibiotic (Sigma) 
and used for the experiments when they were 70% confluent. 
Cell line Culture medium Frequency of 
subculture 
Dilution upon 
subculture 
H1299/RFP RPMI 5-6 days 1:10-1:20 
H1299/ALDH7A1 RPMI 5-6 days 1:10- 1:20 
           Table 12 Maintenance of H1299 cell lines. 
 Evaluation of ALDH gene expression 4.2.2
To evaluate the gene expression of ALDH in both H1299/RFP and 
H1299/ALDH7A1 cell lines, cells were seeded into 75 cm2 flasks at a 
concentration of 2 × 105 cells/flask. After 5 days of incubation at 37ºC, 5% 
CO2 and 100% humidity, cells were harvested for RNA extraction and cDNA 
synthesis as previously described (Chapter 2, Materials and Methods, 
section 2.2.1.3.1-3). Gene expression analysis of ALDH1A1, 1A2, 1A3, 1B1, 
2, 3A1, 7A1 and β-actin (internal control gene) was carried out as previously 
described (Chapter 2, Materials and Methods, section 2.2.1.3.5-6). 
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 Evaluation of ALDH7A1 protein expression 4.2.3
Cells were seeded into 75 cm2 flasks at a concentration of 2 × 105 cells/flask. 
After 5 days of incubation at 37ºC, 5% CO2 and 100% humidity, cells were 
harvested for protein extraction. Protein expression analysis of ALDH7A1, 2, 
1A3 and actin (internal control protein) was carried out using western blot as 
previously described (Chapter 2, Materials and Methods, section 2.2.1.4). 
 Evaluation of ALDH activity using the ALDEFLUOR assay 4.2.4
ALDH activity was assessed using the ALDEFLUOR Assay System 
(StemCell Technologies) according to the manufacturer’s recommendations. 
This system uses an immunofluorescent method to detect intracellular 
enzyme activity of ALDH (Chapter 1, Introduction, section 1.4.5.1.1). Single 
cells obtained by trypsinisation from fresh H1299/RFP and H1299/ALDH7A1 
cell cultures (70% confluent) were washed in PBS and re-suspended in 1 ml 
of ALDEFLUORTM assay buffer. This suspension was divided equally in two 
microcentrifuge tubes (test sample and control sample) and ALDEFLUORTM 
DEAB inhibitor was added to control sample to block ALDH activity. 2.5 µl of 
the fluorescent-activated ALDEFLUORTM reagent, BAAA, was then added to 
each sample. The “test” and “control” samples were incubated for 30-40 min 
at 37°C. Following incubation, samples were centrifuged for 5 min at 250 rcf 
and supernatants were discarded. Samples were then re-suspended in 0.5 
ml of ALDEFLUORTM assay buffer and placed immediately on ice. Samples 
were washed and analysed with a flow cytometer. Each FACS analysis was 
performed on at least 10,000 events. First the mean number of ALDH 
positive cells was calculated for each cell line using the following formula: 
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Mean ALDH+ = Mean ALDH+ of t sample – Mean ALDH+ of control sample 
The fold change of ALDH activity between H1299/RFP and H1299/ALDH7A1 
cells was calculated using the following formula: 
ALDH activity (fold change) = Mean ALDH+ (H1299/ALDH7A1)/ Mean ALDH+ 
(H1299/RFP) 
 Effect of ALDH7A1 overexpression on cell proliferation 4.2.5
The cell lines were seeded in six 96-well microtitre plates by adding 200 µl of 
5×103 cells/ml cell suspension to the relevant wells (1 × 103 cells/well). 200 
µl of cell free media was added to blank wells. Plates were incubated at 
37ºC, 5% CO2 and 100% humidity until ready to be assayed by the MTT 
assay on day 1, 3, 4, 5 and 6. See Appendix II for the composition of MTT 
assay. 
On day 0, the 96-well plate was centrifuged at 1000 rcf for 5 min. The 
supernatants were removed carefully and 200 µl of MTT (Sigma) solution 
(0.5 mg /ml) was added to each well. The plate was incubated for 4h at 37ºC, 
5% CO2 and 100% humidity before being centrifuged at 1,000 rcf for 5 min to 
pellet down the cells. Supernatants were carefully removed and 150 µl of 
DMSO (Sigma) was added to each well and gently pipetted up and down to 
dissolve the formazan blue crystals. The absorbance of each well was 
determined using a plate reader (Thermo Electron Corporation) at 540 nm. 
On day 1, 3, 4, 5 and 6, one plate was removed on the relevant day. The 
MTT assay was carried out as described above but without centrifugation. 
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The mean of the absorbance values for each cell concentration minus the 
mean of the blank absorbance values was calculated. Results were 
generated in Microsoft Excel 2010 and plotted as a histogram with the mean 
absorbance values on the Y-axis and time (days) on the X-axis. 
 Effect of ALDH7A1 overexpression on cell migration 4.2.6
Cells were seeded in 6 well plates at a concentration of 7 × 105 cells/well in 2 
ml RPMI. After 24h of incubation at 37ºC, 5% CO2 and 100% humidity, the 
cells formed monolayer and were scraped in a straight line to create a 
"scratch" with a p200 pipet tip. The cells were then washed to remove the 
debris and smooth the edge of the scratch using 1 ml of RPMI. Next, 2 ml of 
RPMI containing 2% FBS was added to each well. Photos were taken at time 
0 (initial scratch before migration) as well as after 15h of incubation at 37˚C 
and 5% CO2. Image J was used for migration analysis by calculating the 
cells free area and quantify the migration rate of the cells. 
 Effect of ALDH7A1 overexpression on reactive oxygen 4.2.7
species (ROS) generation 
In order to study the antioxidant activity of ALDH7A1 enzyme, the effect of 
ALDH7A1 overexpression on ROS generation was evaluated using FACS. 
The cells were seeded in phenol red free RPMI medium (Gibco) into 25 cm2 
flasks at a concentration of 2 × 105 cells/flask and incubated at 37˚C and 5% 
CO2. After 72h of incubation, the cells were harvested and treated with 
carboxy-H2DCFDA (Fisher scientific) as previously described in Chapter 3, 
Materials and Methods, section 3.2.6 before ROS analysis was carried out 
using FACS.  
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 Effect of ALDH7A1 overexpression on double strand DNA 4.2.8
damage 
The possible protective role of ALDH7A1 against DNA damage that might be 
caused by ROS was evaluated using phosphorylated H2AX as a marker of 
cellular dsDNA damage (KUO and YANG, 2008). In brief, the cells were 
seeded and harvested for protein extraction as previously described in 
section 4.2.3. Western blot was carried out as previously described (Chapter 
2, Materials and Methods, section 2.2.1.4) using rabbit anti phosphorylated 
H2AX primary antibody (New England Biolabs, concentration: 1:1000) and 
HRP based antirabbit secondary antibody (Dako, concentration: 1:2500). 
 Effect of ALDH7A1 overexpression on osmoregulation 4.2.9
H1299 cells were seeded into 96-well plates by adding 180 µl of cell 
suspension with a concentration of 0.55 × 104 cells/ml (1 × 103 cells/well) to 
each well. Plates were incubated for 24h at 37ºC, 5% CO2 and 100% 
humidity. The following day, medium was removed and cells were treated 
with NaCl or sucrose dissolved in RPMI by adding 200 µl of working 
solutions to the relevant wells (final NaCl concentrations in wells were 
12.5:200 mM, final sucrose concentrations in the wells were 18.75:300 mM). 
The control cells and blank wells were treated only with complete RPMI 
medium. Plates were incubated for 24h at 37ºC, 5% CO2 and 100% humidity. 
The next day, medium was removed and replaced with fresh RPMI medium. 
The cells were incubated for further 72h before the cell survival was 
measured using the MTT assay as previously described (Chapter 2, 
Materials and Methods, section 2.2.4.1) 
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 Effect of ALDH7A1 overexpression on spheroids 4.2.10
formation 
Spheroids were generated from H1299/RFP and H1299/ALDH7A1 cells 
using a hanging drop technique (Del Duca et al., 2004). In brief, 4 × 103 cells 
in 40 µl of complete RPMI media containing 20% (v/v) methylcellulose 
(Sigma) (Appendix VIII) were seeded as drops on the inner side of the lid of 
a 10 cm Petri dish using 200 µl tips. PBS was added to the dish below the 
drops to maintain a humidified atmosphere and to prevent dehydration. The 
dish was gently covered with the lid and incubated at 37°C and 5% CO2 for 
48h. The diameter of the spheroids was measured using calibrated graticule 
fixed to the light microscope at 10 × objective lens. 
 Effect of ALDH7A1 overexpression on spheroids 4.2.11
invasion 
After 48h of cell seeding for spheroid formation, H1299/RFP and 
H1299/ALDH7A1 spheroids were embedded in collagen matrix to evaluate 
their invasion ability. In brief, collagen matrix was prepared on ice by 
dissolving collagen stock solution (collagen type 1 rat tail, Corning) in 5x 
PBS, NaOH (1M) and distilled water (Appendix VIII). 75 µl of invasion 
collagen matrix (pH 7.4) was added to each well of flat bottomed 96 well 
plates and allowed to set at 37°C for 30 min. Next, one spheroid in 2 µl 
medium was transferred to each well, which was allowed to settle down and 
covered with another layer of collagen matrix (75 µl). The plate was 
incubated at 37°C for 30 min after which 150 µl of RPMI containing 40%, 
20%, and 4% of FBS was added to relevant wells to obtain final 
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concentration of 20%, 10% and 2% FBS, respectively. The plate was then 
incubated at 37°C, 5% CO2 and 100% humidity. Spheroid invasion was 
visualised at 0h and 48h after incubation. Photographs were taken at 10 × 
objective lens using Lumascope 500 microscope and data analysis was 
performed using Image J software. 
 Effect of ALDH7A1 overexpression on the anti-4.2.12
proliferative activity of anticancer drugs 
4.2.12.1 Drug stock solution 
H1299 cells were treated with anticancer drugs and compounds listed in 
Table 13. Cytotoxic drugs (cisplatin, doxorubicin, paclitaxel (Avachem 
scientific), oxaliplatin, irinotecan and 5-FU (Sigma)), molecularly-targeted 
drugs (gefitinib, sunitinib, dasatinib, masitinib, imatinib and vandetinib (LC 
laboratories)), ALDH inhibitors (DEAB, disulfiram, pargyline and salinomycin 
(Sigma)) and Maybridge compounds (BTB10142, HAN00316, RJC00145, 
DSHS00561, HC00017, KM06288, BTB04710, SEW03901 and SO6259) 
were dissolved in DMSO (Sigma). The stock solutions were kept at -20ºC 
and working solutions were prepared in complete RPMI medium (Sigma) 
immediately prior to use. 
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Drug category example Mode of action 
Cytotoxic drugs Cisplatin Platinum compounds/intra-strand DNA crosslinking 
Doxorubicin Anthracycline antibiotic/topoisomerase II inhibitor 
Paclitaxel Taxanes/microtubule polymer stabilisation and 
prevention from disassembly 
Oxaliplatin Platinum compounds inter- and intra-strand DNA 
crosslinking 
Irinotecan topoisomerase 1 inhibitor 
5-Flurouracil Antimetabolite/pyrimidine analogue 
Targeted drugs Gefitinib EGFR inhibitor 
Sunitinib PDGF-Rs, VEGFRs, c-Kit, RET and others 
Dasatinib BCR/Abl (the "Philadelphia chromosome"), Src, c-Kit, 
ephrin receptors inhibitor 
Masitinib c-Kit, PDGFR, and FGFR inhibitor 
Imatinib BCR/Abl, PDGFR, and c-Kit inhibitor 
Vandetanib VEGFR, EGFR and RET inhibitor 
Non-selective 
inhibitors 
DEAB ALDH1, 2 and 7A1 inhibitor 
Disulfiram ALDH1A1 and 2 inhibitor 
Pargyline Non-selective monoamine oxidase (MAO) inhibitor 
Salinomycin Induce apoptosis, potassium ionophore (Kills CSCs) 
ALDH7A1 
inhibitors 
BTB10142 
HAN00316 
RJC00145 
DSHS00561 
HC00017 
KM06288 
BTB04710 
SEW03901 
SO6259 
ALDH7A1 inhibitors 
Table 13 Drug category, examples and mode of action.  
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4.2.12.2 Drug treatment using the MTT assay 
Cells were seeded into 96-well plates by adding 180 µl of cell suspension 
with a concentration of 0.55×104 cells/ml (1 × 103 cells/well) to each well. 
Plates were incubated for 24h at 37ºC, 5% CO2 and 100% humidity to enable 
the cells to attach to the plastic surface. Next, 20 µl of working solutions of 
drug in appropriate concentration range were added to the wells. The control 
cells were treated with 20 µl of DMSO in complete RPMI medium (final 
concentration in wells: less than 0.1 % v/v), while blank wells contained cell 
free media. Plates were incubated for 96h at 37ºC, 5% CO2 and 100% 
humidity. After exposure, the chemosensitivity was evaluated by the MTT 
assay as previously described (Chapter 2, Materials and Methods, section 
2.2.4.1). Additionally, the cells were treated with the Maybridge compounds 
and DEAB for 24h to assess the non-toxic concentrations, which were used 
to probe the importance of ALDH7A1 in the isogenic H1299/RFP and 
H1299/ALDH7A1 cell line pair. 
 Effect of Maybridge compounds on ROS generation 4.2.13
The cells were seeded in phenol red free RPMI medium (Gibco) into 25 cm2 
flasks at a concentration of 2 × 105 cells/flask and incubated at 37˚C and 5% 
CO2. After 48h of incubation, the cells were treated with DEAB (200 µM), 
HAN00316 (20 µM), KM06288 (20 µM), DSHS00561 (25 µM) or DMSO 
(0.1% v/v) for 24h. Next, the cells were harvested and treated with carboxy-
H2DCFDA (Fisher scientific) as previously described in section 4.2.7 and the 
ROS formation was evaluated using FACS. 
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 Effect of Maybridge compounds on cell migration 4.2.14
The migration assay was carried out using the scratch assay as previously 
described in section 4.2.6. 2 ml of 2% RPMI containing DEAB (100 µM), 
HAN00316 (10 µM), KM06288 (10 µM), DSHS00561 (20 µM) or DMSO 
(0.1% v/v) was added to wells after creating the scratch. Photos were taken 
at time 0 (initial scratch before migration) as well as after 15h of treatment 
(15h after scratch). Image J was used for migration analysis by calculating 
the cells free area and quantify the migration rate of the cells. 
 Statistical data analysis 4.2.15
The significance of results was assessed through a comparison of means 
using two-tailed student t-test. Results were expressed as the mean ± 
standard deviation. P values were calculated to determine statistical 
significance of the results. 
.  
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4.3 Results 
 ALDH expression analysis 4.3.1
Figure 66A shows the ALDH gene expression analysis of H1299/RFP cells. 
ALDH 1A1, 1A2, 1A3, 1B1, 2, 3A1, and 7A1 genes were expressed at low 
level. As expected, the expression of ALDH7A1 was induced 85-fold at the 
gene level (Figure 66B) and 9-fold at the protein level (Figure 66C) 
compared to H1299/RFP (control). 
The effect of ALDH7A1 overexpression on other members of the ALDH 
family was also explored. Figure 66D shows that the ALDH7A1 transfection 
also had effect on inducing ALDH1A3 (4-fold) and ALDH2 (1.8-fold) at the 
gene level compared to H1299/RFP cells. However, the expression of these 
isoforms was not detected at the protein level (Figure 66E). 
 ALDH activity 4.3.2
The ALDEFLUOR assay was employed to detect the intracellular enzymatic 
activity of ALDH in both H1299 cell lines. Figure 67 shows that 
H1299/ALDH7A1 cells had 17-fold increase in ALDEFLUOR activity 
compared to H1299/RFP cells. The detection of higher ALDEFLUOR activity 
in H1299/ALDH7A1 cells combined with significant ALDH7A1 expression, 
suggests that ALDH7A1 might be the isoform responsible for the reported 
activity. 
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D 
Figure 66 The expression of ALDH in H1299/RFP and H1299/ALDH7A1 cells. ALDH 
gene expression analysis in H1299/RFP using qRT-PCR (A), ALDH7A1 gene expression 
using qRT-PCR (B), ALDH7A1 protein expression using western blot (C), comparison of 
ALDH gene expression using qRT-PCR (D) and protein expression of ALDH1A3 and 2 
(E). Results represent 1 experiment. 
E 
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E 
Figure 67 ALDH activity detection in H1299 isogenic cell pair using the ALDEFLUOR assay. 
H1299/RFP (Control) (A), H1299/RFP (test) (B), H1299/7A1 (Control) (C), H1299/7A1 (test) (D). Fold 
change of ALDH activity (E). Dots represent ALDEFLUOR positive cells and values are the mean of 2 
experiments. 
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 Effects of ALDH7A1 overexpression on cell proliferation 4.3.3
Results from Chapter 3 showed that knockdown of ALDH7A1 resulted in 
reduction of DLD-1 live cell number, which is in agreement with ALDH7A1’s 
effect on cell proliferation and clonal efficiency in prostate cancer (van den 
Hoogen et al., 2011). Here, the cell proliferation was evaluated using the 
MTT assay to detect differences in daily cell growth. Overexpression of 
ALDH7A1 increased the proliferation rate compared to H1299/RFP cells 
(Figure 68). 
  
Figure 68 The effect of ALDH7A1 overexpression on H1299 cell proliferation using the MTT 
assay. Values are the mean of at least 3 experiments and error bars are SD. P values: * p< 0.05, ** 
p<0.01, *** p<0.001. 
** 
*** 
*** * 
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 Effects of ALDH7A1 overexpression on cell migration 4.3.4
The effect of ALDH7A1 overexpression on H1299 cells migration was 
explored using the scratch assay. ALDH7A1 increased the migration rate by 
10% as compared to H1299/RFP (Figure 69A and B). 
  
* 
Figure 69 The effect of ALDH7A1 overexpression on H1299 cell migration using the scratch 
assay. Photos of H1299/RFP cells and H1299/ALDH7A1 cells at initial scratch (0h) and after 15h of 
migration (A), Migration rate after 15h of initial scratch (B). Values are the mean of 3 independent 
experiments and error bars are SD. P value: * p<0.05. Photos are at 10x lens and scale bar = 100 
µm. 
A 
B 
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 Effect of ALDH7A1 overexpression on reactive oxygen 4.3.5
species (ROS) generation and DNA damage 
The role of ALDH7A1 on ROS generation was explored using FACS. Figure 
70A and B shows that ALDH7A1 overexpression resulted in significantly less 
ROS formation compared to H1299/RFP (curve shifted to left) with more than 
90% reduction in ROS generation.  
Direct effects of ROS include dsDNA breaks that might cause cell death (Li 
et al., 1994) and hence the expression of phosphorylated histone protein, 
H2AX was evaluated as a marker of dsDNA damage (KUO and YANG, 
2008). Figure 71 shows that overexpression of ALDH7A1 has a protective 
role against the dsDNA breaks that might be caused by ROS. The 
expression level of phosphorylated H2AX was significantly downregulated in 
H1299/ALDH7A1 cells with approximately 70% reduction in its expression 
compared to H1299/RFP.  
Figure 70 The antioxidant properties of ALDH7A1 in H1299 isogenic cell pair. ROS 
generation curves in H1299/RFP and H1299/ALDH7A1 cells using FACS (A), and fold change of 
ROS generation using the geometric means of area under the curve (B). Values are the mean of 3 
independent experiments and error bars are SD. P value: *** p<0.001. 
A B 
*** 
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 Effect of ALDH7A1 overexpression on osmoregulation 4.3.6
The effect of ALDH7A1 overexpression on osmoregulation was evaluated as 
recent study showed that ALDH7A1 has potential protective role against 
osmotic stress (Brocker et al., 2010). The two H1299 cell lines were treated 
with NaCl or sucrose and the effect on cell survival was evaluated using MTT 
assay as previously described in section 4.2.9. However, both H1299/RFP 
and H1299/ALDH7A1 cells showed similar response to NaCl and sucrose 
treatment (Figure 72A and B, respectively).  
A B 
Figure 72 Cell survival of H1299 cell lines using the MTT assay after 24h of treatment with NaCl (A) 
or Sucrose (B). Values are the mean of 3 independent experiments and error bars are SD. 
Figure 71 Evaluation of phosphorylated H2AX as a 
marker of dsDNA damage in H1299/RFP and 
H1299/ALDH7A1 cells. 
Phospho- 
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 Effect of ALDH7A1 overexpression on spheroids formation 4.3.7
and invasion 
Both H1299/RFP and H1299/ALDH7A1 cell lines were able to form compact 
spheroids using a hanging drop technique (Figure 73). The diameter of 
formed spheroids after 48h of cell seeding was 320 µm and 380 µm for 
H1299/RFP and H1299/ALDH7A1, respectively. 
Next, the ability of H1299/RFP and H1299/ALDH7A1 spheroids to invade in 
3D ECM-like environment was evaluated. After 48h of embedding, both 
spheroids were able to invade through the collagen matrix (Figure 75). 
Figure 74 shows the analysis of spheroid invasion. The percentage of area 
before and after migration was calculated using Image J and the percentage 
of invasion after migration was calculated using the following equation:  
% of invasion = B – A 
A is the % area before migration and B is the % area after migration. 
Figure 75 shows that the invasion rate was also directly correlated with the 
concentration of FBS in the growth medium. 
Figure 73 H1299 spheroids using the hanging drop technique after 48h of cell seeding. 
H1299/RFP spheroids (A), and H1299/ALDH7A1 spheroids (B). Images are at 10x objective 
lens.  
A B 
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Figure 74 Analysis of spheroids invasion. Images were taken using Lumascope 500 
microscope and changed into binary before calculating the total invasion area using Image 
J software. Images are at 10x objective lens. 
Figure 75 H1299 spheroids invasion after 48h of embedding in collagen matrix. Images of 
H1299/RFP and H1299/ALDH7A1 spheroids invasion at 10x objective lens (A) and analysis of invasion 
rate normalised to H1299/RFP spheroids with 20% FBS (B). Values are the mean of two independent 
experiments.  
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 Effect of ALDH7A1 overexpression on anticancer drugs 4.3.8
sensitivity 
To examine the in vitro anti-proliferative activity of conventional anticancer 
drugs and molecularly-targeted drugs, the H1299 cell lines were exposed to 
various concentrations of these drugs for 96h. The MTT assay was 
employed to measure the antiproliferative effects. The dose-response curves 
obtained for 96h exposure for conventional anticancer drugs (Figure 76) and 
molecularly-targeted drugs (Figure 77) essentially reveal that ALDH7A1 
overexpression had no effect on treatment outcomes. 
 H1299 cell survival upon treatment with non- specific ALDH 4.3.9
inhibitors 
The H1299 cell lines were also treated with disulfiram (ALDH inhibitor), 
salinomycin (stem cell-targeting agent) and parygline (non-specific 
monoxidase/ALDH inhibitor), however no difference in treatment outcome 
was observed (Figure 78). 
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Figure 76 The cell survival of H1299 isogenic cell pair after 96h exposure to conventional anticancer drugs 
using the MTT assay. 5-FU (A), Oxaliplatin (B), Cisplatin (C), Irinotecan (D), Paclitaxel (E) and Doxorubicin (F). 
Values are the mean of 3 independent experiments with the exception to A and C and error bars are SD. 
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Figure 77 The cell survival of H1299 isogenic cell pair after 96h exposure to targeted anticancer drugs 
(TKIs) using the MTT assay. Gefitinib (A), Sunitinib (B), Vandetanib (C), Dasatinib (D), Imatinib (E) and Masitinib 
(F). Values are the mean of 3 independent experiments with the exception to E and F and error bars are SD. 
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Figure 78 The cell survival of H1299 isogenic cell pair after 96h exposure to 
Disulfiram (A), Salinomycin (B) and Pargyline (C) using the MTT assay. 
Values represent 1 experiment. 
Pargyline 
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 Targeting ALDH7A1 activity using Maybridge 4.3.10
compounds 
4.3.10.1 H1299 cell survival using the MTT assay 
The H1299 cell lines were treated with 9 compounds purchased from 
Maybrige/UK (Table 13, section 4.2.12). At first, the effect of these 
compounds on cell survival was evaluated after 96h of treatment using the 
MTT assay. H1299/ALDH7A1 cells were slightly more sensitive to 
HAN00316 compared with H1299/RFP cells (Figure 79A) and accordingly it 
was chosen for further investigation. KM06288 and DSHS00561 were used 
as controls (Figure 79C and D, respectively). Cells were treated with 
HAN00316, KM06288, DSHS00561 and DEAB for 24h. DEAB was chosen 
because a recent study showed that it acts as an irreversible inhibitor to 
ALDH7A1 activity (Luo et al., 2015). The 24h treatment was carried out in 
order to choose a non-toxic concentration for further evaluation of the effect 
of these compounds on ALDH7A1 activity (Figure 80). 
.  
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4.3.10.2 The effect of Maybridge compounds on ROS generation 
H1299/ALDH7A1 cells showed significantly less ROS generation compared 
to H1299/RFP cells (Figure 70, section 4.3.5). To evaluate the possibility of 
inhibiting ALDH7A1 activity, the H1299 cell lines were treated with 
HAN00316 (20 µM), KM06288 (20 µM), DSHS00561 (25 µM), DEAB (200 
µM) or only DMSO (control, 0.1% v/v) for 24h before evaluation of ROS 
generation. Results obtained from H1299/RFP are illustrated in Figure 81A-E 
and showed that neither DEAB nor HAN00316 had any effect on ROS 
generation in comparison to DMSO control cells. In contrast, both 
DSHS00561 and KM06288 reduced the generation of ROS. 
  
Figure 80 The cell survival of H1299 isogenic cell pair after 24h treatment with DEAB (A), HAN00316 (B), 
KM06288 (C) and DSHS00561 (D) using the MTT assay. Values are the mean of 3 independent experiments 
and error bars are SD.  
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Next, the effect of these compounds on ROS generation was evaluated in 
H1299/ALDH7A1 cells. Figure 82A shows that DEAB treatment resulted in 
more ROS in comparison to DMSO treated cells. HAN00316 was also found 
to increase the generation of ROS (Figure 82D). This was observed 
selectively in the 7A1 overexpressing cells suggesting that DEAB and 
E 
Figure 81 The effect of Maybridge compounds on ROS generation in 
H1299/RFP cells. ROS generation curves of DEAB (A), DSHS00561 (B). 
KM06288 (C) and HAN00316 (D), and fold change of ROS generation (E). 
Values are the mean of 3 independent experiments and error bars are SD. P 
values: ** p<0.01. For raw data, see Appendix XI. 
** ** 
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HAN00316 may promote ROS generation through inhibition of 7A1 
antioxidant activity. The generation of ROS may also contribute to the 
cytotoxic effects of DEAB and HAN00316 observed by MTT (Figure 79, 
section 4.3.10.1). In contrast, neither DSHS00561 nor KM06288 showed any 
difference in ROS generation compared with DMSO treated cells (Figure 82B 
and C, respectively). 
  
Figure 82 The effect of Maybridge compounds on ROS generation in 
H1299/ALDH7A1 cells. ROS generation curves of DEAB (A), DSHS00561 (B). 
KM06288 (C) and HAN00316 (D), and fold change of ROS generation (E). P values: * 
p<0.05, ** p<0.01. 
E 
** 
* 
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4.3.10.3 The effect of Maybridge compounds on cell migration 
H1299/ALDH7A1 cells showed more ability to migrate compared with 
H1299/RFP cells (Figure 69, section 4.3.4). Accordingly the effect of 24h 
treatment of HAN00316 (10 µM), KM06288 (10 µM), DSHS00561 (20 µM) or 
DEAB (100 µM) on cell migration was evaluated. These concentrations were 
chosen as they showed no toxic effect upon 24h treatment (Figure 80). 
Figure 83 shows the analysis of scratch assay results of H1299 cells. None 
of these compounds or DEAB inhibited the migration ability of H1299/RFP 
cells (Figure 84). HAN00316 appeared to suppress the migration of 
H1299/ALDH7A1 cells (Figure 85). 
   
Figure 83 The migration rate of H1299/RFP and H1299/ALDH7A1 cells after treatment with 
DMSO, DEAB, DSHS00561, HAN00316 and KM06288 using the scratch assay. Values are the 
mean of 2 independent experiments.  
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  Figure 84 The cell migration of H1299/RFP cells using the scratch assay. The cells were 
treated with DMSO, DEAB, DSHS00561, HAN00316 and KM06288. Images are at 10x 
objective lens and scale bar = 100 µm. 
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  Figure 85 The cell migration of H1299/ALDH7A1 cells using the scratch assay. The cells 
were treated with DMSO, DEAB, DSHS00561, HAN00316 and KM06288. Images are at 10x 
objective lens and scale bar = 100 µm. 
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4.4 Discussion 
The main focus of this Chapter was on the effects of ALDH7A1 
overexpression. The role of ALDH7A1 enzyme was investigated using an 
isogenic system of the H1299 lung cancer cell line. H1299 is a NSCLC cell 
line that was considered as a negative model for ALDH expression (Moreb et 
al., 2012). Subsequent to this study, Moreb and co-workers transfected the 
H1299 cell line with lentiviral vectors containing the full cDNA for ALDH7A1 
or red fluorescent protein (RFP). The isogenic cell line pair was made 
available for this study, enabling a more in-depth investigation to be carried 
out with focus on ALDH7A1. 
First, the expression of ALDHs in the H1299 cell lines was evaluated and this 
showed very low level of expression in H1299/RFP cells, confirming that they 
are low in ALDH expression (Moreb et al., 2012). In contrast, significant 
upregulation of ALDH7A1 was found in H1299/ALDH7A1 cells at both the 
gene (85-fold) and protein (9-fold) levels in comparison to H1299/RFP cells. 
Gene analysis also showed upregulation of ALDH1A3 (4-fold) and ALDH2 
(1.5-fold) in H1299/ALDH7A1 cells. However, these isoform were not 
detected at the protein level. Accordingly, a reasonable assumption to make 
is that any difference between these cell lines is due to direct or indirect 
effect of differential expression of ALDH7A1 enzyme. 
The activity of ALDH in H1299 cells was measured using the ALDEFLUOR 
assay (Chapter 1, Introduction, section 1.4.5.1.1). This assay has been 
reported to be specific to ALDH1A1 (Marcato et al., 2011a), however, recent 
information suggests this assay can detect other ALDH isoforms, which have 
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implication for SC isolation (Levi et al., 2009, Marcato et al., 2011b). 
Accordingly, the ALDEFLUOR assay was employed to evaluate whether it 
can be used to measure the activity of ALDH7A1 in this study. It was found 
that H1299/ALDH7A1 cells had 17-fold increase in ALDH activity compared 
to H1299/RFP cells. This suggests that ALDEFLUOR assay is not solely 
specific for ALDH1A1 and supports the findings of other studies (Levi et al., 
2009, Marcato et al., 2011b, Moreb et al., 2012). Levi et al. showed that 
ALDH1A1 deficiency did not reduce ALDEFLUOR activity of HSC and other 
ALDH isoforms (ALDH2, ALDH3A1 and ALDH9A1) have been detected and 
suggested to contribute to ALDEFLUOR activity (Levi et al., 2009). 
Knockdown studies in breast cancer showed that only suppression of 
ALDH1A3 expression resulted in the reduction of ALDH activity in 
ALDEFLUOR positive cells (Marcato et al., 2011b). Moreb et al. also showed 
that the enzymatic activity of ALDH1A2 and ALDH2 was detected by 
ALDEFLUOR assay (Moreb et al., 2012). The detection of higher 
ALDEFLUOR activity in H1299/ALDH7A1 cells combined with 9-fold higher 
ALDH7A1 protein levels suggests that ALDH7A1 might contribute to the 
ALDEFLUOR activity, and thus any difference between the responses of 
H1299 cells pair toward the functional assays explored in this study can be 
attributed to ALDH7A1. 
The role of ALDH7A1 in mediating cell proliferation was investigated. It was 
found that H1299/ALDH7A1 cells proliferate at higher rate compared to 
H1299/RFP cells. This supports the findings of Chapter 3 where knockdown 
studies showed reduction in DLD-1 live cell number and is in agreement with 
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the role of ALDH7A1 in prostate cancer where ALDH7A1 knockdown led to 
significantly decreased cell clonogenicity and proliferation (van den Hoogen 
et al., 2011). The results from microarray analysis performed by Moreb’s 
group on the cells with knockdown of ALDH1A1 and ALDH3A1 showed 
significant  modulation in the expression of genes that are related to cell 
proliferation and cell cycle pathways (e.g. PPARG, CCNG1, BCAT1) (Moreb 
et al., 2008). In this regard, it is possible that the overexpression of 
ALDH7A1 affect similar genes that result in increased proliferation. Our 
results are in contrast to Moreb’s group findings (Moreb et al, 2013), however 
this might be caused by difference in the cell density used in this study or 
difference in the day of evaluation (Time dependent). 
The role of ALDH7A1 in mediating cell migration was evaluated and it was 
found that H1299/ALDH7A1 cells migrate at significantly higher rate 
compared to H1299/RFP cells (P value < 0.05). This supports the reported 
role of ALDH7A1 in mediating prostate cancer metastasis (van den Hoogen 
et al., 2011). However, further studies are needed to fully understand the 
mechanism(s) by which ALDH7A1 might promote cell migration. This might 
include evaluation of a number of genes/factors involved in migration, 
invasion and metastasis such transcription factors (snail, snail2, and twist) 
and osteopontin, an ECM molecule involved in metastasis which were found 
to be affected upon ALDH7A1 knockdown in PC-3M-Pro4lucA6, a prostate 
cancer cell line (van den Hoogen et al., 2011). 
The potential role of ALDH7A1 in reducing ROS was evaluated and it was 
found that H1299/ALDH7A1 cells had significantly less ROS production 
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compared with H1299/RFP cells (> 90% reduction), which supports the 
antioxidant role previously described for this enzyme (Brocker et al., 2011). 
Further evidence for the potential involvement of ALDH7A1 in reducing ROS 
levels was described in Chapter 3 where knockdown of ALDH7A1 
expression in DLD-1 cells resulted in more ROS generation. Direct effects of 
ROS include dsDNA breaks which if left unrepaired can lead to cell death (Li 
et al., 1994). Accordingly, the expression of phosphorylated H2AX histone 
protein as a marker of dsDNA damage (KUO and YANG, 2008) was 
measured and it was found that H1299/ALDH7A1 cells had significantly less 
phosphorylated H2AX expression, indicating less DNA damage, which is 
likely to be due to the protective properties of ALDH7A1. 
Previous studies showed that ALDH7A1 also has a protective role against 
osmotic stress caused by sodium chloride (NaCl) or sucrose (Brocker et al., 
2010). However, this role has not been investigated in cancer. In this study it 
was found that upon NaCl or sucrose treatment no differential in cell survival 
was observed between H1299/ALDH7A1 and H1299/RFP cell lines. 
However, this might be caused by the presence of other defence 
mechanisms in cancer cells that protect them against osmotic stress. This 
might include the activation of MAPKs, ERK1/2 and JNK in response to 
hyperosmolarity which for example has been shown to be mediated by HB-
EGFdependent EGFR activation (Fischer et al., 2004). 
Cancer cells possess varying capacities for spheroid formation and this 
correlates positively with tumourigenicity, invasive ability and drug resistance 
(Kelm et al., 2003, Ahmed et al., 2007). Thus, deciphering the mechanisms 
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that enable spheroid formation, with the goal of inhibiting this process, may 
improve therapeutic efficacy (Sodek et al., 2009). Accordingly, the ability of 
the H1299 cell line pair to form spheroids was evaluated in an attempt to 
understand whether ALDH7A1 is involved in spheroid formation. However, 
both cell types were able to generate similar sized compact spheroids after 
48h of seeding using the hanging drop technique (Del Duca et al., 2004). 
The ability of spheroids generated from both cell lines to invade in 3D 
through ECM- like environment such as collagen matrix was explored and 
both spheroids were able to invade through the matrix with similar efficiency. 
This suggests that ALDH7A1 is not a critical protein for spheroids formation 
or invasion, at least for H1299 lung cancer cells. 
The role of ALDH in mediating drug resistance for cytotoxic and targeted 
therapeutics has been described (Chapter 1, Introduction, section 1.4.4). 
However, only one recent study has revealed high expression of ALDH7A1 
in a zoledronic acid-resistant prostate cancer cell line (DU145) via 
proteomics analysis (Milone et al., 2015). To further evaluate if ALDH7A1 
has implications on drug sensitivity, a wide panel of conventional cytotoxic 
drugs and tyrosine kinase inhibitors was evaluated using the MTT assay 
(Results, section 4.3.8). However, both H1299 cell lines showed similar 
sensitivity upon drug exposure, suggesting that ALDH7A1 is not involved in 
mediating resistance to these drugs. 
Because of the functional involvement of ALDH in CSCs and their correlation 
with poor clinical outcomes as well as drug resistance, the development of 
selective ALDH inhibitors is highly needed (Honoki et al., 2010). These 
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inhibitors can act as tools to probe the various roles of ALDHs in cancer 
and/or as leads in drug development (Pors and Moreb, 2014). However, 
selective targeting seems to be difficult for two main reasons. First, ALDH 
enzymes are characterised by being widely distributed in normal tissue, with 
the highest concentrations most often occurring in the liver and/or kidney. In 
addition, ALDHs have been shown to have broad substrate specificity 
although some more selective small molecules have been identified, which 
suggests that selectivity can be achieved (Pors and Moreb, 2014). Currently, 
the pharmacological inhibitors have been developed for only four ALDH 
isozymes: ALDH1A1, ALDH1A2, ALDH2 and ALDH3A1 that have been 
studied for their potential as pharmacologically relevant therapeutic targets 
(Koppaka et al., 2012). 
DEAB is a well-known, but poorly characterized, ALDH inhibitor that has 
been described as a reversible competitive inhibitor of ALDH1 (competitive 
with the aldehyde substrate) (Russo et al., 1995) and it is employed as an 
allegedly ALDH1A1-specific inhibitor in the widely used ALDEFLUOR assay 
(Balber, 2011). However, more recent studies suggest that DEAB may be a 
broad inhibitor of ALDHs including 1A2 and 2 isoforms (Moreb et al., 2012). 
The first crystal structure of ALDH complexed with DEAB has only been 
described recently (Luo et al., 2015). Interestingly, Luo et al. showed that 
DEAB irreversibly inactivated ALDH7A1 via formation of a stable, covalent 
acyl-enzyme species (Luo et al., 2015). The evaluation of cell survival of 
H1299 cell lines upon treatment with DEAB showed that 24h exposure 
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resulted in more cell kill in H1299/ALDH7A1 cells than in H1299/RFP cells, 
suggesting that ALDH7A1 might be inhibited by DEAB. 
The cell survival upon treatment by other non-specific inhibitors was also 
investigated The monoamine oxidase inhibitor pargyline is activated by 
CYP2E1 to yield a highly reactive propiolaldehyde that irreversibly 
inactivates ALDH2 (DeMaster and Nagasawa, 1978). Both cell lines were not 
sensitive to pargyline treatment. The anti-proliferative effect of salinomycin 
was also evaluated. Salinomycin has been shown to kill breast cancer stem 
cells in mice at least 100 times more effectively than the anti-cancer drug 
paclitaxel (Gupta et al., 2009). In addition, studies have shown that 
salinomycin is able to effectively eliminate CSCs and to induce partial clinical 
regression of heavily pretreated and therapy-resistant cancers (Naujokat and 
Steinhart, 2012). However, both H1299 cell lines showed similar sensitivity 
toward salinomycin treatment, indicating that high ALDH7A1 expression is 
not involved in mediating sensitivity to this compound. 
Recent focused studies on the discovery of chemical modulators of ALDH 
resulted in broad-spectrum and specific inhibitors with in vitro activity 
(Khanna et al., 2011). The encouraging results were made feasible using 
computational modelling and in vitro screening assays as recently reviewed 
(Pors and Moreb, 2014). In this study, nine compounds identified from 
computational modelling to have high affinity for ALDH7A1 binding (Table 13, 
Materials and Methods, section 4.2.12) were purchased from Maybridge/UK 
and evaluated. First, the cell survival upon 96h treatment was evaluated 
using the MTT assay. H1299/ALDH7A1 cells were more sensitive toward 
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treatment with three compounds, HAN00316, KM06288 and DSHS00561 
and thus these were considered for further evaluation. As a recent study 
showed DEAB to act as irreversible inhibitor of ALDH7A1 (Luo et al., 2015), 
it was also included in these assays. Cells were treated with HAN00316, 
KM06288, DSHS00561 and DEAB for 24h to choose non-toxic 
concentrations for the experiments to be carried out. Subsequently, the effect 
of these compounds on ROS generation was explored. It was found that both 
DEAB and HAN00316 resulted in significant more ROS generation in 
H1299/ALDH7A1 treated cells, suggesting that both compounds may have 
inhibited ALDH7A1 functional activity and hence accumulation of ROS. 
Next the effect of HAN00316, KM06288, DSHS00561 and DEAB on cell 
migration was evaluated and it was found that only HAN00316 resulted in 
slight suppression of H1299/ALDH7A1 cell migration suggesting that its 
effect on ALDH7A1 activity might have contributed to this observation. 
In summary, an isogenic system of ALDH7A1 expression was used to 
explore the biological roles of ALDH7A1 and study the possibility of targeting 
its activity. ALDH7A1 overexpression was found to enhance cell proliferation 
and migration. In addition, ALDH7A1 was found to reduce ROS levels and 
phosphorylated H2AX levels, suggesting a potential role in protecting cells 
from oxidative stress and DNA damage. The results with ALDH7A1 inhibitors 
suggest that DEAB and HAN00316 could be good starting points for 
medicinal chemistry to be performed, leading to more potent and selective 
ALDH7A1 inhibitors to be developed and used as tool compounds to explore 
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the importance of ALDH7A1 in cancer and other pathological diseases where 
this enzyme may be playing a key role. 
The main findings of this Chapter were: 
• ALDH7A1 overexpression increased H1299 cell proliferation. 
• ALDH7A1 overexpression increased H1299 cell migration. 
• ALDH7A1 overexpression significantly reduced the level of ROS and 
dsDNA damage. 
• HAN00316 compound inhibited the activity of ALDH7A1 in reducing 
ROS level.  
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 Chapter 5: General discussion, 
conclusion and future work  
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Colorectal cancer (CRC) is the third most common form of cancer in the UK 
and is one of the leading causes of cancer related deaths worldwide (Jemal 
et al., 2011). The overall survival rate of CRC patients has not improved 
dramatically over the last decade despite substantial progress in our 
understanding of the molecular mechanisms of CRC pathogenesis as well as 
the improvement in the current systemic chemotherapy and novel targeted 
drugs for CRC treatment (American Cancer Society, 2014). 
One of the major challenges facing the clinicians is the lack of diagnostic kit 
to predict patients at risk of CRC relapsing and recurrence. Current 
screening tests including high-sensitivity faecal occult blood tests (FOBT), 
sigmoidoscopy or colonoscopy are not useful for predicting recurrence of 
aggressive CRC (Lieberman, 2010, Jorgensen and Knudtson, 2015). 
Additionally, characterisation of CRC based on molecular classification 
including microsatellite instability (MSI), CpG island methylator phenotype 
(CIMP), chromosomal instability (CIN), BRAF and KRAS mutations is at 
present not considered sufficiently accurate for prediction of CRC recurrence 
due to the complex heterogeneous nature of CRC (Winder and Lenz, 2010). 
It is well established that solid tumours contain hypoxic regions that have 
been correlated with an aggressive cancer cell phenotype, and resistance to 
radiotherapy and chemotherapy (Semenza, 2012). Accumulative evidence 
supports important roles of selected ALDH isoforms in contributing to the 
aggressiveness of colorectal cancer (Chapter 2, Introduction, section 2.1). 
Given the importance of hypoxia on tumourigenesis and resistance, 
information about how selective ALDHs adapt to hypoxia in the tumour 
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microenvironment could have a profound impact on the understanding of 
drug resistance and CRC aggressiveness, which might help to predict cancer 
recurrence. Accordingly, the aim of this project was to explore if ALDH 
expression was affected by the presence of hypoxia in the tumour 
microenvironment. 
To address this question, four CRC cell lines (HT29, DLD-1, HCT116 and 
SW480) were exposed to hypoxia (0.1% O2) and its effect on 7 ALDH 
isoforms (1A1, 1A2, 1A3, 1B1, 2, 3A1 and 7A1) was evaluated. Notably, 
increased expression of ALDH7A1 was observed in HT29 and DLD-1 cells 
exposed to hypoxia. Spheroids generated from HT29 and DLD-1 cell lines 
showed high ALDH7A1 expression in the peripheral region that also 
increased toward the hypoxic region at both the mRNA and protein levels. 
Immunohistochemistry experiments of paraffin-embedded spheroids showed 
clear staining of ALDH7A1 in hypoxic regions, which was confirmed using 
intrinsic and extrinsic hypoxic markers, CAIX and pimonidazole, respectively 
(Results discussed in Chapter 2). Although ALDH7A1 was not induced in 
HCT116 and SW480 under the hypoxic conditions, it is possible that longer 
exposure to hypoxia such as 72h or 96h may show elevation in ALDH7A1 
expression. It may also be possible that modulation of ALDH7A1 expression 
is cell-specific and hence further analysis of CRC molecular phenotype is 
required. Further supporting ALDH7A1 as an important enzyme in CRC was 
the observation of its abundant expression in 5 CRC xenografts. 
Unfortunately, due to technical issues using CAIX, the assessment of 
ALDH7A1 correlation and distribution with hypoxic regions was not possible. 
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As a consequence, future studies need to determine the inclusion of other 
intrinsic hypoxic markers such GLUT-1 (Airley et al., 2003) for co-localisation 
of ALDH7A1 with hypoxic regions of xenograft tumours. 
In collaboration with Prof Federica Di Nicoleantonio (Candiolo Cancer 
Institute, Turin, Italy), investigation of ALDH expression in a panel of 150 
CRC cell lines was carried out using Affymetrix Microarray (Medico et al., 
2015) (Figure 86A). Log2 expression <10 is likely not to be translated into 
protein expression (personal communication, Prof Di Nicoleantonio). This 
revealed a wide range of expression of ALDH1 isoforms apart from 1A2, 
which is considered not expressed. This is in agreement with the cell lines 
used in this thesis and the study by Kim et al., which suggested ALDH1A2 to 
act as TSG that is epigenetically silenced in prostate cancer (Kim et al., 
2005). The results obtained from Prof Di Nicoleantonio’s microarray data 
(Medico et al., 2015) (Figure 86B) is consistent with the ALDH gene 
expression profile discussed in Chapter 2, section 2.3.1.1.1. High expression 
of both ALDH1B1 and ALDH7A1 in most of the 150 cell lines was observed 
(Figure 86A and C). Very little is known regarding the regulation of 
ALDH1B1, but its high and reliable expression in clinical samples could be 
used as a potential biomarker for diagnosing the presence of CRC (Chen et 
al., 2011), while hypoxia-induced ALDH7A1 might be used to diagnose 
aggressive forms of CRC.  
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Figure 86 ALDH expression in a panel of 150 CRC cell lines. Data mining of ALDH1A1, 1A2, 1A3, 1B1 and 
7A1 gene expression using Log 2 expression (A). Log2 expression of ALDH1A1, 1A2, 1A3, 1B1 and 7A1 gene  
in DLD-1, HCT116, HT29 and SW480 cell lines (B). Log2 expression of ALDH7A1 gene in 150 CRC cell lines 
(C). Adopted from Medico et al. 2015. 
A 
B 
C 
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Human ALDH7A1 plays an important role in the protection of cells against 
hyperosmotic stress (Brocker et al., 2010). In addition, it was found to 
possess antioxidant activity preserving cells from oxidative stress induced 
cytotoxicity (Brocker et al., 2011). Mounting evidence indicates that hypoxic 
cancer cells undergoing exposure to oxidative stress develop adaptive 
strategies to survive hostile milieu (Fiaschi and Chiarugi, 2012), such as 
increasing antioxidant functionalities that may result in increased 
aggressiveness. Given the results observed with ALDH7A1 (Chapter 2), it is 
suggested that one of these adaptive responses is the upregulation of the 
antioxidant enzyme, ALDH7A1. 
It is well known that major adaptive responses in hypoxic cells are mediated 
by HIFs (Semenza, 2012). To gain a better understanding of whether the 
regulation of ALDH7A1 is regulated by HIFs, cobalt chloride (CoCl2) 
treatment was used to induce HIF-1α. Whilst CoCl2 treatment induced HIF-
1α, ALDH7A1 expression in both HT29 and DLD-1 cell lines was not 
affected, which point towards ALDH7A1 regulation being independent of the 
HIF-1α master regulator. Knockdown studies of HIF-1α and HIF-2α also 
indicated that ALDH7A1 is HIF-1α/HIF-2α independent and might be 
controlled by another cellular mechanism (Chapter 2). The role of other 
hypoxia-inducible transcriptional factors such as nuclear factor ҝB (NF-ҝB), 
activator protein I (AP-I) and p53 (Carroll and Ashcroft, 2005) need to be 
considered and future studies will be directed to understand whether they are 
involved in the regulation of ALDH7A1 expression. 
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To further evaluate the antioxidant properties of ALDH7A1, knockdown 
studies were carried out (discussed in Chapter 3) and their effect on the 
generation of DNA damaging reactive oxygen species (ROS) showed that 
ALDH7A1 presence is important in decreasing ROS generation. The use of 
isogenic cell line pair (H1299/RFP and H1299/ALDH7A1) further 
substantiated these findings (discussed in Chapter 4). These observations 
are in good accordance with ALDH7A1 as a key enzyme in combating 
oxidative stress signals and further emphasises a potential role of this 
enzyme in the hypoxic regions of solid tumours. To further unravel the 
antioxidant role of ALDH7A1, future studies may involve exploring oxidative 
stress biomarkers such as measuring superoxide dismutase (SOD), 
glutathione reductase/peroxidase, or benzo(a)pyrene diolepoxide (BPDE) 
(Ziech et al., 2010, Fan et al., 2008) in attempt to understand mechanistically 
if ALDH7A1 operates independently as an antioxidant enzyme or in 
conjunction with other enzymes or pathways in the CRC microenvironment. 
In addition, given the role of hypoxia and mitochondrial dysfunction in the 
generation of reactive nitrogen species (RNS) (Reuter et al., 2010), the role 
of ALDH7A1 in the protection of CRC cells against different types of radicals 
ought to be considered for evaluation (Haklar et al., 2001). Collectively, this 
might broaden the understanding of ALDH7A1 and enhance the knowledge 
of how CRC cells adapt to acute or chronic exposure to hypoxia. 
Previously, the role of ALDH7A1 has been described in enhancing cell 
proliferation and colony formation in prostate cancer (van den Hoogen et al., 
2011). Here, results using knockdown experiments in DLD-1 CRC cell line 
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and the isogenic H1299 cell line pair (Chapter 3 and 4, respectively) are 
suggestive of ALDH7A1 role in mediating cancer cell proliferation. Although 
the exact mechanism has not been investigated in this thesis, future work will 
be conducted to study possible downstream signalling pathways that 
mediate cell proliferation and survival. This might include oncogenic 
pathways such as ERK and MAPK pathways that are predominant in CRC 
(Fang and Richardson, 2005, Urosevic et al., 2014). 
One of the main challenges in achieving successful CRC treatment outcome 
is the presence of intrinsic or acquired drug resistance (Holohan et al., 2013). 
It is well known that hypoxia mediates resistance and supresses the 
pharmacological activities of both chemotherapy and radiotherapy treatment 
modalities that ultimately will affect treatment outcome (Wouters et al., 2007). 
In this context, it was interesting to assess whether ALDH7A1 expression 
might also contribute to drug resistance. Using knockdown studies and the 
isogenic H1299 lung cancer cell line pair, the anti-proliferative activities of a 
wide panel of anticancer drugs including conventional cytotoxic and 
molecular-targeted drugs were evaluated. On the basis of these results 
(Chapters 3 and 4), the activity of ALDH7A1 has been shown not to be 
involved in causing drug resistance. 
The possibility of inhibiting ALDH7A1 functional activity was also evaluated in 
order to study its potential as a pharmacological target. In collaboration with 
Dr Zoe Cournia (Athens Academy Biomedical Research Foundation), a 
Maybridge database consisting of 24,000 compounds were included in a 
virtual screen using the ALDH7A1 crystal protein structure. Nine compounds 
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with the highest binding affinity for ALDH7A1 were purchased from 
Maybridge and were used to probe ALDH7A1 activity using the isogenic 
H1299 lung cancer cell line pair. Results from cell survival assay and ROS 
generation assay showed that the compound HAN00316 could be a good 
starting point for medicinal chemistry to be performed. This can lead to more 
potent and selective ALDH7A1-affinic compounds which could be used as 
tool compounds to explore the importance of ALDH7A1 in cancer and other 
diseases. In addition to using the isogenic H1299 lung cancer cell line pair, 
HT29 and DLD-1 CRC cell lines, future studies will require a cell-free based 
assay using recombinant ALDH7A1 which is only recently has become 
commercially available. Although ALDH7A1 recombinant plasmid can be 
constructed as previously described (Brocker et al., 2010), it was not 
attempted in this PhD due to time limitation. However, for effective drug 
discovery to be carried out, the lack of recombinant ALDH7A1 protein is 
clearly a limitation in chemical probes discovery and will be required in future 
studies aimed at optimising compounds such as HAN00316. 
Another challenge in CRC is the presence of CSCs which are characterised 
by being resistant to current cancer therapeutics and possessing the ability 
to cause cancer recurrence (Maugeri-Saccà et al., 2011). Hypoxia has been 
described to enhance the survival of CSC by acting as a niche and the 
dynamic interactions between CSCs and the microenvironment has been 
found to promote metastasis and development of drug resistance 
(Heddleston et al., 2010). ALDH1 has been shown to act as CSC marker in 
CRC, however the role of specific ALDH isoforms is not well understood. In 
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this study, the expression of ALDH in CSCs has not been explored due to 
time limitation. It is possible that CSCs will express elevated levels of ALDHs 
due their chemo-protecting properties and involvement in cell differentiation 
via the retinoic acid pathways (Chapter 1, Introduction, section 1.4.5). In this 
regard, it is proposed that future studies will interrogate the expression of 
ALDHs in CSCs derived from CRC cell lines and primary tissues to 
understand their potential as biomarkers for CSC identification and isolation. 
This information will be important to collate as well as how CSCs adapt to 
hypoxic environment. In this regard, it will be key issue to understand which 
ALDH1 isoforms are expressed and whether ALDH7A1 is present and 
induced under hypoxia, thereby potentially providing protection to the stem 
cell component of colon tumours. 
All the work presented in this thesis was conducted using CRC cell lines, 
however to evaluate the significance of ALDH7A1 in a clinical context, future 
work should include the investigation of ALDH in clinical samples derived 
from patients at different stages of CRC. Specifically, it would be important to 
understand the context of ALDH expression with a specific focus on 
ALDH1A1 and 1A3 in the stem cell component, 1B1 in the different CRC 
molecular subtypes and 7A1 in the hypoxic fractions of clinical specimens. 
To compare, ALDH expression should also be analysed in normal colon 
tissue distant to the tumour tissue to assess if ALDH expression is 
significantly different, thereby providing a signature of CRC and perhaps 
stage of malignancy. 
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One of the important roles of ALDH7A1 that was not explored in this study is 
its role in lysine metabolism. ALDH7A1 plays a major role in lysine 
catabolism in the pipecolic acid pathway where it catalyses the oxidation of 
alpha-aminoadipic semialdehyde (α-AASA) to alpha-aminoadipate. Mutation 
in ALDH7A1 has been linked to pyridoxine-dependent epilepsy (PDE) as a 
result of defective lysine catabolism (Mills et al., 2010), which causes 
accumulating piperidine-6-carboxylate (PC6) to condense with pyridoxal 5’-
phosphate (PLP) to inactivate this enzyme cofactor that is essential for 
normal metabolism of neurotransmitters (Mills et al., 2010) (Figure 87). As 
the investigations carried out in this thesis suggest ALDH7A1 as an indicator 
of aggressive forms of CRC due to hypoxia-related induction, development of 
a diagnostic assay to predict which patients are at risk of progressing to 
more advanced disease might be feasible. In PDE patients, this diagnostic kit 
relies on measuring α-AASA and PC6 compounds that are excreted from 
intracellular pools into urine and plasma, provides a simple way of confirming 
the diagnosis of PDE, while ALDH7A1 gene analysis provides a means for 
prenatal diagnosis as confirmed in clinical trials (Mills et al., 2010). Similarly, 
such a technology would allow CRC patients after stage I-III surgery to be 
routinely monitored for signs of tumour recurrence based on 
hypoxia/ALDH7A1 presence in tissue biopsies and measuring lysine 
metabolites as surrogate markers in urine and blood samples before and 
after surgical resection. Ultimately, earlier detection of aggressive forms of 
CRC could lead to better treatment options and thereby improve quality of 
life and survival rate. Another option for future research work could be 
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focussed around addressing the role of ALDH7A1 in lysine metabolism and 
how it might be linked to aggressive forms of CRC.  
In conclusion, the data presented in this thesis points to ALDH7A1 isoform 
as being modulated by tumour hypoxia, however the regulation of its 
expression was shown to be independent of HIF1-α and HIF2-α. Results 
from knockdown studies and isogenic cell pair revealed that ALDH7A1 
expression is associated with less ROS generation which points to its role as 
an antioxidant enzyme. This suggests that it is one of the adaptive responses 
by which hypoxia enhances cancer cell survival and progression. ALDH7A1 
has also been suggested to be associated with cell proliferation as 
knockdown studies showed reduction in DLD-1 live cell number upon 
ALDH7A1 siRNA transfection, while ALDH7A1 overexpression in H1299 
cells increased proliferation rate. Further work is needed to assess whether it 
is also involved in evading apoptosis. To further support the findings 
presented in this thesis, conducting knockdown studies using another CRC 
cell lines such as HT29 should be considered. Future work will be directed 
Figure 87 Catabolism of L-pipecolic acid. P6C is the cyclic Schiff base of a-AASA; in solution they are in 
equilibrium). The dotted arrow indicates the activated methylene that has been proposed to react with the 
carbonyl group of pyridoxal 5’-phosphate (PLP) by forming a Knoevenagel condensation product. Adopted from 
Brocker et al. 2010 (permission is not required for reuse in thesis) and Mills et al. 2006 with License Number: 
3858771236223. 
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toward studying ALDH7A1 expression in primary colon cancer tissues and 
normal tissues. This will provide better understanding to whether a possible 
link between ALDH7A1 and CRC aggressive phenotypes exists as recent 
studies have shown ALDH7A1 to be highly expressed in ovarian cancer 
compared to normal tissue and to be associated with recurrence in patients 
with surgically resected NSCLC. Further exploration of the antioxidant 
properties of ALDH7A1 against e.g. ROS and RNS may provide a better 
understanding of the mechanisms of CSC survival, which are associated with 
resistance and cancer recurrence. This will be made feasible through the 
discovery of ALDH7A1-affinic compounds, e.g. by structural optimisation of 
HAN00316 compound, which was found to inhibit the antioxidant activity of 
ALDH7A1 and hence, can be used as tool compounds to probe ALDH7A1 
functional activities in cancer and other diseases. Considering the 
association between ALDH7A1 expression and the aggressive nature of 
hypoxic cells, developing screening assays to detect biomarkers associated 
with ALDH7A1 might provide a diagnostic tool for the earlier detection of 
recurrent disease, which is currently an unmet clinical need. 
The novel findings of this work include: 
• This is the first time to show that ALDH7A1 expression is increased by 
tumour hypoxia using both 2D and 3D CRC culture models (Chapter 
2). 
• This is the first time to show that ALDH7A1 is involved in the reduction 
of ROS in cancer setting using CRC DLD-1 cells under normoxic and 
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hypoxic conditions and H1299 isogenic cell lines system (Chapter 3 
and 4). 
• ALDH7A1 knockdown resulted in the upregulation of ALDH3A1, 
suggesting a cross talk between both enzymes that might be caused 
by compensatory mechanisms (Chapter 3). 
The limitations of this work include: 
• The expression of ALDH in 2D and 3D culture models was only 
explored using cell lines, however, to evaluate the significance of 
ALDH7A1 in a clinical context, investigation of ALDH should be 
carried out using clinical samples derived from patients at different 
stages of CRC (Chapter 2). 
• The study of the functional roles of ALDH7A1 in CRC using 
knockdown experiments was only investigated in DLD-1 cells, 
however, the inclusion of another cell line such as HT29 will provide 
better understanding of the role of ALDH7A1 in CRC (Chapter 3). 
• Knockdown experiments were conducted using single siRNA 
sequence, however, to confirm the specificity of the consequences of 
ALDH7A1 knockdown two siRNAs sequences targeting ALDH7A1 
should be used (Chapter 3). 
• The evaluation of ALDH7A1-affinic compounds was carried out using 
isogenic cell line system, however, for better understanding of the 
binding affinity of these compounds and ALDH7A1, the use of cell free 
based assays including ALDH7A1 recombinant enzyme should be 
considered (Chapter 4). 
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The hypothesis for future work is ALDH7A1 plays an important role in tumour 
hypoxia including the reduction of ROS level and protection of CSCs 
component from oxidative stress and helps in the diagnosis of aggressive 
CRC phenotypes. Future work will include: 
• Investigation of ALDH7A1 expression in clinical samples derived from 
patients at different stages of CRC and normal colon tissues. 
• Investigation of ALDH7A1 expression in CSCs component of CRC 
under normoxic and hypoxic conditions. 
• Exploring the role of ALDH7A1 in protecting CRC cells against 
oxidative stress. This include knockdown studies of ALDH7A1 and 
evaluation of the effect of different oxidant sources such as hydrogen 
peroxide and superoxide on cell survival  
• The development of a diagnostic assay to predict which patients with 
CRC are at risk of progressing to more advanced disease based on 
hypoxia/ALDH7A1 presence in tissue biopsies and measuring lysine 
metabolites as surrogate markers in urine and blood samples before 
and after surgical resection. 
• Further structural optimisation of HAN00316 compound, which was 
found to inhibit the role of ALDH7A1 in reducing ROS levels and 
hence, can be used as tool compounds to probe ALDH7A1 functional 
activities in cancer and other diseases. 
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Appendix I: Composition and storage of cell culture media 
(Storage in brackets). 
Phosphate buffer saline (PBS, pH 7.4) 
PBS was obtained from sigma and stored at room temperature. 
1x RPMI culture media 
Complete RPMI 1640 (4ºC) was prepared from incomplete RPMI 1640 
(Sigma) (4ºC), foetal bovine serum (Sigma) (-20ºC) 10% (v/v), L-glutamine 
(Sigma) (-20ºC) 1% (v/v) and sodium pyruvate (Sigma) (4ºC) 1% (v/v). 
2x RPMI culture media 
Complete RPMI 1640 (4ºC) was prepared from incomplete RPMI 1640 
(Sigma) (4ºC), foetal bovine serum (Sigma) (-20ºC) 20% (v/v), L-glutamine 
(Sigma) (-20ºC) 2% (v/v) and sodium pyruvate (Sigma) (4ºC) 2% (v/v). 
1x RPMI phenol red free culture media 
Complete RPMI (4ºC) was prepared from incomplete phenol red free RPMI 
(Gibco) (4ºC), foetal bovine serum (Sigma) (-20ºC) 10% (v/v), L-glutamine 
(Sigma) (-20ºC) 1% (v/v) and sodium pyruvate (Sigma) (4ºC) 1% (v/v). 
2x RPMI phenol red free culture media 
Complete RPMI (4ºC) was prepared from incomplete phenol red free RPMI 
(Gibco) (4ºC), foetal bovine serum (Sigma) (-20ºC) 20% (v/v), L-glutamine 
(Sigma) (-20ºC) 2% (v/v) and sodium pyruvate (Sigma) (4ºC) 2% (v/v). 
Trypsin/ EDTA solution 
Trypsin/ EDTA solution 0.25% was obtained from sigma (-20ºC). 
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Appendix II: Composition and storage of MTT assay 
solutions. 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
stock solution 
The MTT stock solution (5 mg/ml) was prepared by dissolving MTT powder 
(sigma) in ultrapure water, which was then passed through a 0.2 µM sterile 
syringe filter (corning incorporated). The resulting solution was stored at 4ºC 
for a maximum 4-6 weeks. 
The MTT working solution (0.5 mg/ml) was prepared immediately before use 
by diluting 2 ml of MTT stock solution in 18 ml of complete RPMI medium. 
Dimethyl sulfoxide (DMSO) solution 
DMSO was obtained from sigma and stored at room temperature. 
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Appendix III: qRT-PCR primers 
 All primers were purchased from PrimerDesignTM.  
Target 
gene 
Sense Primer Anti-sense Primer Amplicon 
length (bp) 
Tm 
(C˚) 
ALDH 1A1 CCAAGTGCTCTATCAGAA
CCAAAT 
TCGGTGAGTAGGACAGG
TAAGT 
108 74.9 
ALDH1A2 AATAACTCAGACTTTGGAC
TCGTA 
TGGGCATTTAAGGCATT
GTAAC 
125 72.2 
ALDH1A3 CAGCAGCCGTGTTCACAA
A 
ATAGAGGGCGTTGTAGC
AGTT 
98 73.5 
ALDH1B1 CAGTCACAGTCCAGCAAT
TCC 
GCTTTATTTGTGGGGTTT
CTTCTAA 
119 71.5 
ALDH 2 GTGGGTCAACTGCTATGA
TGTG 
TATGAGTTCTTCTGAGGC
ACTTTG 
150 77.3 
ALDH 3A1 GATGAGCCCGTGGAGAAG
A 
GCTGGATGGTGAGGTTG
AAG 
121 79.4 
ALDH7A1 TGTCACAAAGATAATAGCC
AAGGTT 
CAGCAGGTTCACTCGTT
CATC 
124 74 
VEGFA CCAGGAAAGACTGATACA
GAACG 
GGTTTCTGGATTAAGGA
CTGTTC 
93 85.3 
HIF1α TGCCACATCATCACCATAT
AGAG 
TGACTCAAAGCGACAGA
TAACA 
132 72.8 
HIF2α 
(EPAS1) 
CCTCCCCACCTTCAATGA
CT 
CTCCCTACAGAAGAACA
GACATG 
121 71.9 
Table 14 qRT-PCR primers. 
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Appendix IV: Solutions for molecular biology (Western blot) 
All reagents were purchased from Sigma unless otherwise specified. 
RIPA lysis buffer stock solution 
150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% 
SDS (GE Healthcare), 50 mM Tris, pH 8.0. 
RIPA lysis buffer working solution 
940 µl RIPA buffer, 50 µl protease inhibitor (1x cOmplete mini EDTA free, 
S8830) , 10 µl 1x phosphatase inhibitor (P5726)  
4x sample loading buffer (Lammeli buffer) 
300 mM Tris-HCl pH 6.8, 35% glycerol (GE Healthcare), 12% SDS, 0.02% 
bromophenol blue, 6% mercaptoethanol, made up to 20 ml with deionised 
water. 
12% Resolving gel 
H2O 6.6 ml 
30% acrylamide mix 8.0 ml 
1.5 M Tris-HCl (pH 8.8) 5.0 ml 
10% SDS (GE Healthcare) 0.2 ml 
10% ammonium persulfate 0.2 ml 
TEMED 0.01 ml 
15% Resolving gel 
H2O 4.6 ml 
30% acrylamide mix 10.0 ml 
1.5 M Tris-HCl (pH 8.8) 5.0 ml 
10% SDS (GE Healthcare) 0.2 ml 
10% ammonium persulfate 0.2 ml 
TEMED 0.01 ml 
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5% Stacking gel 
H2O 6.8 ml 
30% acrylamide mix 1.7 ml 
1 M Tris-HCl (pH 8.8) 1.25 ml 
10% SDS (GE Healthcare) 0.1 ml 
10% ammonium persulfate 0.1 ml 
TEMED 0.01 ml 
10x Running buffer 
15 g Tris base, 72 g Glycine, 5 g SDS (GE Healthcare) in 500 ml deionised 
water. 
10x Transfer buffer  
30 g Tris base, 144 g Glycine in 1 L deionised water. 
1x Transfer buffer  
100 ml 10x Transfer buffer, 200 ml methanol, 10 ml 10% SDS (GE 
Healthcare) and 690 ml deionised water. 
PBS Tween 20 (PBST) 
1 ml of Tween 20 in 1 L PBS (pH 7.4) 
5% blocking solution 
5 g milk (less than 0.1% fat) in 100 ml of 0.1% PBST. 
Developing solution 
50 ml multigrade developer (ILFORD) in 500 ml d.H2O. 
Fixation solution 
50 ml rapid fixer (ILFORD) in 500 ml d.H2O 
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Appendix V: Primary and secondary antibodies for western blot 
Table 15 Primary and secondary antibodies for western blot. 
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Appendix VI: Buffers and antibodies for histology (IHC) 
1x Citrate buffer 
2.1 g citric acid monohydrate in 1000 ml dH2O. PH was adjusted to 6.0 with 2M NaOH. 
Primary and secondary antibodies for IHC 
Table 16 Primary and secondary antibodies for IHC. 
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Appendix VII: siRNAs information 
siRNAs for target genes were purchased from Ambion/Life Technologies.  
ALDH1A3 siRNA Sense Antisense 
Sequence (5’->3’) GUAUCGAAGAAGUGAUAAAtt UUUAUCACUUCUUCGAUACtt 
Length 21 21 
Percent G/C 29% 29% 
Molecular Weight 6800 6500 
Molar Extinction 
Coefficient 
231700 200600 
Annealed Molecular 
Weight 
13300 13300 
ALDH7A1 siRNA Sense Antisense 
Sequence (5’->3’) GGAAAUUAUGUAGAACCGAtt UCGGUUCUACAUAAUUUCCag 
Length 21 21 
Percent G/C 33% 38% 
Molecular Weight 6800 6600 
Molar Extinction 
Coefficient 
223100 208700 
Annealed Molecular 
Weight 
13400 13400 
ALDH3A1 siRNA Sense Antisense 
Sequence (5’->3’) GGAACUCAGUGGUCCUCAAtt UUGAGGACCACUGAGUUCCct 
Length 21 21 
Percent G/C 48% 52% 
Molecular Weight 6700 6600 
Molar Extinction 
Coefficient 
205100 199900 
Annealed Molecular 
Weight 
13400 13400 
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HIF1α siRNA Sense Antisense 
Sequence (5’->3’) CCUCAGUGUGGGUAUAAGAtt UCUUAUACCCACACUGAGGtt 
Length 21 21 
Percent G/C 43% 43% 
Molecular Weight 6800 6600 
Molar Extinction 
Coefficient 
213200 201400 
Annealed Molecular 
Weight 
13400 13400 
HIF2α siRNA Sense Antisense 
Sequence (5’->3’) CAAUAGCCCUGAAGACUAUtt AUAGUCUUCAGGGCUAUUGgg 
Length 21 21 
Percent G/C 38% 48% 
Molecular Weight 6700 6700 
Molar Extinction 
Coefficient 
208800 213100 
Annealed Molecular 
Weight 
13400 13400 
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Appendix VIII: Solutions for spheroids formation and 
invasion 
Methylcellulose for spheroids formation 
6 g methylcellulose (Sigma) was autoclaved in a 500ml flask containing a 
magnetic stirrer. 250 ml of RPMI medium (preheated at 60°C) was added 
and mixed for 30 min. Another 250 ml medium was added and stirred for 
further 30 min at room temperature. The methylcellulose solution was left for 
1-2 h at 4°C to ensure that it was completely dissolved. The 500 ml of 
methylcellulose solution was then centrifuged (5,000 rcf, 2h, room 
temperature). The clear highly viscous supernatant was kept at 4°C until 
required. 
Collagen matrix for invasion assay 
To prepare collagen matrix on ice: 
 Volume of collagen stock (4.88 mg/ml, collagen type 1 rat tail, 
Corning) to achieve final concentration of 1.5 mg/ml 
 Volume of NaOH (1M) = volume of collagen stock/40 
 Volume of PBS (5x) to achieve 1x final concentration 
 Volume of distilled water= Volume of collagen matrix – (Volume of 
collagen stock+ Volume of NaOH+ Volume of PBS) 
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Appendix IX: Raw data for ∆Ct values from qRT-PCR of 
ALDH1A1, 1A2, 1A3, 1B1, 2, 3A1 and 7A1 in DLD-1 cells. 
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
ALDH1A2 Control 13.83 14.52 14.31 14.22 0.29
6h 14.09 15.24 14.57 14.63 0.47 0.36
24h 14.42 14.43 14.69 14.51 0.12 0.29
48h 12.27 12.72 12.71 12.57 0.21 0.00
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
ALDH1A1 Control 14.23 13.05 13.34 13.54 0.50
6h 15.96 13.85 13.83 14.55 1.00 0.16
24h 15.09 13.35 13.33 13.92 0.82 0.61
48h 13.38 12.65 13.23 13.09 0.31 0.35
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
ALDH1B1 Control 4.93 4.75 5.14 4.94 0.16
6h 4.28 3.62 4.89 4.26 0.52 0.20
24h 5.17 4.65 5.93 5.25 0.53 0.50
48h 4.52 5.01 5.35 4.96 0.34 0.95
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
ALDH1A3 Control 9.16 8.94 9.23 9.11 0.12
6h 9.08 8.68 8.57 8.78 0.22 0.15
24h 9.6 8.52 9.07 9.06 0.44 0.90
48h 8.38 8.41 8.69 8.49 0.14 0.01
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
ALDH2 Control 5.76 5.65 5.53 5.65 0.09
6h 6.55 6.35 6.36 6.42 0.09 0.001
24h 5.64 5.56 5.34 5.51 0.13 0.30
48h 6.05 5.34 5.38 5.59 0.33 0.83
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
ALDH3A1 Control 5.77 6.7 6.49 6.32 0.40
6h 5.97 6.76 6.4 6.38 0.32 0.88
24h 5.36 6.05 5.70 5.70 0.28 0.16
48h 5.64 6.38 5.96 6.00 0.30 0.42
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
ALDH7A1 Control 6.96 7.07 7.05 7.03 0.05
6h 7.23 7.15 7.21 7.20 0.03 0.02
24h 5.64 4.94 5.44 5.34 0.30 0.01
48h 5.68 4.70 5.95 5.44 0.54 0.05
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Appendix X: Raw data for geometric mean values of area 
under the curve from ROS detection in DLD-1 cells after 
knockdown under normoxic and hypoxic conditions 
I. ROS in normoxia: 
 
II. ROS in hypoxia:  
 
  
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
H Mock 11.86 11.96 11.85 11.89 0.0497
H H2O2 23.36 23.42 23.36 23.38 0.0283 4.22E-08
N Lipo 21.2 21.28 20.91 21.13 0.159
H Lipo 12.66 12.42 12.43 12.503 0.1109 1.43E-06
H Lipo 12.66 12.42 12.43 12.503 0.1109
H 1A3 siRNA 12.74 12.67 12.6 12.67 0.0572 0.155393
H 3A1 siRNA 13.96 14.36 14.46 14.26 0.216 0.002034
H 7A1 siRNA 15.31 15.04 14.91 15.087 0.1666 0.00014
H 3A1 & 7A1 siRNAs 16.54 16.57 16.53 16.547 0.017 0.000283
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
Lipo 21.77 21.55 19.82 21.047 0.872
Lipo/H2O2 27.51 25.28 23.32 25.37 1.7117 0.050629
3A1 siRNA 22.48 20.67 19.6 20.917 1.1886 0.907282
7A1 siRNA 24.87 24.22 22.62 23.903 0.9455 0.035127
3A1 & 7A1 siRNAs 24.78 23.63 22.18 23.53 1.0638 0.065446
1A3 siRNA 17.87 17.28 16.49 17.213 0.5654 0.009739
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Appendix XI: Raw data for geometric mean values of area 
under the curve from ROS detection in H1299 cells 
I. H1299/RFP and H1299/7A1 
 
II. H1299/RFP treated with ALDH7A1 inhibitors 
 
III. H1299/7A1 treated with ALDH7A1 inhibitors 
  
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
RFP/DMSO 178.39 164.02 171.205 171.205 5.8665
RFP/DEAB 171.25 158.11 164.68 164.68 5.3644 0.3108
RFP/DSHS00561 135.99 132.77 134.38 134.38 1.3146 0.0097
RFP/KM06288 143.77 135.12 139.445 139.445 3.5313 0.0054
RFP/HAN00316 163.54 151.09 157.315 157.315 5.0827 0.0659
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
7A1/DMSO 12.78 13.32 13.57 13.223 0.3297
7A1/DEAB 16.27 17.06 16.68 16.67 0.3226 0.0005
7A1/DSHS00561 13.59 14.23 13.93 13.917 0.2614 0.0836
7A1/KM06288 13.54 13.98 13.72 13.747 0.1806 0.1406
7A1/HAN00316 14.54 14.62 14.62 14.593 0.0377 0.0265
Experiment 1 Experiment 2 Experiment 3 Average SD T.Test
H1299/RFP 58.47 56.74 60.67 58.627 1.6082
H1299/7A1 4.01 3.9 3.96 3.9567 0.045 0.0004
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Appendix XII: Abstracts presented to attended conferences 
Poster: School of Life Sciences, Research and Development Open Day, 
March 2013, University of Bradford 
Modulation of drug metabolising enzymes and ABC drug transporters 
with decitabine has no bearing on the chemosensitivity of paclitaxel 
L. Cosentino1, L. Elsalem1, N. Masrour2, J. Burns3, R.M. Phillips1, R. 
Brown2, P. Burns3 and K. Pors1 
1Institute of Cancer Therapeutics, University of Bradford, BD7 1DP, U.K.; 
2Imperial College London, Hammersmith Hospital Campus, London W12 
0NN,U.K.; 3Leeds Institute of Molecular Medicine, St James’s Hospital, 
Leeds LS9 7TF, U.K. 
The literature describes the role of DNA methylation in regulation of tumour 
suppressor genes, DNA repair genes, but not much attention has been paid 
to drug metabolising enzymes (DMEs). Some evidence has been reported 
and includes methylation in the promoter regions of CYP450 and ABC 
transporters. Cotreatment of decitabine (DAC) and paclitaxel (PAC) has 
been reported in several studies, but few of these have in a focused manner 
reported on the effect on DMEs. As a consequence, the major DMEs 
involved in the detoxification of PAC (namely ABCB1, CYP2C8 and 
CYP3A4) were investigated. Also the aldehyde dehydrogenase enzymes 
(ALDH1A1, ALDH2 and ALDH3A1) were explored, as they recently have 
been shown to play a chemo-protective role against taxanes. A549, HT29, 
HeLa and MCF7 cells were treated with DAC (0.1 or 1uM for 24 h). DNA 
methylation was analysed using pyrosequencing. Gene expression was 
determined by quantitative RT-PCR (qRT-PCR). Western blotting analysis 
was used for protein expression analysis. The chemosensitivity of 
cotreatment of DAC (0.1 uM 24 h) and paclitaxel (0.0001 to 10 uM) on day 6 
or 8 was evaluated by the MTT assay. Analysis of the CpG island 
methylation level indicated that all the above-mentioned DMEs were densely 
methylated and that treatment of MCF-7 cells with DAC resulted in a 
decrease in methylation within the gene promoter region. Furthermore, 
correlation of decrease in DNA methylation with increase in gene expression 
of ABCB1, CYP3A4, ALDH2 and ALDH3A1 was observed, but not in 
CYP2C8 and ALDH1A1. However, only the ABCB1 protein level was shown 
to noticeably increase. Evaluation of the cotreatment of DAC and PAC on 
cell survival demonstrated that the cytotoxic potential of PAC was not 
significantly affected by the exposure to DAC suggesting that modification of 
ABCB1 at the protein level was not sufficient to alter the activity of PAC. The 
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same experiments were also conducted in HeLa, HT29 and A549 cells and 
similar results were observed: no significant modification at the protein level 
despite changes to the DNA methylation and gene levels and hence no 
alteration in the chemosensitivity of PAC after pretreatment of these cancer 
cells with DAC.  
Our data demonstrates that pretreatment of four different cancer cell lines 
with DAC has no significant affect on the chemosensitivity of PAC, indicating 
that modulation of drug metabolising enzymes and drug transporters at the 
DNA methylation and gene level is not translated into modified protein levels. 
Our observations provide vital information for further clinical evaluation of 
combination strategies that involves the use of DAC. 
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Poster: YCR Annual Scientific Meeting, June 2013, Pavilions of Harrogate, 
Great Yorkshire Showground 
Re-engineering of the Duocarmycin Structural Architecture Enables 
Tumour-Selective CYP2W1-mediated Drug Activation in Human Colon 
Cancer Xenografts. 
Klaus Pors, Sandra Travica**, Paul M. Loadman, Steven D. Shnyder, Lina 
Elsalem, Mark Sutherland, Helen M. Sheldrake, Mark Searcey*, Inger 
Johansson**, Souren Mkrtchian**, Magnus Ingelman-Sundberg** and 
Laurence H. Patterson. 
University of Bradford, BD7 1DP, *University of East Anglia, NR4 7TJ;** 
Karolinska Institute, SE-17177, Sweden. 
CYP2W1 is detected in 30% of colon cancers while its protein expression in 
non-transformed adult tissues is absent or insignificant CYP2W1. Here we 
present data on furanoindole-based duocarmycins that have the potential to 
be used as a chemical probe (e.g. ICT2726) to show CYP2W1 functional 
activity. Significantly, we also demonstrate indoline-based bioprecursors 
ICT2705 and ICT2706 to elicit potent antiproliferative activity in CYP2W1-
transfected human HEK293 and SW480 cells but not in mock-transfected 
cells. Moreover, ICT2706 was shown to prevent tumour growth when 
administered to SCID mice bearing SW480-2W1 xenografts (dosed daily with 
100 mg/kg for 8 days). Using H2A.X phosphorylation as a marker for DNA 
damage, our data revealed a time-dependent increase in expression 
supporting CYP2W1-mediated activation of ICT2706 in vivo. Our findings 
reveal the opportunities in targeting CYP2W1 as a novel therapeutic 
approach in colon cancer chemotherapy. 
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Poster: School of Life Sciences, Research and Development Open Day, 
March 2014, University of Bradford, UK 
The impact of hypoxia on the expression of aldehyde dehydrogenases 
in colon cancer. 
Lina Elsalem1, Mark Sutherland1, Roger Phillips1, Klaus Pors1 
1Institute of Cancer Therapeutics/ School of Life Sciences, Bradford, West 
Yorkshire, UK 
     Introduction: Cancer cells become resistant to chemotherapy by a variety 
of different mechanisms. One of the main components is due to increased 
expression of drug metabolising enzymes (DMEs) including, aldehyde 
dehydrogenases (ALDHs). Currently, it is well known that tumour hypoxia is 
associated with invasive and metastatic properties of cancer tissues as well 
as resistance to chemotherapy and radiation therapy, which together 
constitute the lethal cancer phenotype and ultimately lead to patient 
mortality. The contribution of hypoxia to anticancer drugs resistance through 
different mechanisms is well established, however, its role in the regulation 
of drug metabolising enzyme expression, particularly ALDHs, is still to be 
elucidated. This research project is focussed on investigating the expression 
of ALDH in colon cancer cells and aims to understand the impact of hypoxia 
might have on the expression of specific ALDHs.  
     Methods: Monolayer cells (HT29, DLD-1, SW480 and HCT116) were 
either incubated at normoxic conditions or exposed to very low oxygen level 
(0.1 %) for 6, 24 and 48 h. Multicellular spheroids (MCS) were grown from 
HT29 using spinner flasks culture technique. Paraffin embedded spheroids 
were sectioned and stained with haematoxylin and eosin. Hypoxia was 
detected in spheroid frozen sections using immunofluorescence staining for 
the hypoxia marker, pimonidazole. Cells residing in the hypoxic regions or in 
the surface layers were isolated using sequential trypsinisation. The gene 
expression analysis of ALDH isoforms (1A1, 1A2, 1A3, 1B1, 2, 3A1 and 7A1) 
in monolayer cells and MCS was evaluated using quantitative RT-PCR. 
     Results: The gene analysis data of monolayer cells revealed that hypoxia 
exerts cell type specific effects on ALDHs expression, whether this effect 
was manifested as an up-regulation or down-regulation of the specific genes. 
The ALDH gene expression profile of cells residing in the surface layer of 
HT29 spheroids was variable, with up-regulation of ALDH (1A1, 1A2, 1B1, 
and 7A1), down-regulation of ALDH (1A3 and 3A1) and no change in the 
expression of ALDH2 compared to monolayer cells. Interestingly, cells 
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residing in the hypoxic region showed further up-regulation of ALDH (2 and 
7A1), no change in the expression of ALDH (1A3 and 3A1) and down-
regulation of ALDH(1A and 1B1) compared to surface layer cells. 
     Conclusion: Our data reveals that the expression of ALDHs in colon 
cancer cells can be modulated as a result of tumour hypoxia exposure, at 
least at the gene level. Knowledge about the location of ALDHs within the 
tumour microenvironment and how these enzymes are affected by hypoxic 
conditions will contribute to a better understanding of cancer drug resistance 
mechanisms, and ultimately will enhance the development of ALDH-targeted 
cancer therapeutics in hypoxic cells and potentially also cancer stem cells. 
Therefore, in order to fully establish the role of hypoxia, future work will 
include investigation of a wide panel of ALDH isoforms in monolayer cell 
lines, MCS tumour models and primary colon cancer cells. 
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Oral presentation: Postgraduate Research Mini conference 2014, Faculty of 
life Sciences, University of Bradford, UK 
The impact of hypoxia on the expression of aldehyde dehydrogenases 
in colon cancer. 
Lina Elsalem1, Mark Sutherland1, Roger Phillips1, Klaus Pors1 
1Institute of Cancer Therapeutics/ School of Life Sciences, Bradford, West 
Yorkshire, UK 
Cancer cells become resistant to chemotherapy by a variety of different 
mechanisms. One of the main components is due to increased expression of 
drug metabolising enzymes (DMEs) including, aldehyde dehydrogenases 
(ALDHs). Currently, it is well known that tumour hypoxia contributes to 
anticancer drugs resistance through different mechanisms; however, its role 
in the regulation of ALDHs is still to be elucidated. This research project is 
focussed on investigating the expression of ALDH in colon cancer cells and 
aims to understand the impact of hypoxia might have on the expression of 
specific ALDHs. Monolayer cells were exposed to 0.1% O2 and gene 
analysis data of revealed that hypoxia exerts cell type specific effects on 
ALDHs expression, whether this effect was manifested as an up-regulation 
or down-regulation of the specific genes. The ALDH gene expression profile 
was also investigated in multicellular spheroids (MCS) and showed that the 
expression of certain isoforms was enhanced in cells residing in the hypoxic 
region compared to cells in the surface layer. Our data reveals that the 
expression of ALDHs in colon cancer cells can be modulated as a result of 
tumour hypoxia, at least at the gene level. This knowledge will contribute to a 
better understanding of cancer drug resistance mechanisms, and ultimately 
will enhance the development of ALDH-targeted cancer therapeutics in 
hypoxic cells and potentially in cancer stem cells. Therefore, in order to fully 
establish the role of hypoxia, future work will include investigation of a wide 
panel of ALDH isoforms in monolayer cell lines, MCS tumour models and 
primary colon cancer cells.  
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Poster: The 10th National Cancer Research Institute Conference November 
2014, Liverpool, UK 
The impact of hypoxia on the expression of aldehyde dehydrogenases 
in colon cancer. 
Lina Elsalem1, Mark Sutherland1, Roger Phillips1, Klaus Pors1, 
1Institute of Cancer Therapeutics/ School of Life Sciences, Bradford, West 
Yorkshire, UK, 
Background: Cancer cells become resistant to chemotherapy by different 
mechanisms. One of the main components is due to increased expression of 
drug metabolising enzymes (DMEs) including, aldehyde dehydrogenases 
(ALDHs). It is well known that tumour hypoxia contributes to anticancer drugs 
resistance, however, its effect on the regulation of ALDHs is still to be 
elucidated. Accordingly, the focus of our research was to investigate the 
expression of ALDH in colon cancer cells under normoxic and hypoxic 
conditions in attempt to gain information of these isoforms as potential 
biomarkers. 
Method: Monolayer cells (HT29, DLD-1, SW480 and HCT116) were 
incubated at normoxic conditions or exposed to (0.1 %) oxygen level for 6, 
24 and 48h. Multicellular spheroids (MCS) were grown from HT29 and DLD-
1 cells using spinner flasks culture technique. Paraffin embedded spheroids 
were stained with haematoxylin and eosin. Hypoxia was detected using 
immunofluorescence staining for the hypoxia marker, pimonidazole. Cells 
residing in the hypoxic regions or in the surface layers were isolated using 
sequential trypsinisation. The gene expression of ALDH isoforms (1A1, 1A2, 
1A3, 1B1, 2, 3A1 and 7A1) was evaluated using quantitative RT-PCR. 
Results: Gene analysis data of monolayer cells revealed that hypoxia exerts 
cell type specific effects on ALDHs expression, whether this effect was 
manifested as an up-regulation or down-regulation of the specific genes. The 
ALDH gene profile of MCS showed that ALDH2 and 7A1 were up-regulated 
in the hypoxic region compared to the surface layer in both HT29 and DLD-1 
MCS. 
Conclusion: Our data reveals that the gene expression of ALDHs in colon 
cancer cells can be modulated upon exposure to hypoxic conditions. This 
knowledge will contribute to a better understanding of cancer drug resistance 
mechanisms present in colon cancer, but further studies are required to 
correlate the increased expression of specific ALDHs in hypoxic fractions of 
colon tumours. 
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Oral presentation: Postgraduate Research Mini conference 2015, Faculty of 
life Sciences, University of Bradford, UK 
Exploration of the role of ALDH in colon cancer progression and 
influence on chemotherapy 
L. Elsalem1, S. Allison1, R.M. Phillips2 and K. Pors1  
1: Institute of Cancer Therapeutics, Faculty of Life Sciences, University of 
Bradford, UK 
2: Department of Pharmacy, University of Huddersfield, UK 
Introduction: Colorectal cancer is the third most common cancer in the world. 
For patients with advanced colon cancer, the 5 year survival rate is less than 
10%. Recently, ALDHs were used as markers to isolate, propagate and track 
colon cancer stem cells. In addition, the expression of certain ALDH isoforms 
in primary colon cancer samples was found to be significantly associated 
with shorter overall survival, suggesting its clinical relevance as prognostic or 
predictive marker in colorectal cancer. The aim of this study is to investigate 
the expression of ALDH isoforms in colorectal cancer cell lines and study 
their functional role in colorectal cancer progression and chemotherapy. 
Methods: in this study we used siRNA duplexes to knockdown one (1A3, 3A1 
or 7A1) or two isoforms together (3A1 and 7A1) in the DLD-1 colorectal 
cancer cell line in order to investigate the role of each one in mediating cells 
proliferation, migration, drug resistance and inhibition of reactive oxygen 
species (ROS) generation. 
Result: The results show that significant and specific knockdown of each 
isoform can be achieved at both the gene and protein levels with a role of 
ALDH7A1 in regulating the expression of ALDH3A1. Only ALDH7A1 was 
found to be associated with enhanced cell proliferation and inhibition of ROS 
generation. In addition ALDH3A1 and 7A1 were found to promote cell 
migration. However, no significant role of the three isoforms was observed in 
mediating drug resistance. 
Conclusion: Our data suggests that ALDH7A1 has an important role in colon 
cancer progression through mediating cell proliferation and migration. In 
addition, it might be involved in protection against cell death caused by 
(ROS) through antioxidant regulatory pathways. 
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Poster: EACR-AACR-SIC Special Conference June 2015, Florence, Italy 
Hypoxia modulates the expression of aldehyde dehydrogenases in 
colon cancer cells with ALDH7A1 emerging as a key enzyme whose 
functional involvement is dependent on the tumour microenvironment 
L. Elsalem1, S. Allison1, R.M. Phillips2 and K. Pors1  
1: Institute of Cancer Therapeutics, Faculty of Life Sciences, University of 
Bradford, UK 
2: Department of Pharmacy, University of Huddersfield, UK 
Introduction: Most solid tumours generate hypoxic regions as a consequence 
of poorly developed and incomplete neovasculature. It is well known that 
hypoxia is associated with an aggressive cancer phenotype, causing 
resistance to both radiotherapy and chemotherapy.The aldehyde 
dehydrogenase (ALDH) superfamily, which belongs to the class of phase 1 
drug metabolising enzymes, is thought to be involved in drug resistance. 
However, their regulation and expression within the tumour 
microenvironment is poorly understood. Accordingly, we have initiated an 
investigation to understand the role of ALDHs in tumour tissues and explored 
the impact hypoxia might have on the expression of these enzymes in colon 
cancer. 
Methods: Colon cancer cell lines (HT29, DLD-1, SW480 and HCT116) were 
grown under normoxic or hypoxic conditions (0.1% O2) for 6, 24 and 48h. 
HT29 and DLD-1 cells were also grown in spinner flasks until multicellular 
spheroids (MCS) were obtained (diameter ≈600µm). The hypoxic regions of 
the MCS were detected using the hypoxia marker, pimonidazole, and 
isolated using sequential trypsinisation. Gene expression analysis of ALDH 
isoforms (1A1, 1A2, 1A3, 1B1, 2, 3A1 and 7A1) in monolayer cells and MCS 
was carried out using quantitative RT-PCR. The protein expression was 
evaluated using Western blot and immunohistochemistry. 
Results: The gene analysis data of monolayer cells showed that hypoxia 
exerts upregulation of ALDH(1A1, 1A2 and 7A1) in DLD-1 and HT29, 
ALDH1A3 in SW480 and all investigated ALDH in HCT116 with the 
exception to ALDH(2 and 7A1). However, on the protein level, only 
ALDH7A1 was upregulated in HT29 and DLD-1 and ALDH1A3 in HCT116 
and SW480. Cells residing in the hypoxic region of HT29 and DLD-1 MCS 
showed upregulation of ALDH7A1 compared to surface layer cells and 
monolayer cells at both gene and protein levels. 
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Conclusion: Our results reveal that tumour hypoxia has impact on the 
expression of ALDHs in colon cancer cells at both gene and protein levels. 
An understanding of how these enzymes are affected by hypoxic conditions 
and their location within the tumour microenvironment will elucidate the role 
of these enzymes in colon cancer progression and drug resistance. Our data 
suggests that ALDH7A1 is increased by exposure to hypoxia and current 
studies are focussed on understanding how this enzyme may be linked to 
HIF-1 and/or metabolic signalling pathways. The data from these studies will 
also be presented at the meeting. 
